<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="572794a1-b7ec-4327-ab8a-ed6ab8020129"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use SKYRIZI safely and effectively. See full prescribing information for SKYRIZI.</content>
      <br/>
      <content styleCode="bold">
         <br/>SKYRIZI</content>
      <content styleCode="bold">
         <sup>Â®</sup>
      </content>
      <content styleCode="bold"> (risankizumab-rzaa) injection, for subcutaneous </content>
      <content styleCode="bold">or intravenous </content>
      <content styleCode="bold">use</content>
      <content styleCode="bold">
         <br/>Initial U.S. Approval: 2019</content>
      <br/>
      <br/>
   </title>
   <effectiveTime value="20250507"/>
   <setId root="7148c8eb-b39e-e20a-6494-a6df82392858"/>
   <versionNumber value="162"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="078458370" root="1.3.6.1.4.1.519.1"/>
            <name>AbbVie Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="67cbe729-4e4e-45be-addc-218c4a80f573"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250514"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0074-2042" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Skyrizi</name>
                        <formCode code="C47916" displayName="KIT" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Risankizumab-rzaa</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0074-2042-02" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20190423"/>
                                    <high value="20230131"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0074-2042-71" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20190423"/>
                                    <high value="20221031"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator unit="mL" value="1.66"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>Skyrizi</name>
                              <formCode code="C42945" displayName="INJECTION, SOLUTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Risankizumab-rzaa</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="75"/>
                                    <denominator unit="mL" value="0.83"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="90ZX3Q3FR7" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>RISANKIZUMAB</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="90ZX3Q3FR7" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>RISANKIZUMAB</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.049"/>
                                    <denominator unit="mL" value="0.83"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="AB6MNQ6J6L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SUCCINIC ACID</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="34"/>
                                    <denominator unit="mL" value="0.83"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="506T60A25R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SORBITOL</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.17"/>
                                    <denominator unit="mL" value="0.83"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="7T1F30V5YH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSORBATE 20</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>WATER</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.53"/>
                                    <denominator unit="mL" value="0.83"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="V8ZGC8ISR3" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM SUCCINATE ANHYDROUS</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="mL" value="0.83"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43202" displayName="SYRINGE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102836" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA761105" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" displayName="BLA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20190423"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38299" displayName="SUBCUTANEOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator unit="mL" value="2"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>Alcohol Swab</name>
                              <formCode code="C47898" displayName="SWAB" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>isopropyl alcohol</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mL" value="0.70"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="ND2M416302" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ISOPROPYL ALCOHOL</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="ND2M416302" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>ISOPROPYL ALCOHOL</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>WATER</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="mL" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43199" displayName="PACKET" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="M003" root="2.16.840.1.113883.3.9421"/>
                                 <code code="C200263" displayName="OTC Monograph Drug" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20190423"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38304" displayName="TOPICAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761105" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" displayName="BLA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20190423"/>
                              <high value="20230131"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0074-1050" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Skyrizi</name>
                        <formCode code="C42946" displayName="INJECTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>risankizumab-rzaa</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="150"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="90ZX3Q3FR7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>RISANKIZUMAB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="90ZX3Q3FR7" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>RISANKIZUMAB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.054"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="Q40Q9N063P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ACETIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.2"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7T1F30V5YH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 20</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.75"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4550K0SC9B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM ACETATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="63.33"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="B8WCK70T7I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TREHALOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43202" displayName="SYRINGE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0074-1050-70" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20210426"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102836" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43202" displayName="SYRINGE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0074-1050-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20210426"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102836" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761105" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" displayName="BLA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20210426"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" displayName="SUBCUTANEOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0074-2100" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Skyrizi</name>
                        <formCode code="C42946" displayName="INJECTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>risankizumab-rzaa</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="150"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="90ZX3Q3FR7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>RISANKIZUMAB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="90ZX3Q3FR7" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>RISANKIZUMAB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.054"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="Q40Q9N063P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ACETIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.2"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7T1F30V5YH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 20</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="63.33"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="B8WCK70T7I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TREHALOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.75"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4550K0SC9B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM ACETATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43202" displayName="SYRINGE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0074-2100-70" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20210426"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102836" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43202" displayName="SYRINGE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0074-2100-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20210426"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102836" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761105" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" displayName="BLA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20210426"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" displayName="SUBCUTANEOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0074-1070" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Skyrizi</name>
                        <formCode code="C47916" displayName="KIT" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Risankizumab-rzaa</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0074-1070-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20220616"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0074-1070-02" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20220616"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator unit="mL" value="2.4"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="0074-1069" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Skyrizi</name>
                              <formCode code="C42945" displayName="INJECTION, SOLUTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Risankizumab-rzaa</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="360"/>
                                    <denominator unit="mL" value="2.4"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="90ZX3Q3FR7" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>RISANKIZUMAB</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="90ZX3Q3FR7" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>RISANKIZUMAB</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.13"/>
                                    <denominator unit="mL" value="2.4"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="Q40Q9N063P" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ACETIC ACID</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.48"/>
                                    <denominator unit="mL" value="2.4"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="7T1F30V5YH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSORBATE 20</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="1.8"/>
                                    <denominator unit="mL" value="2.4"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="4550K0SC9B" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM ACETATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>WATER</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="152"/>
                                    <denominator unit="mL" value="2.4"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="B8WCK70T7I" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TREHALOSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="mL" value="2.4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0074-1069-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43183" displayName="CARTRIDGE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102842" displayName="Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                              <asContent>
                                 <quantity>
                                    <numerator unit="mL" value="2.4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0074-1069-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43183" displayName="CARTRIDGE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102842" displayName="Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA761105" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" displayName="BLA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20220616"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38299" displayName="SUBCUTANEOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761105" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" displayName="BLA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220616"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" displayName="INTRAVENOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0074-5015" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Skyrizi</name>
                        <formCode code="C42946" displayName="INJECTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>risankizumab-rzaa</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="600"/>
                              <denominator unit="mL" value="10"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="90ZX3Q3FR7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>RISANKIZUMAB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="90ZX3Q3FR7" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>RISANKIZUMAB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.54"/>
                              <denominator unit="mL" value="10"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="Q40Q9N063P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ACETIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="2"/>
                              <denominator unit="mL" value="10"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7T1F30V5YH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 20</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="633.3"/>
                              <denominator unit="mL" value="10"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="B8WCK70T7I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TREHALOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="7.5"/>
                              <denominator unit="mL" value="10"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4550K0SC9B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM ACETATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" displayName="VIAL, SINGLE-DOSE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0074-5015-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220616"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" displayName="VIAL, SINGLE-DOSE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0074-5015-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220616"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761262" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" displayName="BLA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220616"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" displayName="INTRAVENOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0074-1065" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Skyrizi</name>
                        <formCode code="C47916" displayName="KIT" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Risankizumab-rzaa</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0074-1065-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102836" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20220923"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0074-1065-02" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102836" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20220923"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator unit="mL" value="1.2"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="0074-1066" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Skyrizi</name>
                              <formCode code="C42945" displayName="INJECTION, SOLUTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Risankizumab-rzaa</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="180"/>
                                    <denominator unit="mL" value="1.2"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="90ZX3Q3FR7" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>RISANKIZUMAB</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="90ZX3Q3FR7" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>RISANKIZUMAB</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.065"/>
                                    <denominator unit="mL" value="1.2"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="Q40Q9N063P" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ACETIC ACID</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.24"/>
                                    <denominator unit="mL" value="1.2"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="7T1F30V5YH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSORBATE 20</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.9"/>
                                    <denominator unit="mL" value="1.2"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="4550K0SC9B" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM ACETATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="76"/>
                                    <denominator unit="mL" value="1.2"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="B8WCK70T7I" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TREHALOSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>WATER</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="mL" value="1.2"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0074-1066-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43183" displayName="CARTRIDGE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102842" displayName="Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                              <asContent>
                                 <quantity>
                                    <numerator unit="mL" value="1.2"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0074-1066-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43183" displayName="CARTRIDGE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102842" displayName="Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA761105" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" displayName="BLA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20220616"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38299" displayName="SUBCUTANEOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761105" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" displayName="BLA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220923"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" displayName="INTRAVENOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0074-7034" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Skyrizi</name>
                        <formCode code="C47916" displayName="KIT" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Risankizumab-rzaa</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="2"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0074-7034-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20230322"/>
                                          <high value="20240621"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator unit="mL" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="0074-7032" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Skyrizi</name>
                              <formCode code="C42945" displayName="INJECTION, SOLUTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Risankizumab-rzaa</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="90"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="90ZX3Q3FR7" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>RISANKIZUMAB</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="90ZX3Q3FR7" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>RISANKIZUMAB</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.2"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="7T1F30V5YH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSORBATE 20</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.63"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="V8ZGC8ISR3" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM SUCCINATE ANHYDROUS</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="41"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="506T60A25R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SORBITOL</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.059"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="AB6MNQ6J6L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SUCCINIC ACID</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>WATER</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="mL" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0074-7032-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43203" displayName="SYRINGE, GLASS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                    <asContent>
                                       <quantity>
                                          <numerator unit="1" value="2"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="0074-7032-90" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       </containerPackagedProduct>
                                    </asContent>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102836" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA761105" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" displayName="BLA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230322"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38299" displayName="SUBCUTANEOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761105" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" displayName="BLA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20230322"/>
                              <high value="20240621"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0074-7036" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Skyrizi</name>
                        <formCode code="C47916" displayName="KIT" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Risankizumab-rzaa</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0074-7036-04" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20230322"/>
                                          <high value="20240621"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator unit="mL" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="0074-7032" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Skyrizi</name>
                              <formCode code="C42945" displayName="INJECTION, SOLUTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Risankizumab-rzaa</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="90"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="90ZX3Q3FR7" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>RISANKIZUMAB</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="90ZX3Q3FR7" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>RISANKIZUMAB</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.2"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="7T1F30V5YH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSORBATE 20</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.63"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="V8ZGC8ISR3" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM SUCCINATE ANHYDROUS</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="41"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="506T60A25R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SORBITOL</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.059"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="AB6MNQ6J6L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SUCCINIC ACID</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>WATER</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="mL" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0074-7032-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43203" displayName="SYRINGE, GLASS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102836" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA761105" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" displayName="BLA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230322"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38299" displayName="SUBCUTANEOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761105" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" displayName="BLA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20230322"/>
                              <high value="20240621"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0074-7040" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Skyrizi</name>
                        <formCode code="C47916" displayName="KIT" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Risankizumab-rzaa</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="2"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0074-7040-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240304"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator unit="mL" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="0074-7032" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Skyrizi</name>
                              <formCode code="C42945" displayName="INJECTION, SOLUTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Risankizumab-rzaa</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="90"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="90ZX3Q3FR7" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>RISANKIZUMAB</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="90ZX3Q3FR7" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>RISANKIZUMAB</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.2"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="7T1F30V5YH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSORBATE 20</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.63"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="V8ZGC8ISR3" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM SUCCINATE ANHYDROUS</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="41"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="506T60A25R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SORBITOL</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.059"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="AB6MNQ6J6L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SUCCINIC ACID</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>WATER</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="mL" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0074-7032-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43203" displayName="SYRINGE, GLASS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102836" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA761105" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" displayName="BLA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20240304"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38299" displayName="SUBCUTANEOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761105" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" displayName="BLA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240304"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0074-7042" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Skyrizi</name>
                        <formCode code="C47916" displayName="KIT" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Risankizumab-rzaa</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0074-7042-04" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240304"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator unit="mL" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="0074-7032" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Skyrizi</name>
                              <formCode code="C42945" displayName="INJECTION, SOLUTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Risankizumab-rzaa</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="90"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="90ZX3Q3FR7" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>RISANKIZUMAB</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="90ZX3Q3FR7" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>RISANKIZUMAB</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.2"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="7T1F30V5YH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSORBATE 20</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.63"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="V8ZGC8ISR3" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM SUCCINATE ANHYDROUS</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="41"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="506T60A25R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SORBITOL</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.059"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="AB6MNQ6J6L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SUCCINIC ACID</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>WATER</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="mL" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0074-7032-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43203" displayName="SYRINGE, GLASS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102836" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA761105" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" displayName="BLA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20240304"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38299" displayName="SUBCUTANEOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761105" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" displayName="BLA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240304"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="57ed8f90-21a9-4a98-ad55-85b60bfab1f1"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43683-2" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250507"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table>
                           <col width="487"/>
                           <col width="151"/>
                           <tbody>
                              <tr>
                                 <td>Indications and Usage, Ulcerative Colitis (<linkHtml href="#_1_4_Ulcerative_Colitis">1.4</linkHtml>)</td>
                                 <td align="right">6/2024</td>
                              </tr>
                              <tr>
                                 <td>Dosage and Administration, Recommended Dosage for Ulcerative Colitis (<linkHtml href="#_2_7_Recommended_Dosage">2.7</linkHtml>)</td>
                                 <td align="right">6/2024</td>
                              </tr>
                              <tr>
                                 <td>Dosage and Administration, Preparation and Administration Instructions (Crohnâs Disease and Ulcerative Colitis) (<linkHtml href="#_2_8_Preparation_and">2.8</linkHtml>)</td>
                                 <td align="right">5/2025</td>
                              </tr>
                              <tr>
                                 <td>Warnings and Precautions, Hepatotoxicity in Treatment of Inflammatory Bowel Disease (<linkHtml href="#_5_4_Hepatotoxicity_in">5.4</linkHtml>)</td>
                                 <td align="right">6/2024</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="bffe10fa-293e-4356-899e-a71053b217e6"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">1 INDICATIONS AND USAGE</content>
               </title>
               <effectiveTime value="20250507"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>SKYRIZI is an interleukin-23 antagonist indicated for the treatment of:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. (<linkHtml href="#_1_1_Plaque_Psoriasis">1.1</linkHtml>) <br/>
                           </item>
                           <item>active psoriatic arthritis in adults. (<linkHtml href="#_1_2_Psoriatic_Arthritis">1.2</linkHtml>)<br/>
                           </item>
                           <item>moderately to severely active Crohn's disease in adults. (<linkHtml href="#_1_3_Crohn_s_Disease">1.3</linkHtml>)<br/>
                           </item>
                           <item>moderately to severely active ulcerative colitis in adults. (<linkHtml href="#_1_4_Ulcerative_Colitis">1.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_1_1_Plaque_Psoriasis">
                     <id root="82f44017-4300-4fe0-b1a6-511ac255ed4f"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.1 Plaque Psoriasis</content>
                     </title>
                     <text>
                        <paragraph>SKYRIZI<sup>Â®</sup> is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. </paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
               <component>
                  <section ID="_1_2_Psoriatic_Arthritis">
                     <id root="29791f98-19d7-42ec-bbe9-697e77cb0b35"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.2 Psoriatic Arthritis</content>
                     </title>
                     <text>
                        <paragraph>SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults.</paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
               <component>
                  <section ID="_1_3_Crohn_s_Disease">
                     <id root="2fd5b2c0-dc31-4fdf-abd0-0efe664604c2"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.3 Crohnâs Disease</content>
                     </title>
                     <text>
                        <paragraph>SKYRIZI is indicated for the treatment of moderately to severely active Crohn's disease in adults.</paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
               <component>
                  <section ID="_1_4_Ulcerative_Colitis">
                     <id root="48754655-19bf-4719-9345-4423b0d12e34"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.4 Ulcerative Colitis</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">SKYRIZI is indicated for the treatment of moderately to severely active ulcerative colitis in adults.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="b12acd9e-66a5-4e46-b695-78ab320ad7e4"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">2 </content>
                  <content styleCode="bold">DOSAGE AND ADMINISTRATION</content>
               </title>
               <effectiveTime value="20250507"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list>
                           <item>For the treatment of Crohnâs disease and ulcerative colitis: Obtain liver enzymes and bilirubin levels prior to initiating treatment with SKYRIZI. (<linkHtml href="#_2_1_Procedures_Prior">2.1</linkHtml>, <linkHtml href="#_5_4_Hepatotoxicity_in">5.4</linkHtml>) <br/>
                           </item>
                           <item>Complete all age-appropriate vaccinations as recommended by current immunization guidelines (<linkHtml href="#_2_1_Procedures_Prior">2.1</linkHtml>, <linkHtml href="#_5_5_Administration_of">5.5</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Recommended Dosage</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Plaque Psoriasis and Psoriatic Arthritis:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter. (<linkHtml href="#_2_3_Recommended_Dosage">2.3</linkHtml>, <linkHtml href="#_2_4_Recommended_Dosage">2.4</linkHtml>) <br/>
                           </item>
                           <item>In patients with psoriatic arthritis SKYRIZI can be administered alone or in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs). (<linkHtml href="#_2_4_Recommended_Dosage">2.4</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="italics">Crohnâs Disease:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>The recommended induction dosage is 600 mg administered by intravenous infusion over at least one hour at Week 0, Week 4, and Week 8. The recommended maintenance dosage is 180 mg or 360 mg administered by subcutaneous injection at Week 12, and every 8 weeks thereafter. Use the lowest effective dosage to maintain therapeutic response. (<linkHtml href="#_2_6_Recommended_Dosage">2.6</linkHtml>)Â </item>
                        </list>
                        <paragraph>
                           <content styleCode="italics">Ulcerative Colitis:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>The recommended induction dosage is 1,200 mg administered by intravenous infusion over at least two hours at Week 0, Week 4, and Week 8. The recommended maintenance dosage is 180 mg or 360 mg administered by subcutaneous injection at Week 12, and every 8 weeks thereafter.  Use the lowest effective dosage to maintain therapeutic response. (<linkHtml href="#_2_7_Recommended_Dosage">2.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_2_1_Procedures_Prior">
                     <id root="21157c94-810f-463e-9b62-4d35889552c7"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.1 </content>
                        <content styleCode="bold">Procedures Prior to Treatment Initiation</content>
                     </title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>For the treatment of Crohnâs disease and ulcerative colitis, obtain liver enzymes and bilirubin levels prior to initiating treatment with SKYRIZI <content styleCode="italics">[see Warnings and Precautions (</content>
                              <content styleCode="italics">
                                 <linkHtml href="#_5_4_Hepatotoxicity_in">5.4</linkHtml>
                              </content>
                              <content styleCode="italics">)]</content>
                              <br/>
                           </item>
                           <item>Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with SKYRIZI <content styleCode="italics">[see Warnings and Precautions (</content>
                              <content styleCode="italics">
                                 <linkHtml href="#_5_3_Tuberculosis">5.3</linkHtml>
                              </content>
                              <content styleCode="italics">)]</content>.Â <br/>
                           </item>
                           <item>Complete all age-appropriate vaccinations as recommended by current immunization guidelines <content styleCode="italics">[see Warnings and Precautions (</content>
                              <content styleCode="italics">
                                 <linkHtml href="#_5_5_Administration_of">5.5</linkHtml>
                              </content>
                              <content styleCode="italics">)].</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="667fb160-fb1a-4251-801c-077f2fbd35a3"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.2 </content>
                        <content styleCode="bold">General Considerations for Administration</content>
                     </title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Visually inspect SKYRIZI for particulate matter and discoloration prior to administration. The solution may contain a few translucent to white particles.<list listType="unordered" styleCode="Circle">
                                 <item>SKYRIZI 150 mg/mL, 180 mg/1.2 mL,Â and 360 mg/2.4 mL: a colorless to yellow, and clear to slightly opalescent solution.<br/>
                                 </item>
                                 <item>SKYRIZI 90Â mg/mL and 600 mg/10 mL: a colorless to slightly yellow, and clear to slightly opalescent solution.<br/>
                                 </item>
                                 <item>Do not use if the solution contains large particles or is cloudy or discolored.</item>
                              </list>
                              <br/>
                           </item>
                           <item>Discard after use. Do not reuse.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_3_Recommended_Dosage">
                     <id root="354e7f42-aec5-4b56-8e71-94b0b57ac0ae"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.</content>
                        <content styleCode="bold">3</content>
                        <content styleCode="bold">Â </content>
                        <content styleCode="bold">Recommended Dosage for Plaque Psoriasis</content>
                        <content styleCode="bold">Â </content>
                     </title>
                     <text>
                        <paragraph>The recommended dosage is 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.</paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_4_Recommended_Dosage">
                     <id root="9cbc7513-7ca6-4994-bb69-f88f26a404c1"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.</content>
                        <content styleCode="bold">4</content>
                        <content styleCode="bold">Â </content>
                        <content styleCode="bold">Recommended Dosage for Psoriatic Arthritis</content>
                        <content styleCode="bold">Â </content>
                     </title>
                     <text>
                        <paragraph>The recommended dosage is 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.</paragraph>
                        <paragraph>SKYRIZI may be administered alone or in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs).</paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="528515d5-d492-42cd-bf7d-65b762648a48"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.</content>
                        <content styleCode="bold">5</content>
                        <content styleCode="bold">Â </content>
                        <content styleCode="bold">Preparation and Administration Instruction</content>
                        <content styleCode="bold">s</content>
                        <content styleCode="bold"> (Plaque Psoriasis and Psoriatic Arthritis)</content>
                     </title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Administer SKYRIZI 150 mg/mL prefilled pen or prefilled syringe subcutaneously.<br/>
                           </item>
                           <item>Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of SKYRIZI.<br/>
                           </item>
                           <item>Before injecting, remove the carton with SKYRIZI from the refrigerator and without removing the prefilled pen or prefilled syringe from the carton, allow SKYRIZI to reach room temperature out of direct sunlight (30 to 90 minutes for the prefilled pen and 15 to 30 minutes for the prefilled syringe).<br/>
                           </item>
                           <item>Do not inject into areas where the skin is tender, bruised, erythematous, indurated or affected by psoriasis. Administration of SKYRIZI in the upper, outer arm may only be performed by a healthcare professional or caregiver.<br/>
                           </item>
                           <item>If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.</item>
                        </list>
                        <paragraph>The SKYRIZI âInstructions for Useâ contains more detailed instructions on the preparation and administration of SKYRIZI <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#InstructionsforUse">Instructions for Use</linkHtml>
                           </content>
                           <content styleCode="italics">].</content> Instruct the patient to read the Instructions for Use before administration.</paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_6_Recommended_Dosage">
                     <id root="17b8f047-a5ac-49b6-aac3-61efbeafc678"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.6 Recommended Dosage for Crohnâs Disease</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Adult Patients: Induction</content>
                        </paragraph>
                        <paragraph>The recommended induction dosage of SKYRIZI is 600 mg administered by intravenous infusion over a period of at least one hour at Week 0, Week 4, and Week 8.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Adult Patients: Maintenance</content>
                        </paragraph>
                        <paragraph>The recommended maintenance dosage of SKYRIZI is 180 mg or 360 mg administered by subcutaneous injection at Week 12, and every 8 weeks thereafter. Use the lowest effective dosage needed to maintain therapeutic response.</paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_7_Recommended_Dosage">
                     <id root="1912dd29-319f-427c-aa43-29cb6957bee8"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.7 </content>
                        <content styleCode="bold">Recommended Dosage for Ulcerative Colitis</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="underline">Adult Patients: Induction</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">The recommended induction dosage of SKYRIZI is 1,200 mg administered by intravenous infusion over a period of at least two hours at Week 0, Week 4, and Week 8. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="underline">Adult Patients: Maintenance</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">The recommended maintenance dosage of SKYRIZI is 180 mg or 360 mg administered by subcutaneous injection at Week 12, and every 8 weeks thereafter. Use the lowest effective dosage needed to maintain therapeutic response.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_8_Preparation_and">
                     <id root="7e475291-1d1c-4a2a-9a57-71f789e3ad22"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.8 Preparation and Administration Instructions (Crohnâs Disease and Ulcerative Colitis)</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="underline">Intravenous Induction Dosing Regimen:</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">1. SKYRIZI vial for intravenous administration is intended for administration by a healthcare provider using aseptic technique. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">2. Prior to intravenous administration, determine the dose and number of SKYRIZI vials needed based on the patientâs indication (see table below).  WithdrawÂ 10 mL of SKYRIZI solution from a vial (600 mg/10 mL) and inject into an intravenous infusion bag or glass bottle containing 5% Dextrose Injection or 0.9% Sodium Chloride Injection (see <linkHtml href="#Table1">Table 1</linkHtml> below) for a final concentration of approximately 1.2 mg/mL to 6 mg/mL. Discard any remaining solution in the vial.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>
                        </paragraph>
                        <table ID="Table1">
                           <caption>Table 1. Total Volume of Diluent Required for Intravenous Induction Dose</caption>
                           <col width="84"/>
                           <col width="142"/>
                           <col width="185"/>
                           <col width="185"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <br/>
                                    <content styleCode="bold">Indication</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">I</content>
                                    <content styleCode="bold">ntravenous</content>
                                    <content styleCode="bold"> Induction Dose</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Number of SKYRIZI 600 mg/10 mL Vials</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Total Volume of 5% Dextrose </content>
                                    <content styleCode="bold">or </content>
                                    <br/>
                                    <content styleCode="bold">0.9% Sodium Chloride</content>
                                    <content styleCode="bold"> Injection</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">Crohnâs disease</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">600 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">100 mL, or 250 mL, or 500 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">Ulcerative colitis</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1,200 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">250 mL, or 500 mLÂ </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="xmChange">3. Infuse the diluted solution intravenously over a period of at least one hour for the SKYRIZI 600Â mg dose; at least two hours for the SKYRIZI 1,200 mg dose. If stored refrigerated, allow the diluted SKYRIZI solution in the infusion bag or glass bottle to warm to room temperature prior to the start of the intravenous infusion.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">4. Do not administer SKYRIZI diluted solution concomitantly in the same intravenous line with other medicinal products.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Handling and </content>
                           <content styleCode="underline">Storage of </content>
                           <content styleCode="underline">the Vial and the </content>
                           <content styleCode="underline">Diluted Solution: </content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Do not shake the vial or diluted solution in the infusion bag or glass bottle.<br/>
                           </item>
                           <item>Use the prepared infusion immediately. If not used immediately, store the diluted SKYRIZI solution refrigerated and protected from light for up to 20 hours between 36Â°F to 46Â°F (2Â°C to 8Â°C). <br/>
                           </item>
                           <item>Immediately after preparation or removal from refrigeration, the diluted SKYRIZI solution can be stored at room temperature at up to 77Â°F (25Â°C) (protected from sunlight) for up to 8 hours. Storage time at room temperature begins once the diluted solution has been prepared. The infusion should be completed within 8 hours after dilution in the infusion bag.<br/>
                           </item>
                           <item>Exposure to indoor light is acceptable during room temperature storage and administration.<br/>
                           </item>
                           <item>Do not freeze.</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Subcutaneous Maintenance Dosing Regimen: </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Using the single-dose 180 mg or 360 mg prefilled cartridge with On-Body Injector: </content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>SKYRIZI is intended for use under the guidance and supervision of a healthcare professional.  <br/>
                           </item>
                           <item>Patients may self-inject SKYRIZI using the on-body injector with prefilled cartridge after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of SKYRIZI. <br/>
                           </item>
                           <item>Before using the on-body injector with prefilled cartridge, remove the carton from the refrigerator and allow to reach room temperature out of direct sunlight (45 to 90 minutes) without removing the prefilled cartridge or on-body injector from the carton.<br/>
                           </item>
                           <item>Use the on-body injector to administer SKYRIZI 180 mg/1.2 mL or SKYRIZI 360 mg/2.4 mL prefilled cartridge subcutaneously on thigh or abdomen.<br/>
                           </item>
                           <item>Start the injection within 5 minutes after inserting the prefilled cartridge into the On-Body Injector. <br/>
                           </item>
                           <item>Do not inject into areas where the skin is tender, bruised, erythematous, indurated or affected by any lesions. <br/>
                           </item>
                           <item>If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.</item>
                        </list>
                        <paragraph>The SKYRIZI âInstructions for Useâ contains more detailed instructions on the preparation and administration of SKYRIZI <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#InstructionsforUse">Instructions for Use</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>. Instruct the patient to read the Instructions for Use before administration.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Using the 90 mg/mL prefilled syringe:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Administer each SKYRIZI 90 mg/mL prefilled syringe subcutaneously.<br/>
                           </item>
                           <item>Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of SKYRIZI.<br/>
                           </item>
                           <item>Before injecting, remove the carton from the refrigerator and without removing the prefilled syringes from the carton, allow SKYRIZI to reach room temperature out of direct sunlight (15 to 30 minutes).<br/>
                           </item>
                           <item>Use the 90 mg/mL prefilled syringes to administer SKYRIZI 180 mg or SKYRIZI 360 mg subcutaneously as follows: <br/>â¦ When using SKYRIZI 90 mg/mL prefilled syringes, for a 180 mg maintenance dose, two 90 mg prefilled syringes are required. Inject one prefilled syringe after the other in different anatomic locations (such as thighs or abdomen). <br/>â¦ When using SKYRIZI 90 mg/mL prefilled syringes, for a 360 mg maintenance dose, four 90 mg prefilled syringes are required. Inject one prefilled syringe after the other in different anatomic locations (such as thighs or abdomen). <br/>
                           </item>
                           <item>Do not inject into areas where the skin is tender, bruised, erythematous, indurated or affected by any lesions. Administration of SKYRIZI in the upper, outer arm may only be performed by a healthcare professional or caregiver.<br/>
                           </item>
                           <item>If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.</item>
                        </list>
                        <paragraph>The SKYRIZI âInstructions for Useâ contains more detailed instructions on the preparation and administration of SKYRIZI <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#IFU_2x90">Instructions for Use</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>. Instruct the patient to read the Instructions for Use before administration.</paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_3_DOSAGE_FORMS">
               <id root="84edade7-0109-43a5-bc73-bdfa0ca343a1"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>
                  <content styleCode="bold">3 DOSAGE FORMS AND STRENGTHS</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Subcutaneous Injection</content>
                  </paragraph>
                  <paragraph>SKYRIZI Pen</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Injection: 150 mg/mLÂ as a colorless to yellow and clear to slightly opalescent solution in each single-dose prefilled pen.</item>
                  </list>
                  <paragraph>SKYRIZI Prefilled Syringe</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Injection: 90 mg/mL as a colorless to slightly yellow and clear to slightly opalescent solution in each single-dose prefilled syringe.<br/>
                     </item>
                     <item>Injection: 150 mg/mL as a colorless to yellow and clear to slightly opalescent solution in each single-dose prefilled syringe. </item>
                  </list>
                  <paragraph>SKYRIZI Prefilled CartridgeÂ with Supplied On-Body Injector</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Injection: 180 mg/1.2 mL (150 mg/mL) as a colorless to yellow, and clear to slightly opalescent solution in each single-dose prefilled cartridge for use with the on-body injector.<br/>
                     </item>
                     <item>Injection: 360 mg/2.4 mL (150 mg/mL) as a colorless to yellow, and clear to slightly opalescent solution in each single-dose prefilled cartridge for use with the on-body injector.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Intravenous</content>
                     <content styleCode="underline">Â </content>
                     <content styleCode="underline">Infusion</content>
                  </paragraph>
                  <paragraph>Â SKYRIZI Vial</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Injection: 600 mg/10 mL (60 mg/mL) as a colorless to slightly yellow, and clear to slightly opalescent solution in each single-dose vial.</item>
                  </list>
               </text>
               <effectiveTime value="20250507"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Subcutaneous injection</content> (<linkHtml href="#_3_DOSAGE_FORMS">3</linkHtml>)</paragraph>
                        <list>
                           <item>Injection: 150 mg/mL in each single-dose prefilled pen. <br/>
                           </item>
                           <item>Injection: 90 mg/mL in each single-dose prefilled syringe.<br/>
                           </item>
                           <item>Injection: 150 mg/mL in each single-dose prefilled syringe.<br/>
                           </item>
                           <item>Injection: 180 mg/1.2 mL (150 mg/mL) in each single-dose prefilled cartridge.<br/>
                           </item>
                           <item>Injection: 360 mg/2.4 mL (150 mg/mL) in each single-dose prefilled cartridge.</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Intravenous infusion</content> (<linkHtml href="#_3_DOSAGE_FORMS">3</linkHtml>)</paragraph>
                        <list>
                           <item>Injection: 600 mg/10 mL (60 mg/mL) in each single-dose vial.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_4_CONTRAINDICATIONS">
               <id root="ca6f0bc2-c29b-496f-9ca3-2efe7137d94d"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34070-3" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">4 CONTRAINDICATIONS</content>
               </title>
               <text>
                  <paragraph>SKYRIZI is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of the excipients <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_1_Hypersensitivity_Reactions">5.1</linkHtml>
                     </content>
                     <content styleCode="italics">)].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250507"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list>
                           <item>Â SKYRIZI is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of the excipientsÂ (<linkHtml href="#_4_CONTRAINDICATIONS">4</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="3f48e8e7-a984-4123-b4de-59e197e60dbc"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">5 WARNINGS AND PRECAUTIONS</content>
               </title>
               <effectiveTime value="20250507"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list>
                           <item>Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylaxis, may occur. (<linkHtml href="#_5_1_Hypersensitivity_Reactions">5.1</linkHtml>)<br/>
                           </item>
                           <item>Infections: SKYRIZI may increase the risk of infection. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If such an infection develops, do not administer SKYRIZI until the infection resolves. (<linkHtml href="#_5_2_Infections">5.2</linkHtml>) <br/>
                           </item>
                           <item>Tuberculosis (TB): Evaluate for TB prior to initiating treatment with SKYRIZI. (<linkHtml href="#_5_3_Tuberculosis">5.3</linkHtml>) <br/>
                           </item>
                           <item>Hepatotoxicity in Treatment of Inflammatory Bowel Disease: Drug-induced liver injury during induction has been reported. Monitor liver enzymes and bilirubin levelsÂ at baseline and, during induction, up to at least 12 weeks of treatment. Monitor thereafter according to routine patient management. (<linkHtml href="#_5_4_Hepatotoxicity_in">5.4</linkHtml>)<br/>
                           </item>
                           <item>Administration of Vaccines: Avoid use of live vaccines. (<linkHtml href="#_5_5_Administration_of">5.5</linkHtml>)Â </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_5_1_Hypersensitivity_Reactions">
                     <id root="0d2daced-7d42-4269-b029-36c65a8f246c"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.1 Hypersensitivity Reactions</content>
                     </title>
                     <text>
                        <paragraph>Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of SKYRIZI. If a serious hypersensitivity reaction occurs, discontinue SKYRIZI and initiate appropriate therapy immediately <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_6_1_Clinical_Trials">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>Â </paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_2_Infections">
                     <id root="79e9b4c8-5b1f-4331-a313-ab5a4b55cdde"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.</content>
                        <content styleCode="bold">2</content>
                        <content styleCode="bold"> Infections</content>
                     </title>
                     <text>
                        <paragraph>SKYRIZI may increase the risk of infections <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_6_1_Clinical_Trials">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. </paragraph>
                        <paragraph>Treatment with SKYRIZI should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.Â </paragraph>
                        <paragraph>In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, monitor the patient closely and do not administer SKYRIZI until the infection resolves. </paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_3_Tuberculosis">
                     <id root="2d8a2fc8-8312-4768-a262-2d41cf485603"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.</content>
                        <content styleCode="bold">3</content>
                        <content styleCode="bold"> Tuberculosis</content>
                     </title>
                     <text>
                        <paragraph>Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with SKYRIZI. Across the Phase 3 psoriasis clinical studies, of the 72 subjects with latent TB who were concurrently treated with SKYRIZI and appropriate TB prophylaxis during the studies, none developed active TB during the mean follow-up of 61 weeks on SKYRIZI. Two subjects taking isoniazid for treatment of latent TB discontinued treatment due to liver injury. Of the 31 subjects from the PsO-3 study with latent TB who did not receive prophylaxis during the study, none developed active TB during the mean follow-up of 55 weeks on SKYRIZI. Consider anti-TB therapy prior to initiating SKYRIZI in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB. </paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_4_Hepatotoxicity_in">
                     <id root="34c625fa-798f-47ec-9966-4e9b2a1ed93f"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.</content>
                        <content styleCode="bold">4</content>
                        <content styleCode="bold">Â </content>
                        <content styleCode="bold">Hepatotoxicity in Treatment of </content>
                        <content styleCode="bold">Inflammatory Bowel </content>
                        <content styleCode="bold">Disease</content>
                        <content styleCode="bold">Â </content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">A serious adverse reaction of drug-induced liver injury in conjunction with a rash that required hospitalization was reported in a patient with Crohnâs disease (ALT 54x ULN, AST 30x ULN, and total bilirubin 2.2x ULN) following two 600 mg intravenous doses of SKYRIZI. The liver test abnormalities resolved following administration of steroids. SKYRIZI was subsequently discontinued.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">For the treatment of Crohnâs disease and ulcerative colitis, evaluate liver enzymes and bilirubin at baseline, and during induction at least up to 12 weeks of treatment. Monitor thereafter according to routine patient management.</content>
                        </paragraph>
                        <paragraph>Consider other treatment options in patients with evidence of liver cirrhosis. Prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury. Interrupt treatment if drug-induced liver injury is suspected, until this diagnosis is excluded. Instruct patients to seek immediate medical attention if they experience symptoms suggestive of hepatic dysfunction.Â </paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_5_Administration_of">
                     <id root="022cce45-3ebf-4660-9744-55bf49c4a604"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.5 Administration of Vaccines</content>
                     </title>
                     <text>
                        <paragraph>Avoid use of live vaccines in patients treated with SKYRIZI. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating therapy with SKYRIZI, complete all age-appropriate vaccinations according to current immunization guidelines. No data are available on the response to live or inactive vaccines.</paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="37ab4ced-2d47-483c-b87c-c6f2eea47d57"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34084-4" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">6 ADVERSE REACTIONS</content>
               </title>
               <text>
                  <paragraph>The following adverse reactions are discussed in other sections of labeling: </paragraph>
                  <list>
                     <item>Hypersensitivity Reactions <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_1_Hypersensitivity_Reactions">5.1</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                        <br/>
                     </item>
                     <item>Infections <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_2_Infections">5.2</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                        <br/>
                     </item>
                     <item>Tuberculosis <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_3_Tuberculosis">5.3</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                        <br/>
                     </item>
                     <item>Hepatotoxicity in Treatment of Inflammatory BowelÂ Disease <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_4_Hepatotoxicity_in">5.4</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250507"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions are:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Plaque Psoriasis</content>
                              <content styleCode="underline"> and Psoriatic Arthritis</content> (â¥ 1%): upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections. (<linkHtml href="#_6_1_Clinical_Trials">6.1</linkHtml>)<br/>
                           </item>
                           <item>
                              <content styleCode="underline">Crohnâs Disease</content> (&gt;3%): <br/>
                              <content styleCode="italics">â¦ </content>
                              <content styleCode="italics">Induction</content>: upper respiratory infections, headache, and arthralgia. (<linkHtml href="#_6_1_Clinical_Trials">6.1</linkHtml>)<br/>
                              <content styleCode="italics">â¦ </content>
                              <content styleCode="italics">Maintenance</content>: arthralgia, abdominal pain, injection site reactions, anemia, pyrexia, back pain, arthropathy, and urinary tract infection.Â (<linkHtml href="#_6_1_Clinical_Trials">6.1</linkHtml>)<br/>
                           </item>
                           <item>
                              <content styleCode="underline">Ulcerative Colitis</content>
                              <content styleCode="underline">Â </content>(â¥3%):Â <br/>
                              <content styleCode="italics">â¦ </content>
                              <content styleCode="italics">Induction</content>: arthralgia. (<linkHtml href="#_6_1_Clinical_Trials">6.1</linkHtml>)<br/>
                              <content styleCode="italics">â¦ </content>
                              <content styleCode="italics">Maintenance</content>: arthralgia, pyrexia, injection site reactions, and rash. (<linkHtml href="#_6_1_Clinical_Trials">6.1</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">
                              <br/>
                              <br/>To report SUSPECTED ADVERSE REACTIONS, contact AbbVie Inc. at 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_6_1_Clinical_Trials">
                     <id root="5c231a34-ac51-4f46-828a-1b68201985c6"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="90374-0" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.1 Clinical Trials Experience</content>
                     </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse drug reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Plaque Psoriasis</content>
                        </paragraph>
                        <paragraph>A total of 2234 subjects were treated with SKYRIZI in clinical development trials in plaque psoriasis. Of these, 1208 subjects with psoriasis were exposed to SKYRIZI for at least one year. </paragraph>
                        <paragraph>Data from placebo- and active-controlled trials were pooled to evaluate the safety of SKYRIZI for up to 16 weeks. In total, 1306 subjects were evaluated in the SKYRIZI 150 mg group. </paragraph>
                        <paragraph>Table 2 summarizes the adverse drug reactions that occurred at a rate of at least 1% and at a higher rate in the SKYRIZI group than the placebo group during the 16-week controlled period of pooled clinical trials. </paragraph>
                        <table>
                           <caption>Table 2. Adverse Drug Reactions Occurring in â¥ 1% of Subjects with Plaque Psoriasis on SKYRIZI through Week 16</caption>
                           <col width="313"/>
                           <col width="157"/>
                           <col width="157"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Adverse Drug Reactions</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">SKYRIZI</content>
                                    <content styleCode="bold">
                                       <br/>N = 1306</content>
                                    <content styleCode="bold">
                                       <br/>n (%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Placebo</content>
                                    <content styleCode="bold">
                                       <br/>N = 300</content>
                                    <content styleCode="bold">
                                       <br/>n (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Upper respiratory infections<sup>a</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">170 (13.0)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">29 (9.7)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Headache<sup>b</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">46 (3.5)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6 (2.0) </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Fatigue<sup>c</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">33 (2.5)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3 (1.0)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Injection site reactions<sup>d</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">19 (1.5)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3 (1.0)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Tinea infections<sup>e</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">15 (1.1)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1 (0.3)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <sup>a</sup> Includes: respiratory tract infection (viral, bacterial or unspecified), sinusitis (including acute), rhinitis, nasopharyngitis, pharyngitis (including viral), tonsillitis<br/>
                                    <sup>b</sup> Includes: headache, tension headache, sinus headache, cervicogenic headache <br/>
                                    <sup>c</sup> Includes: fatigue, asthenia<br/>
                                    <sup>d</sup> Includes: injection site bruising, erythema, extravasation, hematoma, hemorrhage, infection, inflammation, irritation, pain, pruritus, reaction, swelling, warmth<br/>
                                    <sup>e</sup> Includes: tinea pedis, tinea cruris, body tinea, tinea versicolor, tinea manuum, tinea infection, onychomycosis </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Adverse drug reactions that occurred in &lt; 1% but &gt; 0.1% of subjects in the SKYRIZI group and at a higher rate than in the placebo group through Week 16 were folliculitis and urticaria. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Adverse Drug Reactions</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Infections</content>
                        </paragraph>
                        <paragraph>In the first 16 weeks, infections occurred in 22.1% of the SKYRIZI group (90.8 events per 100 subject-years) compared with 14.7% of the placebo group (56.5 events per 100 subject-years) and did not lead to discontinuation of SKYRIZI. The rates of serious infections for the SKYRIZI group and the placebo group were â¤0.4%. Serious infections in the SKYRIZI group included cellulitis, osteomyelitis, sepsis, and herpes zoster. In Studies PsO-1 and PsO-2, through Week 52, the rate of infections (73.9 events per 100 subject-years) was similar to the rate observed during the first 16 weeks of treatment. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Safety </content>
                           <content styleCode="underline">T</content>
                           <content styleCode="underline">hrough Week 52</content>
                        </paragraph>
                        <paragraph>Through Week 52, no new adverse reactions were identified, and the rates of the adverse reactions were similar to those observed during the first 16 weeks of treatment. During this period, serious infections that led to study discontinuation included pneumonia. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Psoriatic Arthritis</content>
                        </paragraph>
                        <paragraph>The overall safety profile observed in subjects with psoriatic arthritis treated with SKYRIZI is generally consistent with the safety profile in subjects with plaque psoriasis. Additionally, in the Phase 3 placebo-controlled trials the incidence of hepatic events was higher in the SKYRIZI group (5.4%, 16.7 events per 100 patient years) compared to the placebo group (3.9%, 12.6 events per 100 patient years). Of these, the most common events that were reported more frequently in both the placebo group and the SKYRIZI group were ALT increased (placebo: n=12 (1.7%); SKYRIZI: n=16 (2.3%)), AST increased (placebo: n=9 (1.3%); SKYRIZI: n=13 (1.8%)), and GGT increased (placebo: n=5 (0.7%); SKYRIZI: n=8 (1.1%)). There were no serious hepatic events reported. The incidence of hypersensitivity reactions was higher in the SKYRIZI group (n=16, 2.3%) compared to the placebo group (n=9, 1.3%). In the Phase 3 placebo-controlled trials, hypersensitivity reactions reported at a higher rate in the SKYRIZI group included rash (placebo: n=4 (0.6%); SKYRIZI: n=5 (0.7%), allergic rhinitis (placebo: n=1 (0.1%); SKYRIZI: n=2 (0.3%), and facial swelling (placebo: n=0 (0.0%); SKYRIZI n=1 (0.1%). One case of anaphylaxis was reported in a subject who received SKYRIZI in the Phase 2 clinical trial.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Crohnâs Disease </content>
                        </paragraph>
                        <paragraph>SKYRIZI was studied up to 12 weeks in subjects with moderately to severely active Crohnâs disease in two randomized, double-blind, placebo-controlled induction studies (CD-1, CD-2) and a randomized, double-blind, placebo-controlled, dose-finding study (CD-4; NCT02031276). Long-term safety up to 52 weeks was evaluated in subjects who responded to induction therapy in a randomized, double-blind, placebo-controlled maintenance study (CD-3) <content styleCode="italics">[see Clinical Studies (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_14_3_Crohn_s_Disease">14.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. </paragraph>
                        <paragraph>In the two induction studies (CD-1, CD-2) and the dose finding study (CD-4), 620 subjects received the SKYRIZI intravenous induction regimen at Weeks 0, 4 and 8. In the maintenance study (CD-3), 297 subjects who achieved clinical response, defined as a reduction in CDAI of at least 100 points from baseline after 12 weeks of induction treatment with intravenous SKYRIZI in studies CD-1 and CD-2, received a maintenance regimen of SKYRIZI either 180 mg or 360 mg subcutaneously at Week 12 and every 8 weeks thereafter for up to an additional 52 weeks.</paragraph>
                        <paragraph>Adverse reactions reported in &gt; 3% of subjects in induction studiesÂ and at a higher rate than placebo are shown in Table 3.</paragraph>
                        <table>
                           <caption>Table 3. Adverse Drug Reactions Reported in &gt; 3% of Subjects with Crohnâs Disease Treated with SKYRIZI in Placebo-Controlled 12-Week Induction Studies (CD-1, CD-2, and CD-4)</caption>
                           <col width="313"/>
                           <col width="157"/>
                           <col width="157"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Adverse Drug Reactions</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">SKYRIZI</content>
                                    <br/>
                                    <content styleCode="bold">600 mg Intravenous Infusion</content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                    <content styleCode="bold">
                                       <br/>N = 620</content>
                                    <content styleCode="bold">
                                       <br/>n (%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Placebo</content>
                                    <content styleCode="bold">
                                       <br/>N = 432</content>
                                    <content styleCode="bold">
                                       <br/>n (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Upper respiratory infections<sup>b</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">  66 (10.6)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">40 (9.3)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Headache<sup>c</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">41 (6.6) </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">24 (5.6)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Arthralgia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">31 (5.0)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">19 (4.4)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <sup>a</sup>Â SKYRIZI 600 mg as an intravenous infusion at Week 0, Week 4, and Week 8.<br/>
                                    <sup>b</sup> Includes: influenza like illness, nasopharyngitis, influenza, pharyngitis, upper respiratory tract infection, viral upper respiratory tract infection, COVID-19, nasal congestion, respiratory tract infection viral, viral pharyngitis, tonsillitis, upper respiratory tract inflammation<br/>
                                    <sup>c</sup> Includes: headache, tension headache</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Adverse reactions reported in &gt;3% of subjects in the maintenance study and at a higher rate than placebo are shown in Table 4.</paragraph>
                        <table>
                           <caption>Table 4. Adverse Reactions Reported in &gt;3% of Subjects with Crohnâs Disease Treated with SKYRIZI<sup>a</sup> in Placebo-Controlled 52-Week Maintenance Study (CD-3) </caption>
                           <col width="200"/>
                           <col width="142"/>
                           <col width="142"/>
                           <col width="142"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Adverse Drug Reactions</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">SKYRIZI</content>
                                    <br/>
                                    <content styleCode="bold">180 mg Subcutaneous Injection</content>
                                    <content styleCode="bold">
                                       <br/>N = 155</content>
                                    <content styleCode="bold">
                                       <br/>n (%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">SKYRIZI</content>
                                    <br/>
                                    <content styleCode="bold">360 mg Subcutaneous Injection</content>
                                    <content styleCode="bold">
                                       <br/>N = 142</content>
                                    <content styleCode="bold">
                                       <br/>n (%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Placebo</content>
                                    <content styleCode="bold">
                                       <br/>N = 143</content>
                                    <content styleCode="bold">
                                       <br/>n (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Arthralgia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13 (8.4)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13 (9.2)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12 (8.4)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Abdominal pain<sup>b</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">9 (5.8)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12 (8.5)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6 (4.2)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Injection site reactions<sup>c,d</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7 (4.5)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8 (5.6)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4 (2.8) </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Anemia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7 (4.5)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7 (4.9)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6 (4.2)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Pyrexia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4 (2.6)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7 (4.9)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4 (2.8)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Back pain </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3 (1.9)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6 (4.2)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3 (2.1)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Arthropathy</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1 (0.6)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5 (3.5)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2 (1.4)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Urinary tract infection</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1 (0.6)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5 (3.5)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4 (2.8)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">
                                    <sup>a</sup> SKYRIZI 180 mg or 360 mg at Week 12 and every 8 weeks thereafter for up to an additional 52 weeks<br/>
                                    <sup>b</sup>
                                    <sup>Â </sup>Includes: abdominal pain, abdominal pain upper, abdominal pain lower<br/>
                                    <sup>c</sup>Â Includes: injection site rash, injection site erythema, injection site swelling, injection site urticaria, injection site warmth, injection site pain, injection site hypersensitivity, injection site reaction<br/>
                                    <sup>d</sup>Â Some subjects had multiple occurrences of injection site reactions. In this table, injection site reactions are counted only once per subject for the rate calculations.<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Specific Adverse Drug Reactions</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Infections</content>
                        </paragraph>
                        <paragraph>In the maintenance study (CD-3) through Week 52, the rate of infections was 32.3% (50.2 events per 100 subject-years) in subjects who received SKYRIZI 180 mg and 36.6% (60.8 events per 100 subject-years) in subjects who received SKYRIZI 360 mg compared to 36.4% (60.3 events per 100 subject-years) in subjects who received placebo after SKYRIZI induction. The rate of serious infections was 2.6% (2.7 events per 100 subject-years) in subjects who received SKYRIZI 180 mg and 5.6% (7.4 events per 100 subject-years) in subjects who received SKYRIZI 360 mg compared to 2.1% (2.4 events per 100 subject-years) in subjects who received placebo after SKYRIZI induction.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Lipid Elevations</content>
                        </paragraph>
                        <paragraph>Elevations in lipid parameters (total cholesterol and low-density lipoprotein cholesterol [LDL-C]) were first assessed at 4 weeks following initiation of SKYRIZI in the induction trials (CD-1, CD-2). Increases from baseline and increases relative to placebo were observed at Week 4 and remained stable to Week 12. Following SKYRIZI induction, mean total cholesterolÂ increased by 9.4 mg/dL from baseline to a mean absolute value of 175.1 mg/dL at Week 12.Â Similarly, mean LDL-C increased by 6.6 mg/dLÂ from baseline to a mean absolute value of 92.6 mg/dL at Week 12.Â Mean LDL-C increased by 3.1 mg/dL from baseline to a mean absolute value of 99.0 mg/dL at Week 52 with SKYRIZI 180 mg maintenance treatment and by 2.3 mg/dL from baseline to a mean  absolute value of 102.2 mg/dL at Week 52 with SKYRIZI 360 mg maintenance treatment (CD-3).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Ulcerative Colitis</content>
                           <content styleCode="underline">Â </content>
                        </paragraph>
                        <paragraph>SKYRIZI was studied up to 12 weeks in subjects with moderately to severely active ulcerative colitis in a randomized, double-blind, placebo-controlled induction study (UC-1) and a randomized, double-blind, placebo-controlled, dose-finding study (UC-3). Long-term safety up to 52 weeks was evaluated in subjects who responded to induction therapy in a randomized, double-blind, placebo-controlled maintenance study (UC-2) <content styleCode="italics">[see Clinical </content>
                           <content styleCode="italics">Studies (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_14_4_Ulcerative_Colitis">14.4</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>Â </paragraph>
                        <paragraph>In the induction studies (UC-1 and UC-3), 712 subjects received the SKYRIZI 1,200 mg intravenous induction regimen at Weeks 0, 4 and 8. In the maintenance study (UC-2), 347 subjects who achieved clinical response, defined as  a decrease in mMS of â¥2 points and â¥30% from baseline and a decrease in RBS â¥1 from baseline or an absolute RBS â¤1, received a maintenance regimen of SKYRIZI either 180 mg or 360 mg subcutaneously at Week 12 and every 8 weeks thereafter for up to an additional 52 weeks.</paragraph>
                        <paragraph>The adverse reaction reported in â¥3%Â subjects treated with SKYRIZI in the ulcerative colitis induction studies (UC-1 and UC-3) and at a higher rate than placebo was arthralgia (3% SKYRIZI vs 1% placebo). </paragraph>
                        <paragraph>Adverse reactions reported in â¥3% of subjects treated with SKYRIZI in the maintenance study (UC-2) and at a higher rate than placebo are shown in Table 5.</paragraph>
                        <table>
                           <caption>Table 5. Adverse Reactions Reported in â¥3% of Subjects with Ulcerative Colitis Treated with SKYRIZI<sup>a</sup> in Placebo-Controlled 52-Week Maintenance Study (UC-2) </caption>
                           <col width="183"/>
                           <col width="167"/>
                           <col width="163"/>
                           <col width="114"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Adverse Drug Reactions</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">SKYRIZI</content>
                                    <br/>
                                    <content styleCode="bold">180 mg Subcutaneous Injection</content>
                                    <content styleCode="bold">
                                       <br/>N = 170</content>
                                    <content styleCode="bold">
                                       <br/>n (%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">SKYRIZI</content>
                                    <br/>
                                    <content styleCode="bold">360 mg Subcutaneous Injection</content>
                                    <content styleCode="bold">
                                       <br/>N = 177</content>
                                    <content styleCode="bold">
                                       <br/>n (%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Placebo</content>
                                    <content styleCode="bold">
                                       <br/>N = 173</content>
                                    <content styleCode="bold">
                                       <br/>n (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Arthralgia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">9 (5.3)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">17 (9.6)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8 (4.6)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Pyrexia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8 (4.7)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7 (4.0)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6 (3.5)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Injection site reactions<sup>b,c</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5 (2.9)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">  5 (2.8)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"> 2 (1.2)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Rash<sup>d</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7 (4.1)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">Â 1 (0.6)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">Â Â 3 (1.7)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">
                                    <sup>a</sup> SKYRIZI 180 mg or 360 mg at Week 12 and every 8 weeks thereafter for up to an additional 52 weeks<br/>
                                    <sup>b </sup>Includes: application site pain, injection site erythema, injection site pain, injection site pruritus, injection site reaction<br/>
                                    <sup>c</sup>
                                    <sup>Â </sup>Some subjects had multiple occurrences of injection site reactions. In this table, injection site reactions are counted only once per subject for the rate calculations.<br/>
                                    <sup>d</sup>Â Includes:<sup>Â </sup>rashÂ and rash macular</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Specific Adverse Drug Reactions</content>
                        </paragraph>
                        <paragraph>The rates of infections, serious infections, and lipid elevations in subjects with UC who received SKYRIZI compared to subjects who received placebo in the induction studies (UC-1 and UC-3) and maintenance study (UC-2) were similar to the rates in subjects with CD who received SKYRIZI compared to subjects who received placebo in the induction studies (CD-1, CD-2, and CD-4) and maintenance study (CD-3). </paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="0f471be9-3ee0-4540-bb72-d1ee0c3bdc6b"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="88830-5" displayName="IMMUNOGENICITY"/>
                     <title>
                        <content styleCode="bold">6.2 Immunogenicity</content>
                     </title>
                     <text>
                        <paragraph>As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other products, including other risankizumab products, may be misleading. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Plaque Psoriasis</content>
                        </paragraph>
                        <paragraph>By Week 52, approximately 24% (263/1079) of subjects treated with SKYRIZI at the recommended dose developed antibodies to risankizumab-rzaa. Of the subjects who developed antibodies to risankizumab-rzaa, approximately 57% (14% of all subjects treated with SKYRIZI) had antibodies that were classified as neutralizing. Higher antibody titers in approximately 1% of subjects treated with SKYRIZI were associated with lower risankizumab-rzaa concentrations and reduced clinical response. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Psoriatic Arthritis</content>
                        </paragraph>
                        <paragraph>By Week 28, approximately 12.1% (79/652) of subjects treated with SKYRIZI at the recommended dose developed antibodies to risankizumab-rzaa. None of the subjects who developed antibodies to risankizumab-rzaa had antibodies that were classified as neutralizing. Antibodies to risankizumab-rzaa were not associated with changes in clinical response for psoriatic arthritis. A higher proportion of subjects with anti-drug antibodies experienced hypersensitivity reactions (6.3% (5/79)) and injection site reactions (2.5% (2/79)) compared to subjects without anti-drug antibodies (3.8% (22/574) with hypersensitivity reactions and 0.7% (4/574) with injection site reactions). None of these hypersensitivity and injection site reactions led to discontinuation of risankizumab-rzaa.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Crohnâs </content>
                           <content styleCode="underline">D</content>
                           <content styleCode="underline">isease</content>
                        </paragraph>
                        <paragraph>By Week 64, antibodies to risankizumab-rzaa developed in approximately 3.4% (2/58) of subjects treated with SKYRIZI induction followed by 360 mg maintenance regimen.  No subjects (0/57) treated with SKYRIZI induction followed by 180 mg maintenance regimen developed antibodies to risankizumab-rzaa. None of the subjects who developed antibodies to risankizumab-rzaa had antibodies that were classified as neutralizing.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Ulcerative Colitis</content>
                        </paragraph>
                        <paragraph>By Week 64, antibodies to risankizumab-rzaa developed in approximately 8.9% (8/90) or 4.4% (4/91) of subjects treated with SKYRIZI induction followed by the 180 mg or 360 mg maintenance regimen, respectively. Of the subjects who developed antibodies to risankizumab-rzaa, 75% (6.7% of all subjects treated with SKYRIZI induction followed by the 180 mg maintenance regimen) or 50% (2.2% of all subjects treated with SKYRIZI induction followed by the 360 mg maintenance regimen), respectively, had antibodies that were classified as neutralizing. </paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="ab8c3751-36f7-4e0e-a5f3-8827d6921774"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="90375-7" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.3 Postmarketing Experience</content>
                     </title>
                     <text>
                        <paragraph>The following adverse reactions have been reported during post-approval of SKYRIZI. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to SKYRIZI exposure:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Skin and subcutaneous tissue disorders</content>: eczema and rash </item>
                        </list>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="b342fade-2853-4bed-87ce-e773ea4b6ab2"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>
                  <content styleCode="bold">8 USE IN SPECIFIC POPULATIONS</content>
               </title>
               <effectiveTime value="20250507"/>
               <component>
                  <section ID="_8_1_Pregnancy">
                     <id root="cfb29ed7-d7f5-4098-abce-a19346818dd4"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42228-7" displayName="PREGNANCY SECTION"/>
                     <title>
                        <content styleCode="bold">8.1 Pregnancy</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Exposure Registry</content>
                        </paragraph>
                        <paragraph>There is a pregnancy exposure registry that monitors outcomes in women who become pregnant while treated with SKYRIZI. Patients should be encouraged to enroll by calling 1-877-302-2161Â or visiting http://glowpregnancyregistry.com.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Available pharmacovigilance and clinical trial data with risankizumab use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. Although there are no data on risankizumab-rzaa, monoclonal antibodies can be actively transported across the placenta, and SKYRIZI may cause immunosuppression in the in utero<content styleCode="italics">-</content>exposed infant<content styleCode="bold">.</content> There are adverse pregnancy outcomes in women with inflammatory bowel disease <content styleCode="italics">(see Clinical Considerations)</content>.Â </paragraph>
                        <paragraph>In an enhanced pre- and post-natal developmental toxicity study, pregnant cynomolgus monkeys were administered subcutaneous doses of 5 or 50 mg/kg risankizumab-rzaa once weekly during the period of organogenesis up to parturition. Increased fetal/infant loss was noted in pregnant monkeys at the 50 mg/kg dose <content styleCode="italics">(see Data)</content>. The 50 mg/kg dose in pregnant monkeys resulted in approximately 5 times the exposure (AUC) in humans administered the maximum recommended induction dose (1,200 mg) and 32 times the exposure (AUC) to the maximum recommended maintenance dose (360 mg). No risankizumab-rzaa-related effects on functional or immunological development were observed in infant monkeys from birth through 6 months of age. The clinical significance of these findings for humans is unknown.Â </paragraph>
                        <paragraph>All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. </paragraph>
                        <paragraph>Clinical ConsiderationsÂ </paragraph>
                        <paragraph>
                           <content styleCode="italics">Disease-associated maternal and embryo/fetal risk</content>
                        </paragraph>
                        <paragraph>Published data suggest that the risk of adverse pregnancy outcomes in women with inflammatory bowel disease is associated with increased disease activity. Adverse pregnancy outcomes include preterm delivery (before 37 weeks of gestation), low birth weight (less than 2,500Â g) infants, and small for gestational age at birth.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Fetal/Neonatal adverse reactions</content>
                        </paragraph>
                        <paragraph>Transport of endogenous IgG antibodiesÂ across the placenta increases as pregnancy progresses, and peaks during the third trimester. Because risankizumab may interfere with immune response to infections, risks and benefits should be considered prior to administering live vaccines to infants exposed to SKYRIZI in utero. There are insufficient data regarding infant serum levels of risankizumab at birth and the duration of persistence of risankizumab in infant serum after birth. AlthoughÂ a specific timeframe to delay live virus immunizations in infants exposed in utero is unknown, a minimum of 5 months after birth should be considered because of the half-life of the product.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>An enhanced pre- and post-natal developmental toxicity study was conducted in cynomolgus monkeys. Pregnant cynomolgus monkeys were administered weekly subcutaneous doses of risankizumab-rzaa of 5 or 50 mg/kg from gestation day 20 to parturition, and the cynomolgus monkeys (mother and infants) were monitored for 6 months after delivery. No maternal toxicity was noted in this study. There were no treatment-related effects on growth and development, malformations, developmental immunotoxicology, or neurobehavioral development. However, a dose-dependent increase in fetal/infant loss was noted in the risankizumab-rzaa-treated groups (32% and 43% in the 5 mg/kg and 50 mg/kg groups, respectively) compared with the vehicle control group (19%). The increased fetal/infant loss in the 50 mg/kg group was considered to be related to risankizumab-rzaa treatment. The no-observed adverse effect level (NOAEL) for maternal toxicity was identified as 50 mg/kg, and the NOAEL for developmental toxicity was identified as 5 mg/kg. The 5 mg/kg dose in pregnant monkeys resulted in approximately 0.6 times the exposure (AUC) in humans administered the maximum recommended induction dose (1,200Â mg) and 5 times the exposure (AUC) in humans administered the maximum recommended maintenance dose (360 mg).Â Â Â In the infants, mean serum concentrations increased in a dose-dependent manner and were approximately 17%-86% of the respective maternal concentrations. Following delivery, most adult female cynomolgus monkeys and all infants from the risankizumab-rzaa-treated groups had measurable serum concentrations of risankizumab-rzaa up to 91 days postpartum. Serum concentrations were below detectable levels at 180 days postpartum. </paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="db3aa0a6-547d-40a5-9365-608d0f092536"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="77290-5" displayName="LACTATION SECTION"/>
                     <title>
                        <content styleCode="bold">8.2 Lactation</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no data on the presence of risankizumab-rzaa in human milk, the effects on the breastfed infant, or the effects on milk production. Endogenous maternal IgG and monoclonal antibodies are transferred in human milk. The effects of local gastrointestinal exposure and limited systemic exposure in the breastfed infant to risankizumab-rzaa are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for SKYRIZI and any potential adverse effects on the breastfed infant from SKYRIZI or from the underlying maternal condition. </paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="8abcdc41-a86d-404c-b5d9-f985f87492e7"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34081-0" displayName="PEDIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.4 Pediatric Use</content>
                     </title>
                     <text>
                        <paragraph>The safety and effectiveness of SKYRIZI have not been established in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="6879ecae-f6ac-43a9-8fa0-42177384cea8"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34082-8" displayName="GERIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.5 Geriatric Use</content>
                     </title>
                     <text>
                        <paragraph>Of the 6,862 subjects exposed to SKYRIZI, a total of 664 were 65 years or older (243 subjects with plaque psoriasis, 246 subjects with psoriatic arthritis, 72 subjects with Crohnâs disease and 103 subjects with ulcerative colitis), and 71 subjects were 75 years or older. </paragraph>
                        <paragraph>Clinical studies of SKYRIZI, within each indication,  did not include sufficient numbers of subjects 65 years of age and older to determine whether they respond differently from younger adult subjects.</paragraph>
                        <paragraph>No clinically meaningful differences in the pharmacokinetics of risankizumab-rzaa were observed based on age<content styleCode="italics">[see Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="bb29913d-8185-4ccb-9fd4-e104af944a63"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34089-3" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">11 DESCRIPTION</content>
               </title>
               <text>
                  <paragraph>Risankizumab-rzaa, an interleukin-23 (IL-23) antagonist, is a humanized immunoglobulin G1 (IgG1) monoclonal antibody. Risankizumab-rzaa is produced by recombinant DNA technology in Chinese hamster ovary cells and has an approximate molecular weight of 149 kDa. </paragraph>
                  <paragraph>
                     <content styleCode="underline">SKYRIZI (risankizumab-rzaa) injection 90 mg/mL prefilled syringe for subcutaneous use</content>
                  </paragraph>
                  <paragraph>Each SKYRIZI prefilled syringe contains a sterile, preservative-free, colorless to slightly yellow, and clear to slightly opalescent solution. Each syringe delivers 90 mg of risankizumab-rzaa, and inactive ingredients polysorbate 20 (0.2 mg),Â sodium succinate (0.63 mg), sorbitol (41 mg), succinic acid (0.059 mg), and Water for Injection, USP. The pH is 6.2.</paragraph>
                  <paragraph>
                     <content styleCode="underline">SKYRIZI (risankizumab-rzaa) injection 150 mg/mL prefilled syringe or prefilled pen for subcutaneous use</content>
                     <content styleCode="underline">Â </content>
                  </paragraph>
                  <paragraph>Each SKYRIZI prefilled pen or prefilled syringe contains a sterile, preservative-free, colorless to yellow, and clear to slightly opalescent solution. Each syringe and pen delivers 150 mg of risankizumab-rzaa and the inactive ingredients glacial acetic acid (0.054 mg), polysorbate 20 (0.2 mg), sodium acetate (0.75 mg), trehalose (63.33 mg), and Water for Injection, USP. The pH is 5.7.</paragraph>
                  <paragraph>
                     <content styleCode="underline">SKYRIZI </content>
                     <content styleCode="underline">(risankizumab-rzaa) injection</content>
                     <content styleCode="underline">Â </content>
                     <content styleCode="underline">180</content>
                     <content styleCode="underline">Â </content>
                     <content styleCode="underline">mg/</content>
                     <content styleCode="underline">1.2</content>
                     <content styleCode="underline">mL</content>
                     <content styleCode="underline"> (150 mg/</content>
                     <content styleCode="underline">mL</content>
                     <content styleCode="underline">)</content>
                     <content styleCode="underline"> prefilled </content>
                     <content styleCode="underline">cartridge for use with supplied on-body-injector </content>
                     <content styleCode="underline">for subcutaneous use</content>
                  </paragraph>
                  <paragraph>Each SKYRIZI prefilled cartridge contains a sterile, preservative-free, colorless to yellow, and clear to slightly opalescent solution. Each cartridge delivers 180 mg of risankizumab-rzaa, and the inactive ingredients glacial acetic acid (0.065 mg), polysorbate 20 (0.24 mg), sodium acetate (0.9 mg), trehalose (76 mg), and Water for Injection, USP. The pH is 5.7.</paragraph>
                  <paragraph>
                     <content styleCode="underline">SKYRIZI </content>
                     <content styleCode="underline">(risankizumab-rzaa) injection </content>
                     <content styleCode="underline">360 mg/2.4 mL (150 mg/mL) prefilled cartridge</content>
                     <content styleCode="underline">Â </content>
                     <content styleCode="underline">for use with the supplied o</content>
                     <content styleCode="underline">n-</content>
                     <content styleCode="underline">b</content>
                     <content styleCode="underline">ody </content>
                     <content styleCode="underline">i</content>
                     <content styleCode="underline">njector</content>
                     <content styleCode="underline"> for subcutaneous use</content>Â </paragraph>
                  <paragraph>Each SKYRIZIÂ prefilled cartridge contains a sterile, preservative-free, colorless to yellow, and clear to slightly opalescent solution. Each cartridge delivers 360 mg of risankizumab-rzaa, and the inactive ingredients glacial acetic acid (0.13 mg), polysorbate 20 (0.48 mg), sodium acetate (1.8 mg), trehalose (152 mg), and Water for Injection, USP. The pH is 5.7.</paragraph>
                  <paragraph>
                     <content styleCode="underline">SKYRIZI 600 mg/10 mL (60 mg/mL) in </content>
                     <content styleCode="underline">a </content>
                     <content styleCode="underline">vial for </content>
                     <content styleCode="underline">intravenous </content>
                     <content styleCode="underline">infusion</content>
                  </paragraph>
                  <paragraph>SKYRIZI (risankizumab-rzaa) injection 600 mg/10 mL (60 mg/mL) is a sterile, preservative-free, colorless to slightly yellow, and clear to slightly opalescent solution in a 10 mL single-dose vial.</paragraph>
                  <paragraph>Each 10 mL single-dose vial contains 600 mg of risankizumab-rzaa, and the inactive ingredients glacial acetic acid (0.54 mg), polysorbate 20 (2 mg), sodium acetate (7.5 mg), trehalose (633.3 mg), and Water for Injection, USP. The pH is 5.7.</paragraph>
               </text>
               <effectiveTime value="20250507"/>
            </section>
         </component>
         <component>
            <section>
               <id root="5973c2f4-852a-4bf6-9c78-50528d795b4c"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">12 CLINICAL PHARMACOLOGY</content>
               </title>
               <effectiveTime value="20250507"/>
               <component>
                  <section>
                     <id root="ca4414c6-dd38-41e5-abf5-a77ef734d5bb"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43679-0" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>
                        <content styleCode="bold">12.1 Mechanism of Action</content>
                     </title>
                     <text>
                        <paragraph>Risankizumab-rzaa is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. </paragraph>
                        <paragraph>Risankizumab-rzaa inhibits the release of pro-inflammatory cytokines and chemokines. </paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="b6ab0790-3626-42cf-9076-103a3fdaf289"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43681-6" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.2 Pharmacodynamics</content>
                     </title>
                     <text>
                        <paragraph>No formal pharmacodynamics studies have been conducted with risankizumab-rzaa. </paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
               <component>
                  <section ID="_12_3_Pharmacokinetics">
                     <id root="96564d23-548e-426c-8cdb-af7314094e57"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43682-4" displayName="PHARMACOKINETICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.3 Pharmacokinetics</content>
                     </title>
                     <text>
                        <paragraph>Risankizumab-rzaaÂ plasma concentrations, after single dose administration increased dose proportionally from 18 mg to 360 mg when administered subcutaneously (0.12 to 2.4 times the lowest recommended dose and 0.05 to 1 times the highest recommended dose) and from 200 mg to 1,800 mg when administered as an up to 3-hour intravenous infusion (0.2 to 3 times the recommended dose) in healthy subjects. Â </paragraph>
                        <paragraph>In subjects with plaque psoriasis treated with 150 mg subcutaneously at Weeks 0, 4, and every 12 weeks thereafter, steady-state peak concentration (C<sub>max</sub>) and trough concentration (C<sub>trough</sub>) are estimated to be 12 mcg/mL and 2 mcg/mL, respectively.Â </paragraph>
                        <paragraph>With the same subcutaneous dosing regimen, the pharmacokinetics of risankizumab-rzaa in subjects with psoriatic arthritis were similar to that in subjects with plaque psoriasis.</paragraph>
                        <paragraph>In subjects with Crohnâs disease treated with 600 mg intravenous induction dose at Weeks 0, 4, and 8, followed by 180 mg or 360 mg subcutaneous maintenance dose at Week 12 and every 8 weeks thereafter, the median C<sub>max</sub> and C<sub>trough</sub> are estimated to be 156 mcg/mL and 38.8 mcg/mL, respectively, during Weeks 8-12; and the steady state median C<sub>max</sub> and C<sub>trough</sub> are estimated to be 14.0 mcg/mL and 4.1 mcg/mL, respectively for 180 mg or 28.0 mcg/mL and 8.1 mcg/mL, respectively, for 360 mg, during Weeks 40-48.</paragraph>
                        <paragraph>In subjects with ulcerative colitis treated with 1,200 mg intravenous induction dose at Weeks 0, 4, and 8, followed by 180 mg or 360 mg subcutaneous maintenance dose at Week 12 and every 8 weeks thereafter, the median C<sub>max</sub> and C<sub>trough</sub> are estimated to be 350 and 87.7Â mcg/mL, respectively, during the induction period (Weeks 8-12); and the steady state median C<sub>max</sub>
                           <sub>Â </sub>and C<sub>trough</sub> are estimated to be 19.6 and 4.64 Âµg/mL, respectively, for 180 mg or 39.2 mcg/mL and 9.29Â mcg/mL, respectively, for 360 mg, during the maintenance period (Weeks 40-48).</paragraph>
                        <paragraph>Based on population pharmacokinetic analyses, the pharmacokinetics of risankizumab-rzaa in subjects with ulcerative colitis was generally similar to that in subjects with Crohnâs disease.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>The absolute bioavailability of risankizumab-rzaa was estimated to be 74 to 89% following subcutaneous injection. In healthy subjects, following administration of a single subcutaneous dose, C<sub>max</sub> was reached by 3 to 14 days.Â Â </paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>The estimated steady-state volume of distribution (inter-subject CV%) was 11.2 L (34%) in subjects with plaque psoriasis, and 7.68 L (64%) in subjects with Crohnâs disease. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>The estimated systemic clearance (inter-subject CV%) was 0.31 L/day (24%) and 0.30 L/day (34%) and terminal elimination half-life was approximately 28 days and 21 days in subjects with plaque psoriasis and Crohnâs disease, respectively. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>The metabolic pathway of risankizumab-rzaa has not been characterized. As a humanized IgG1 monoclonal antibody, risankizumab-rzaa is expected to be degraded into small peptides and amino acids via catabolic pathways in a manner similar to endogenous IgG. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>Risankizumab-rzaa exposures (C<sub>trough</sub>) in geriatric patients (â¥65 years) are comparable to those in younger adult patients within each indication. No studies have been conducted to determine the effect of renal or hepatic impairment on the pharmacokinetics of risankizumab-rzaa.Â </paragraph>
                        <paragraph>
                           <content styleCode="italics">Body Weight</content>
                        </paragraph>
                        <paragraph>Risankizumab-rzaa clearance and volume of distribution increase and plasma concentrations decrease as body weight increases; however, no dose adjustment is recommended based on body weight. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cytochrome P450 Substrates</content>
                        </paragraph>
                        <paragraph>No clinically significant changes in exposure of caffeine (CYP1A2 substrate), warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate), metoprolol (CYP2D6 substrate), or midazolam (CYP3A substrate) were observed when used concomitantly with risankizumab-rzaa in subjects with plaque psoriasis (risankizumab-rzaa 150 mg administered subcutaneously at Weeks 0, 4, 8, and 12)Â and subjects with Crohnâs disease or ulcerative colitis (risankizumab-rzaa 1,800 mg administered intravenously at Weeks 0, 4, and 8, i.e., 3 times and 1.5 times the recommended dose for Crohnâs disease and ulcerative colitis, respectively). </paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="684f92bc-ac00-40c6-8497-2ae76936c99a"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">13 NONCLINICAL TOXICOLOGY</content>
               </title>
               <effectiveTime value="20250507"/>
               <component>
                  <section>
                     <id root="a10283c7-56e9-4c73-8631-67699d4d24a2"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>
                        <content styleCode="bold">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</content>
                     </title>
                     <text>
                        <paragraph>Carcinogenicity and mutagenicity studies have not been conducted with SKYRIZI. </paragraph>
                        <paragraph>No effects on male fertility parameters were observed in sexually mature male cynomolgus monkeys dosed weekly for 26 weeks with 50 mg/kg risankizumab-rzaa at 4 times the exposure (AUC) in humans administered the maximum recommended induction dose (1,200 mg)  and 39 times the exposure in humans administered the maximum recommended maintenance dose (360 mg). </paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="d5b48060-a65a-4faf-9e8b-2656fb6b26da"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34092-7" displayName="CLINICAL STUDIES SECTION"/>
               <title>
                  <content styleCode="bold">14 CLINICAL STUDIES</content>
               </title>
               <effectiveTime value="20250507"/>
               <component>
                  <observationMedia ID="MM03000001">
                     <text>Figure 1. Percent of Subjects Achieving ACR20 Responses in Study PsA-1 through Week 24</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <section>
                     <id root="bd2331c5-c122-46ab-bbfa-ec752153769c"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.1 Plaque Psoriasis</content>
                     </title>
                     <text>
                        <paragraph>Four multicenter, randomized, double-blind studies [PsO-1 (NCT02684370), PsO-2 (NCT02684357), PsO-3 (NCT02672852), and PsO-4 (NCT02694523)] enrolled 2,109 subjects 18 years of age and older with moderate to severe plaque psoriasis who had a body surface area (BSA) involvement of â¥10%, a static Physicianâs Global Assessment (sPGA) score of â¥3 (âmoderateâ) in the overall assessment (plaque thickness/induration, erythema, and scaling) of psoriasis on a severity scale of 0 to 4, and a Psoriasis Area and Severity Index (PASI) score â¥12. </paragraph>
                        <paragraph>Overall, subjects had a median baseline PASI score of 17.8 and a median BSA of 20%. Baseline sPGA score was 4 (âsevereâ) in 19% of subjects. A total of 10% of study subjects had a history of diagnosed psoriatic arthritis. </paragraph>
                        <paragraph>Across all studies, 38% of subjects had received prior phototherapy, 48% had received prior non-biologic systemic therapy, and 42% had received prior biologic therapy for the treatment of psoriasis. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Studies PsO-1 and PsO-2</content>
                        </paragraph>
                        <paragraph>In studies PsO-1 and PsO-2, 997 subjects were enrolled (including 598 subjects randomized to the SKYRIZI 150 mg group, 200 subjects randomized to the placebo group, and 199 to the biologic active control group). Subjects received treatment at Weeks 0, 4, and every 12 weeks thereafter. </paragraph>
                        <paragraph>Both studies assessed the responses at Week 16 compared with placebo for the two co-primary endpoints: </paragraph>
                        <list>
                           <item>the proportion of subjects who achieved an sPGA score of 0 (âclearâ) or 1 (âalmost clearâ)<br/>
                           </item>
                           <item>the proportion of subjects who achieved at least a 90% reduction from baseline PASI (PASI 90)</item>
                        </list>
                        <paragraph>Secondary endpoints included the proportion of subjects who achieved PASI 100, sPGA 0, and Psoriasis Symptom Scale (PSS) 0 at Week 16. </paragraph>
                        <paragraph>The results are presented in Table 6. </paragraph>
                        <table>
                           <caption>Table 6. Efficacy Results at Week 16 in Adults with Plaque Psoriasis in PsO-1 and PsO-2</caption>
                           <col width="113"/>
                           <col width="113"/>
                           <col width="113"/>
                           <col width="113"/>
                           <col width="113"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold">PsO-1</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold">PsO-2</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">SKYRIZI</content>
                                    <content styleCode="bold">
                                       <br/>(N=304)</content>
                                    <content styleCode="bold">
                                       <br/>n (%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Placebo</content>
                                    <content styleCode="bold">
                                       <br/>(N=102)</content>
                                    <content styleCode="bold">
                                       <br/>n (%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">SKYRIZI</content>
                                    <content styleCode="bold">
                                       <br/>(N=294)</content>
                                    <content styleCode="bold">
                                       <br/>n (%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Placebo</content>
                                    <content styleCode="bold">
                                       <br/>(N=98)</content>
                                    <content styleCode="bold">
                                       <br/>n (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">sPGA 0 or 1 (âclear or almost clearâ)</content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">267 (88)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8 (8)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">246 (84)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5 (5)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">PASI 90</content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">229 (75)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5 (5)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">220 (75)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2 (2)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">sPGA 0 (âclearâ)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">112 (37)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2 (2)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">150 (51)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3 (3)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">PASI 100</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">109 (36)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0 (0)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">149 (51)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2 (2)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="5">
                                    <sup>a</sup> Co-primary endpoints </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Examination of age, gender, race, body weight, baseline PASI score and previous treatment with systemic or biologic agents did not identify differences in response to SKYRIZI among these subgroups at Week 16. </paragraph>
                        <paragraph>In PsO-1 and PsO-2 at Week 52, subjects receiving SKYRIZI achieved sPGA 0 (58% and 60%, respectively), PASI 90 (82% and 81%, respectively), and PASI 100 (56% and 60%, respectively). </paragraph>
                        <paragraph>
                           <content styleCode="italics">Patient Reported Outcomes</content>
                        </paragraph>
                        <paragraph>Improvements in signs and symptoms related to pain, redness, itching and burning at Week 16 compared to placebo were observed in both studies as assessed by the  PSS. In PsO-1 and PsO-2, about 30% of the subjects who received SKYRIZI achieved PSS 0 (ânoneâ) at Week 16 compared to 1% of the subjects who received placebo. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Study </content>
                           <content styleCode="underline">PsO-3</content>
                        </paragraph>
                        <paragraph>Study PsO-3 enrolled 507 subjects (407 randomized to SKYRIZI 150 mg and 100 to placebo). Subjects received treatment at Weeks 0, 4, and every 12 weeks thereafter. </paragraph>
                        <paragraph>At Week 16, SKYRIZI was superior to placebo on the co-primary endpoints of sPGA 0 or 1 (84% SKYRIZI and 7% placebo) and PASI 90 (73% SKYRIZI and 2% placebo). The respective response rates for SKYRIZI and placebo at Week 16 were: sPGA 0 (46% SKYRIZI and 1% placebo); PASI 100 (47% SKYRIZI and 1% placebo); and PASI 75 (89% SKYRIZI and 8% placebo). </paragraph>
                        <paragraph>
                           <content styleCode="underline">Maintenance and Durability of Response</content>
                        </paragraph>
                        <paragraph>In PsO-1 and PsO-2, among the subjects who received SKYRIZI and had PASI 100 at Week 16, 80% (206/258) of the subjects who continued on SKYRIZI had PASI 100 at Week 52. For PASI 90 responders at Week 16, 88% (398/450) of the subjects had PASI 90 at Week 52. </paragraph>
                        <paragraph>In PsO-3, subjects who were originally on SKYRIZI and had sPGA 0 or 1 at Week 28 were re-randomized to continue SKYRIZI every 12 weeks or withdrawal of therapy. At Week 52, 87% (97/111) of the subjects re-randomized to continue treatment with SKYRIZI had sPGA 0 or 1 compared to 61% (138/225) who were re-randomized to withdrawal of SKYRIZI. </paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="1d831ad3-e067-435b-97ef-02dfda2b9089"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.2 Psoriatic Arthritis</content>
                     </title>
                     <text>
                        <paragraph>The safety and efficacy of SKYRIZI were assessed in 1407 subjects in 2 randomized, double-blind, placebo-controlled studies (964 in PsA-1 [NCT03675308] and 443 in PsA-2 [NCT03671148]) in subjects 18 years and older with active psoriatic arthritis (PsA).</paragraph>
                        <paragraph>Subjects in these studies had a diagnosis of PsA for at least 6 months based on the Classification Criteria for Psoriatic Arthritis (CASPAR), a median duration of PsA of 4.9 years at baseline, â¥ 5 tender joints and â¥ 5 swollen joints, and active plaque psoriasis or psoriatic nail disease at baseline. Regarding baseline clinical presentation, 55.9% of subjects had â¥3% BSA with active plaque psoriasis; 63.4% and 27.9% of subjects had enthesitis and dactylitis, respectively. In PsA-1 where psoriatic nail disease was further assessed, 67.3% had psoriatic nail disease.</paragraph>
                        <paragraph>In PsA-1, all subjects had a previous inadequate response or intolerance to non-biologic DMARD therapy and were biologic naÃ¯ve. In PsA-2, 53.5% of subjects had a previous inadequate response or intolerance to non-biologic DMARD therapy, and 46.5% of subjects had a previous inadequate response or intolerance to biologic therapy.  </paragraph>
                        <paragraph>In both studies, subjects were randomized to receive SKYRIZI 150 mg or placebo at Weeks 0, 4, and 16. Starting from Week 28, all subjects received SKYRIZI every 12 weeks. Both studies included a long-term extension for up to an additional 204 weeks. Regarding use of concomitant medications, 59.6% of subjects were receiving concomitant methotrexate (MTX), 11.6% were receiving concomitant non-biologic DMARDs other than MTX, and 28.9% were receiving SKYRIZI monotherapy. </paragraph>
                        <paragraph>For both studies, the primary endpoint was the proportion of subjects who achieved an American College of Rheumatology (ACR) 20 response at Week 24. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Response </content>
                        </paragraph>
                        <paragraph>In both studies, treatment with SKYRIZI resulted in significant improvement in measures of disease activity compared with placebo at Week 24. See <linkHtml href="#Table7">Tables 7</linkHtml> and <linkHtml href="#Table8">8</linkHtml> for key efficacy results.</paragraph>
                        <paragraph>In both studies, similar responses were seen regardless of concomitant non-biologic DMARD use, number of prior non-biologic DMARDs, age, gender, race, and BMI. In PsA-2, responses were seen regardless of prior biologic therapy.</paragraph>
                        <table ID="Table7">
                           <caption>Table 7. Efficacy Results in Study PsA-1</caption>
                           <col width="148"/>
                           <col width="144"/>
                           <col width="159"/>
                           <col width="188"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Endpoint</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Placebo</content>
                                    <br/>
                                    <content styleCode="bold">N=481</content>
                                    <br/>
                                    <content styleCode="bold">Response Rate </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">SKYRIZI </content>
                                    <br/>
                                    <content styleCode="bold">N=483</content>
                                    <br/>
                                    <content styleCode="bold">Response Rate </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Difference from Placebo </content>
                                    <br/>
                                    <content styleCode="bold">(95% CI)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">
                                    <content styleCode="bold">ACR20 Response* </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Week 16 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">33.4%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">56.3%<content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">23.1% (16.8, 29.4)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Week 24 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">33.5%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">57.3%<content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">24.0% (18.0, 30.0)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">
                                    <content styleCode="bold">ACR50 Response* </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Week 16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11.1%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">26.4%<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">15.4% (10.6, 20.2)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Week 24</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11.3%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">33.4<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">22.2% (17.3, 27.2)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">
                                    <content styleCode="bold">ACR70 Response* </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Week 16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2.7%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11.8% </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">9.2% (6.1, 12.4)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Week 24</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4.7%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">15.3%<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10.5% (6.9, 14.2)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">a.Â multiplicity-controlled pâ¤0.001, SKYRIZI vs. placebo comparison.<br/>*A Subject was considered as a non-responder after initiation of rescue medication or concomitant medications for PsA that could meaningfully impact efficacy assessment. </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="Table8">
                           <caption>Table 8. Efficacy Results in Study PsA-2</caption>
                           <col width="148"/>
                           <col width="153"/>
                           <col width="150"/>
                           <col width="188"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Endpoint</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Placebo</content>
                                    <br/>
                                    <content styleCode="bold">N=219</content>
                                    <br/>
                                    <content styleCode="bold">Response Rate</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">SKYRIZI </content>
                                    <br/>
                                    <content styleCode="bold">N=224</content>
                                    <br/>
                                    <content styleCode="bold">Response Rate</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Difference from Placebo (95% CI)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">
                                    <content styleCode="bold">ACR20 Response* </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Week 16 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">25.3%<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">48.3%<content styleCode="bold">
                                       <sup> a</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">22.6% (13.9, 31.2)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Week 24 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">26.5%<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">51.3%<content styleCode="bold">
                                       <sup> a</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">24.5% (15.9, 33.0)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">
                                    <content styleCode="bold">ACR50 Response* </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Week 16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6.8%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">20.3%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13.5% (7.3, 19.7)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Week 24</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">9.3%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">26.3%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">16.6% (9.7, 23.6)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">
                                    <content styleCode="bold">ACR70 Response* </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Week 16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3.4%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11.2%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7.8% (3.0, 12.6)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Week 24</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5.9%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12.0%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6.0% (0.8, 11.3)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">a. multiplicity-controlled pâ¤0.001, SKYRIZI vs. placebo comparison. <br/>*A Subject was considered as a non-responder after initiation of rescue medication or concomitant medications for PsA that could meaningfully impact efficacy assessment. </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The percent of subjects achieving ACR20 responses in study PsA-1 through Week 24 is shown in Figure 1.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 1. Percent of Subjects Achieving ACR20 Responses in Study PsA-1 through Week 24</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM03000001"/>
                        </paragraph>
                        <paragraph>The results of the components of the ACR response criteria for both studies are shown in Table 9. </paragraph>
                        <table>
                           <caption>Table 9. Mean Change from Baseline in ACR Components</caption>
                           <col width="228"/>
                           <col width="110"/>
                           <col width="97"/>
                           <col width="104"/>
                           <col width="89"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold">PsA-1 </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold">PsA-2 </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Placebo</content>
                                    <br/>
                                    <content styleCode="bold">(N=481) </content>
                                    <br/>
                                    <content styleCode="bold">Mean (SD)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">SKYRIZI </content>
                                    <br/>
                                    <content styleCode="bold">(N=483) </content>
                                    <br/>
                                    <content styleCode="bold">Mean (SD)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Placebo</content>
                                    <br/>
                                    <content styleCode="bold">(N=219) </content>
                                    <br/>
                                    <content styleCode="bold">Mean (SD)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">SKYRIZI </content>
                                    <br/>
                                    <content styleCode="bold">(N=224) </content>
                                    <br/>
                                    <content styleCode="bold">Mean (SD)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">
                                    <content styleCode="bold">Â Â </content>
                                    <content styleCode="bold">Number of Swollen Joints (0-66)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule "/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Â Â Baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12.2 (8.0)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12.1 (7.8)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13.6 (9.0)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13.0 (8.7)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Â Â Mean change at Week 16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-5.5 (7.0)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-7.7 (7.2)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-5.4Â (8.5)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-8.0 (7.4)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Â Â Mean change at Week 24</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-6.7 (7.2)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-8.7 (7.2)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-6.5 (7.8)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-9.1 (7.6)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">
                                    <content styleCode="bold">Â Â </content>
                                    <content styleCode="bold">Number of Tender Joints (0-68)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule "/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Â Â Baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">20.5 (12.8)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">20.8 (14.0)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">22.3 (13.8)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">22.8 (14.9)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Â Â Mean change at Week 16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-6.3 (11.1)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-10.7 (11.4)<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-6.0 (13.1)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-11.3 (13.0)<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Â Â Mean change at Week 24</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-7.9 (10.7)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-12.0 (12.3)<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-8.3 (11.3)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-13.0<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>(12.5)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">
                                    <content styleCode="bold">Â Â </content>
                                    <content styleCode="bold">Patientâs Assessment of Pain </content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule "/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Â Â Baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">57.1 (22.6)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">57.1 (22.6)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">57.0 (23.1)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">55.0 (23.5)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Â Â Mean change at Week 16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-8.6 (23.7)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-18.4 (26.3)<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-5.7 (22.7)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-14.4 (26.4)<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Â Â Mean change at Week 24</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-10.9 (25.4)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-21.4 (26.5)<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-8.7 (25.3)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-15.3 (26.5)<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">
                                    <content styleCode="bold">Â Â </content>
                                    <content styleCode="bold">Patientâs Global Assessment </content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule "/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Â Â Baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">57.4 (22.1)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">57.9 (21.7)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">56.2 (23.0)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">56.2 (21.8)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Â Â Mean change at Week 16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-10.2 (23.9)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-19.4 (25.7)<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-4.9 (23.6)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-17.0 (27.1)<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Â Â Mean change at Week 24</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-11.1 (25.1)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-22.6 (26.9)<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-8.7 (25.4)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-17.7 (27.7)<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">
                                    <content styleCode="bold">Â Â </content>
                                    <content styleCode="bold">Physician Global Assessment </content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule "/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Â Â Baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">62.4 (17.0)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">61.3 (17.6)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">60.7 (16.4)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">63.0 (17.0)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Â Â Mean change at Week 16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-18.3 (22.5)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-31.1 (23.4)<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-19.0 (23.3)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-32.7 (24.7)<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Â Â Mean change at Week 24</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-22.2 (22.8)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-34.8 (23.2)<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-21.3 (25.2)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-35.5 (25.6)<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">
                                    <content styleCode="bold">Â Â </content>
                                    <content styleCode="bold">Health Assessment Questionnaire - Disability Index (HAQ-DI) </content>
                                    <content styleCode="bold">
                                       <sup>b</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule "/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Â Â Baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.2 (0.7)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.2 (0.7)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.1 (0.6)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.1 (0.6)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Â Â Mean change at Week 16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-0.1 (0.5)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-0.3 (0.5)<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-0.1 (0.5)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-0.2 (0.5)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Â Â Mean change at Week 24</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-0.1 (0.5)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-0.3 (0.5)<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-0.1 (0.4)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-0.2 (0.5)<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">
                                    <content styleCode="bold">Â Â </content>
                                    <content styleCode="bold">High sensitivity C-reactive protein (hs-CRP) mg/L</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule "/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Â Â Baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11.3 (14.1)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11.9 (15.9)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8.2 (17.1)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7.4 (10.9)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Â Â Mean change at Week 16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-0.3 (14.7)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-4.8 (14.2)<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-0.1 (6.8)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-2.1 (7.5)<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Â Â Â Â Â Mean change at Week 24</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-0.2 (11.7)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-4.3 (12.8)<content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-0.5 (14.5)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-1.8 (13.4)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="5">SD= Standard Deviation.<br/>a. Assessment based on Visual Analog Scale (100 mm) with the left end indicating âno painâ (for patientâs assessment of pain), âvery wellâ (for patient global assessment), or âno arthritis activityâ (for physician global assessment) and the right end indicating âthe worst possible painâ (for patient assessment of pain), âpoorâ (for patient global assessment), or âextremely active arthritisâ (for physician global assessment).<br/>b. Disability Index of the Health Assessment Questionnaire; 0 = no difficulty to 3 = inability to perform, measures the patientâs ability to perform the following: dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living.</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Treatment with SKYRIZI resulted in improvement in dactylitis and enthesitis in subjects with pre-existing dactylitis or enthesitis.</paragraph>
                        <paragraph>In patients with coexistent plaque psoriasis receiving SKYRIZI, the skin lesions of psoriasis improved with treatment, relative to placebo, as measured by the Psoriasis Area Severity Index (PASI 90) at Week 24.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Physical Function </content>
                        </paragraph>
                        <paragraph>In both studies, patients treated with SKYRIZI showed statistically significant improvement from baseline in physical function compared with placebo as assessed by HAQ-DI at Week 24 (<linkHtml href="#Table7">Table 7</linkHtml>). The mean difference (95% CI) from placebo in HAQ-DI change from baseline at Week 24 was -0.20 (-0.26, -0.14) in study PsA-1 and -0.16 (-0.26, -0.07) in study PsA-2.</paragraph>
                        <paragraph>In both studies, a greater proportion of subjects achieved a reduction of at least 0.35 in HAQ-DI score from baseline in the SKYRIZI group compared with placebo at Week 24. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Other Health Related Outcomes</content>
                        </paragraph>
                        <paragraph>In both studies, general health status was assessed by the 36-Item Short Form Health SurveyÂ (SF-36 V2). Fatigue was assessed by Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-Fatigue).  </paragraph>
                        <paragraph>In both studies at Week 24, subjects treated with SKYRIZI showed improvements in the SF-36 physical component summary scores compared with subjects who received placebo. There were also numerical improvements in subjects treated with SKYRIZI in physical functioning, role physical, bodily pain, general health, vitality, social functioning, mental health, role emotional domain scores and mental component summary scores in both studies at week 24 compared to placebo. In both studies at Week 24, subjects treated with SKYRIZI showed improvements in FACIT-Fatigue scores compared with subjects who received placebo.</paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
               <component>
                  <section ID="_14_3_Crohn_s_Disease">
                     <id root="259c6a6d-368e-4de5-a1b3-a5aff224dfc4"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.3 Crohnâs Disease</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Induction Trials (Studies CD-1 and CD-2)</content>
                        </paragraph>
                        <paragraph>In two 12-week induction studies (CD-1; NCT03105128 and CD-2; NCT03104413), subjects with moderately to severely active Crohnâs disease were randomized to receive SKYRIZI 600 mg, SKYRIZI 1,200 mg, or placebo as an intravenous infusion at Week 0, Week 4, and Week 8. Moderately to severely active CD was defined as a Crohnâs Disease Activity Index (CDAI) of 220 to 450 and Simple Endoscopic Score for Crohnâs disease (SES-CD) â¥6 (or â¥4 for isolated ileal disease). Subjects with inadequate response, loss of response, or intolerance to oral aminosalicylates, corticosteroids, immunosuppressants, and/or biologic therapy were enrolled.Â Â </paragraph>
                        <paragraph>At baseline, the median CDAI was 307 (range: 76 â 634) and 307 (range: 72 â 651), and the median SES-CD was 12 (range: 4 â 45) and 13 (range 4 â 40), in CD-1 and CD-2, respectively. In CD-1, 58% (491/850) of subjects had failed or were intolerant to treatment with one or more biologic therapies (prior biologic failure). All subjects in CD-2 had prior biologic failure. At baseline, 30% and 34% of patients were receiving corticosteroids, 24% and 23% of patients were receiving immunomodulators (azathioprine, 6-mercaptopurine, methotrexate), and 31% and 19% of patients were receiving aminosalicylates in CD-1 and CD-2, respectively.Â In CD-1 and CD-2 combined, the median age was 36 years (ranging from 16 to 80 years), 81% (1145/1419) of subjects were white, and 53% (753/1419) were male.</paragraph>
                        <paragraph>In CD-1 and CD-2,Â the co-primary endpoints were clinical remission and endoscopic response at Week 12. Secondary endpoints included clinical response and endoscopic remission (see <linkHtml href="#Table10">Table 10</linkHtml> and <linkHtml href="#Table11">Table 11</linkHtml>). The SKYRIZI 1,200 mg dosage did not demonstrate additional treatment benefit over the 600 mg dosage and is not a recommended regimen <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_6_Recommended_Dosage">2.6</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                        <table ID="Table10">
                           <caption>Table 10. Proportion of Subjects Meeting Efficacy Endpoints at Week 12 â Study CD-1Â </caption>
                           <col width="213"/>
                           <col width="124"/>
                           <col width="139"/>
                           <col width="139"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Endpoint</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Placebo </content>
                                    <br/>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">SKYRIZI</content>
                                    <br/>
                                    <content styleCode="bold">600 mg Intravenous Infusion</content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                    <br/>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Treatment</content>
                                    <br/>
                                    <content styleCode="bold">Difference</content>
                                    <content styleCode="bold">
                                       <sup> b</sup>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">(95% CI)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">
                                    <content styleCode="bold">Clinical Remission</content>
                                    <content styleCode="bold">
                                       <sup>c,d</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Total Population</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=175<br/>25%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=336<br/>45%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">21% </content>
                                    <content styleCode="bold">
                                       <sup>e</sup>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">(12%, 29%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Prior biologic failure<sup>f</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=97<br/>26% </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=195<br/>42% </td>
                                 <td styleCode="Toprule Lrule Rrule "/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">   Without prior biologic failure</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=78<br/>23%<br/>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=141<br/>49%<br/>
                                 </td>
                                 <td styleCode="Lrule Rrule "/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">
                                    <content styleCode="bold">Endoscopic Response</content>
                                    <content styleCode="bold">
                                       <sup>c,</sup>
                                    </content>
                                    <content styleCode="bold">
                                       <sup>g</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Total Population</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=175<br/>12%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=336<br/>40%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">28%</content>
                                    <content styleCode="bold">
                                       <sup> e</sup>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">(21%, 35%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">   Prior biologic failure<sup>f</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=97<br/>11%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=195<br/>33%</td>
                                 <td styleCode="Toprule Lrule Rrule "/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">   Without prior biologic failure</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=78<br/>13%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=141<br/>50%</td>
                                 <td styleCode="Lrule Rrule "/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">
                                    <content styleCode="bold">Clinical Response</content>
                                    <content styleCode="bold">
                                       <sup>h</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Total Population</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=175<br/>37%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=336<br/>60%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">23%</content>
                                    <content styleCode="bold">
                                       <sup> e</sup>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">(14%, 32%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">   Prior biologic failure<sup>f</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=97<br/>34%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=195<br/>58%</td>
                                 <td styleCode="Toprule Lrule Rrule "/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">   Without prior biologic failure</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=78 <br/>40%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=141<br/>62%</td>
                                 <td styleCode="Lrule Rrule "/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">
                                    <content styleCode="bold">Endoscopic Remission</content>
                                    <content styleCode="bold">
                                       <sup>i</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Total Population</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=175<br/>9%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=336<br/>24%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">15%</content>
                                    <content styleCode="bold">
                                       <sup> e</sup>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">(9%, 21%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">   Prior biologic failure<sup>f</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=97<br/>5%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=195<br/>18%</td>
                                 <td styleCode="Toprule Lrule Rrule "/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">   Without prior biologic failure</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=78<br/>14%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=141<br/>32%</td>
                                 <td styleCode="Lrule Rrule "/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">a. SKYRIZI 600 mg as an intravenous infusion at Week 0, Week 4, and Week 8<br/>b. Adjusted treatment difference (95% CI) based on Cochran-Mantel-Haenszel method adjusted for randomization stratification factors <br/>c. Co-primary endpoints<br/>d. CDAI &lt;150<br/>e. p &lt;0.001<br/>f. Prior biologic failure includes inadequate response, loss of response, or intolerance to one or more biologic treatments for CD<br/>g. A decrease in SES-CD &gt; 50% from baseline, or a decrease of at least 2 points for subjects with a baseline score of 4 and isolated ileal disease, based on central reading<br/>h. A reduction of CDAI â¥ 100 points from baseline<br/>i. SES-CD â¤ 4 and at least a 2-point reduction from baseline, with no individual subscore greater than 1, based on central reading</td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="Table11">
                           <caption>Table 11. Proportion of Subjects Meeting Efficacy Endpoints at Week 12 â Study CD-2<sup>a</sup>Â </caption>
                           <col width="274"/>
                           <col width="100"/>
                           <col width="119"/>
                           <col width="147"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Endpoint</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Placebo </content>
                                    <br/>N=187<br/>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">SKYRIZI</content>
                                    <br/>
                                    <content styleCode="bold">600 mg Intravenous Infusion</content>
                                    <content styleCode="bold">
                                       <sup>b</sup>
                                    </content>
                                    <br/>N=191<br/>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Treatment</content>
                                    <br/>
                                    <content styleCode="bold">Difference</content>
                                    <content styleCode="bold">
                                       <sup>c</sup>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">(95% CI)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Clinical Remission</content>
                                    <content styleCode="bold">
                                       <sup>d,</sup>
                                    </content>
                                    <content styleCode="bold">
                                       <sup>e</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">20%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">42%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">22%<sup> f</sup>
                                    <br/>(13%, 31%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Endoscopic Response</content>
                                    <content styleCode="bold">
                                       <sup> d,g</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">29%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">18%<sup> f</sup>
                                    <br/>(10%, 25%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Clinical Response</content>
                                    <content styleCode="bold">
                                       <sup>h</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">30%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">60%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">29%<sup> f</sup>
                                    <br/>(20%, 39%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Endoscopic Remission</content>
                                    <content styleCode="bold">
                                       <sup>i</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">19%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">15%<sup> f</sup>
                                    <br/>(9%, 21%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">a. All subjects enrolled in CD-2 had prior biologic failure. Prior biologic failure includes inadequate response, loss of response, or intolerance to one or more biologic treatments for CD<br/>b. SKYRIZI 600 mg as an intravenous infusion at Week 0, Week 4, and Week 8<br/>c. Adjusted treatment difference (95% CI) based on Cochran-Mantel-Haenszel method adjusted for randomization stratification factors<br/>d. Co-primary endpoints<br/>e. CDAI score &lt;150<br/>f. p &lt; 0.001<br/>g. A decrease in SES-CD &gt; 50% from baseline, or a decrease of at least 2 points for subjects with a baseline score of 4 and isolated ileal disease, based on central reading<br/>h. A reduction of CDAI â¥ 100 points from baseline<br/>i. SES-CD â¤ 4 and at least a 2-point reduction versus from baseline, with and no individual subscore greater than 1, based on central reading</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Onset of clinical response and clinical remission based on CDAI occurred as early as Week 4 in a greater proportion of subjects treated with the SKYRIZI 600 mg induction regimen compared to placebo.</paragraph>
                        <paragraph>Reductions in stool frequency and abdominal pain were observed in a greater proportion of subjects treated with the SKYRIZI 600 mg induction regimen compared to placebo at Week 12.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Study CD-3</content>
                        </paragraph>
                        <paragraph>The maintenance study CD-3 evaluated 382 subjects who achieved clinical response defined as a reduction in CDAI of at least 100 points from baseline after 12 weeks of induction treatment with intravenous SKYRIZI in studies CD-1 and CD-2. Subjects were randomized to receive a maintenance regimen of SKYRIZI 180 mg or SKYRIZI 360 mg or placebo at Week 12 and every 8 weeks thereafter for up to an additional 52 weeks.</paragraph>
                        <paragraph>The co-primary endpoints in CD-3 were clinical remission and endoscopic response at Week 52 (see <linkHtml href="#Table12">Table 12</linkHtml>).  </paragraph>
                        <table ID="Table12">
                           <caption>Â Table 12.Â Proportion of Subjects Meeting Efficacy Endpoints at Week 52 - Study CD-3</caption>
                           <col width="103"/>
                           <col width="70"/>
                           <col width="96"/>
                           <col width="126"/>
                           <col width="120"/>
                           <col width="3"/>
                           <col width="118"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Endpoint</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Placebo</content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                    <br/>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">SKYRIZI </content>
                                    <br/>
                                    <content styleCode="bold">180 mg Subcutaneous Injection</content>
                                    <content styleCode="bold">
                                       <sup>b</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">SKYRIZI </content>
                                    <br/>
                                    <content styleCode="bold">360 mg Subcutaneous Injection</content>
                                    <content styleCode="bold">
                                       <sup>c</sup>
                                    </content>
                                    <br/>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3" align="center">
                                    <content styleCode="bold"> Treatment Difference</content>
                                    <content styleCode="bold">
                                       <sup>Â </sup>
                                    </content>
                                    <content styleCode="bold">vs Placebo</content>
                                    <content styleCode="bold">
                                       <sup>d</sup>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">(95% CI</content>
                                    <content styleCode="bold">)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Lrule Rrule " align="center"/>
                                 <td styleCode="Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">SKYRIZI</content>
                                    <br/>
                                    <content styleCode="bold">180 mg</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3" align="center">
                                    <content styleCode="bold">SKYRIZI</content>
                                    <br/>
                                    <content styleCode="bold">360 mg</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="7">
                                    <content styleCode="bold">Clinical Remission</content>
                                    <content styleCode="bold">
                                       <sup>e,f</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Total Population</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=130<br/>46%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=135<br/>61%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=117<br/>57%</td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">17%<sup>g</sup>
                                    <br/>(6%, 28%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">14%<sup>g</sup>
                                    <br/>(3%, 26%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Prior biologic failure<sup>h</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=99<br/>40%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=95<br/>56%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=83<br/>51%</td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Without prior biologic failure</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=31<br/>65%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=40<br/>75%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=34<br/>71%</td>
                                 <td styleCode="Lrule Rrule " colspan="3"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="7">
                                    <content styleCode="bold">Endoscopic Response</content>
                                    <content styleCode="bold">
                                       <sup>e,i</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Total Population</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=130<br/>22%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=135<br/>50%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=117<br/>48%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">30%<sup>g</sup>
                                    <br/>(20%, 39%)</td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">31%<sup>g</sup>
                                    <br/>(21%, 41%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Prior biologic failure<sup>h</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=99<br/>21%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=95<br/>44%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=83<br/>44%</td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Without prior biologic failure</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=31<br/>23%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=40<br/>65%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=34<br/>59%</td>
                                 <td styleCode="Lrule Rrule " colspan="3"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="7">a. The placebo group consisted of patients who were in response to SKYRIZI and were randomized to receive placebo at the start of maintenance therapy.<br/>b. SKYRIZI 180 mg at Week 12 and every 8 weeks thereafter for up to an additional 52 weeks<br/>c. SKYRIZI 360 mg at Week 12 and every 8 weeks thereafter for up to an additional 52 weeks<br/>d. Adjusted treatment difference and 95% CI computed using Cochran-Mantel-Haenszel method adjusted for randomization stratification factors<br/>e. Co-primary endpoints<br/>f. CDAI &lt;150<br/>g. p &lt;0.05<br/>h. Prior biologic failure includes inadequate response, loss of response, or intolerance to one or more biologic treatments for CD <br/>i. A decrease in SES-CD &gt; 50% from baseline, or a decrease of at least 2 points for subjects with a baseline score of 4 and isolated ileal disease, based on central reading</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Endoscopic remission was observed at Week 52 in 33% (44/135) of subjects treated with the SKYRIZI 180 mg maintenance regimen andÂ 41% (48/117) of subjects treated with the SKYRIZI 360 mg maintenance regimen,Â compared toÂ 13% (17/130) of subjects treated with placebo. This endpoint was not statistically significant under the prespecified multiple testing procedure.</paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
               <component>
                  <section ID="_14_4_Ulcerative_Colitis">
                     <id root="9d486579-0056-4efd-b3c9-0890a39c1387"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.4 Ulcerative Colitis</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Induction Trial (Study UC-1)</content>
                        </paragraph>
                        <paragraph>In the 12-week induction study (UC-1;Â NCT03398148), 966 subjects with moderately to severely active ulcerative colitis were randomized and received SKYRIZI 1,200 mg or placebo as an intravenous infusion at Week 0, Week 4, and Week 8. Disease activityÂ was assessed by the modified Mayo score (mMS), a 3-component Mayo score (0-9) which consists of the following subscores (0 to 3 for each subscore): stool frequency (SFS), rectal bleeding (RBS), and findings on centrally read endoscopy score (ES). An ES of 2 was defined by marked erythema, lack of vascular pattern, any friability, and/or erosions; an ES of 3 was defined by spontaneous bleeding and ulceration. Enrolled subjects had a mMS between 5 and 9, with an ES of 2 or 3. Subjects with inadequate response, or intolerance to oral aminosalicylates, corticosteroids, immunomodulators, biologics, Janus Kinase inhibitors (JAKi), and/or sphingosine-1-phosphate receptorÂ modulators (S1PRM) were enrolled.Â Â </paragraph>
                        <paragraph>At baseline in UC-1,Â the median mMS was 7; 37% had severely active disease (mMS &gt;7); 69% had an ES ofÂ 3. In UC-1, 52% (499/966) of subjects had failed (inadequate response or intolerance) treatment with one or more biologics, JAKi or S1PRM. Of these 499 subjects, 484 (97%) failed biologics and 90 (18%) failed JAK inhibitors.Â Â Enrolled subjects were permitted to use a stable dose of oral corticosteroids (up to 20 mg/day prednisone or equivalent), immunomodulators, and aminosalicylates.Â At baseline, 36% of subjects were receiving corticosteroids, 16% of subjects were receiving immunomodulators (including azathioprine, 6-mercaptopurine, methotrexate), and 73% of subjects were receiving aminosalicylates in UC-1.</paragraph>
                        <paragraph>In UC-1,Â the primary endpoint was clinical remission defined using the mMS at Week 12 (see Table 13). Key secondary endpoints included clinical response, endoscopic improvement, and histologicÂ endoscopic mucosal improvement (see <linkHtml href="#Table13">Table 13</linkHtml>).</paragraph>
                        <table ID="Table13">
                           <caption>Table 13. Proportion of Subjects Meeting Efficacy Endpoints at Week 12 â Study UC-1</caption>
                           <col width="228"/>
                           <col width="126"/>
                           <col width="132"/>
                           <col width="138"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">Endpoint</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Placebo</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">SKYRIZI 1,200 mg Intravenous Infusion</content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Treatment Difference (95% CI)</content>
                                    <content styleCode="bold">
                                       <sup>b</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4" align="left">
                                    <content styleCode="bold">Clinical Remission</content>
                                    <content styleCode="bold">
                                       <sup>c</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Total Population</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=320<br/>8%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=646<br/>24%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">16%<sup>h</sup>
                                    <br/>(12%, 20%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Prior biologic, JAKi, or S1PRM failure<sup>d</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=168<br/>6%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=331<br/>14%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="left"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Without prior biologic, JAKi, or S1PRM failure</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=152<br/>9%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=315<br/>33%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="left"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4" align="left">
                                    <content styleCode="bold">Clinical Response</content>
                                    <content styleCode="bold">
                                       <sup>e</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Total Population</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=320<br/>36%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=646<br/>65%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">29%<sup>h</sup>
                                    <br/>(23%, 35%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Prior biologic, JAKi, or S1PRM failure<sup>d</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=168<br/>32%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=331<br/>56%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Without prior biologic, JAKi, or S1PRM failure</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=152<br/>41%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=315<br/>75%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4" align="left">
                                    <content styleCode="bold">Endoscopic Improvement</content>
                                    <content styleCode="bold">
                                       <sup>f</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Total Population</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=320<br/>12%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=646<br/>36%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">25%<sup>h</sup>
                                    <br/>(20%, 30%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Prior biologic, JAKi, or S1PRM failure<sup>d</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=168<br/>10%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=331<br/>26%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Without prior biologic, JAKi, or S1PRM failure</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=152<br/>14%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=315<br/>47%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4" align="left">
                                    <content styleCode="bold">Histologic Endoscopic Mucosal Improvement (HEMI)</content>
                                    <content styleCode="bold">
                                       <sup>g</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Total Population</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=320<br/>7%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=646<br/>24%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">17%<sup>h</sup>
                                    <br/>(13%, 21%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Prior biologic, JAKi, or S1PRM failure<sup>d</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=168<br/>7%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=331<br/>16%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Without prior biologic, JAKi, or S1PRM failure</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=152<br/>8%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=315<br/>33%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">
                                    <sup>a</sup> SKYRIZI 1,200 mg as an intravenous infusion at Week 0, Week 4, and Week 8<br/>
                                    <sup>b </sup>Adjusted treatment difference (95% CI) based on Cochran-Mantel-Haenszel method adjusted for stratification factors<br/>
                                    <sup>c</sup> Per mMS:  SFS â¤ 1 and not greater than baseline, RBS = 0, and ES â¤ 1 without friability<br/>
                                    <sup>d</sup> Prior failure includes inadequate response or intolerance to treatment with one or more of the following: biologic therapies, Janus Kinase inhibitors (JAKi), and/or sphingosine-1-phosphate receptor modulators (S1PRM)<br/>
                                    <sup>e</sup> Per mMS: decrease â¥ 2 points and â¥ 30% from baseline, and a decrease in RBS â¥ 1 from baseline or an absolute RBS â¤ 1<br/>
                                    <sup>f</sup> ES â¤ 1 without the evidence of friability<br/>
                                    <sup>g</sup> ES <content styleCode="bold">â¤</content> 1 without the evidence of friability and Geboes score â¤ 3.1 (indicating neutrophil infiltration in &lt;5% of crypts, no crypt destruction and no erosions, ulcerations or granulation tissue)<br/>
                                    <sup>h</sup> p &lt; 0.001</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>UC-1 was not designed to evaluate the relationship of histologic endoscopic mucosal improvement at week 12 to disease progression and long-term outcomes.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Rectal Bleeding and Stool Frequency Subscores</content>
                        </paragraph>
                        <paragraph>Decreases in rectal bleeding and stool frequency subscores in subjects treated with SKYRIZI compared to placebo were observed as early as 4 weeks.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Endoscopic Assessment </content>
                        </paragraph>
                        <paragraph>Endoscopic remission was defined as ES of 0. At Week 12, a greater proportion of subjects treated with SKYRIZI compared to placebo achieved endoscopic remission (11% vs 3%). </paragraph>
                        <paragraph>
                           <content styleCode="italics">Bowel Urgency</content>
                        </paragraph>
                        <paragraph>A greater proportion of subjects treated with the SKYRIZI 1,200 mg induction regimen compared to placebo had no bowel urgency (44% vs 27%) at Week 12.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Fatigue</content>
                        </paragraph>
                        <paragraph>In UC-1, subjects treated with SKYRIZI experienced a clinically meaningful improvement in fatigue, assessed by change from baseline in FACIT-F score, at WeekÂ 12, compared to placebo-treated subjects.Â The effect of SKYRIZI to improve fatigue after 12 weeks of induction has not been established.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Other UC Symptoms </content>
                        </paragraph>
                        <paragraph>The proportion of subjects who had no nocturnal bowel movements was greater in subjects treated with SKYRIZI compared to placebo at Week 12 (67% vs 43%).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Maintenance </content>
                           <content styleCode="underline">Study </content>
                           <content styleCode="underline">UC-2</content>
                        </paragraph>
                        <paragraph>The maintenance study (UC-2; NCT03398135) evaluated 547 subjects who received one of three SKYRIZI induction regimens, including the 1,200 mg regimen, for 12 weeks in Studies UC-1 or UC-3 and demonstrated clinical response per mMS after 12 weeks.Â Subjects were randomized to receive a maintenance regimen of subcutaneous (SC) SKYRIZI 180 mg or SKYRIZI 360 mg or placebo at Week 12 and every 8 weeks thereafter for up to an additional 52 weeks.</paragraph>
                        <paragraph>In UC-2, 75% (411/547) of subjects had failed (inadequate response or intolerance) treatment with one or moreÂ biologics, JAKi, or S1PRM. Of these 411 subjects, 407 (99%) failed biologics and 78 (19%) failed JAK inhibitors.Â </paragraph>
                        <paragraph>The primary endpoint in UC-2 was clinical remission using mMS at Week 52 (see <linkHtml href="#Table14">Table 14</linkHtml>). Key secondary endpoints included corticosteroid-free clinical remission, endoscopic improvement, and histologicÂ endoscopic mucosal improvement (see <linkHtml href="#Table14">Table 14</linkHtml>).</paragraph>
                        <table ID="Table14">
                           <caption>Table 14.Â Proportion of Subjects Meeting Efficacy Endpoints at Week 52 - Study UC-2</caption>
                           <col width="212"/>
                           <col width="115"/>
                           <col width="125"/>
                           <col width="190"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Endpoint</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Placebo</content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">SKYRIZI 180 mg SC Injection</content>
                                    <content styleCode="bold">
                                       <sup>b</sup>
                                    </content>
                                    <br/>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">SKYRIZI 360 mg SC Injection</content>
                                    <content styleCode="bold">
                                       <sup>c</sup>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">Clinical remission<sup>d</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Total Population</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=182<br/>26%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=179<br/>45%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=186<br/>41%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Treatment Difference vs Placebo<sup>e</sup> (95% CI)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center">20%<sup>Â </sup>
                                    <sup>j</sup>
                                    <br/>[11%, 29%]</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">16%<sup> j</sup>
                                    <br/>[7%, 25%]</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Prior biologic, JAKi, or S1PRM failure<sup>f</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=138<br/>24%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=134<br/>41%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=139<br/>32%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Without prior biologic, JAKi, or S1PRM failure</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=44<br/>32%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=45<br/>58%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=47<br/>67%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">Corticosteroid-free clinical remission<sup>g</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Total Population</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=182<br/>26%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=179<br/>45%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=186<br/>40%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Treatment Difference vs Placebo<sup>e</sup> (95% CI)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center">20%<sup> j</sup>
                                    <br/>[11%, 29%]</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">16%<sup>j</sup>
                                    <br/>[7%, 25%]</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right"> Prior biologic, JAKi, or S1PRM failure<sup>f</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=138<br/>24%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=134<br/>40%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=139<br/>32%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Without prior biologic, JAKi, or S1PRM failure</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=44<br/>32%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=45<br/>58%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=47<br/>64%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">Endoscopic improvement<sup>h</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Total Population</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=182<br/>31%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=179<br/>51%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=186<br/>48%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Treatment Difference vs Placebo<sup>e</sup> (95% CI)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center">20%<sup>Â </sup>
                                    <sup>j</sup>
                                    <br/>[11%, 30%]</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">18%<sup>Â </sup>
                                    <sup>j</sup>
                                    <br/>[8%, 27%]</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Prior biologic, JAKi, or S1PRM failure<sup>f</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=138<br/>30%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=134<br/>48%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=139<br/>39%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Without prior biologic, JAKi, or S1PRM failure</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=44<br/>34%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=45<br/>60%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=47<br/>76%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">Histologic Endoscopic Mucosal Improvement<sup>i</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Total Population</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=182<br/>24%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=179<br/>43%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=186<br/>42%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Treatment Difference vs Placebo<sup>e</sup> (95% CI)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center">20%<sup> j</sup>
                                    <br/>[11%, 29%]</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">20%<sup> j</sup>
                                    <br/>[11%, 29%]</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Prior biologic, JAKi, or S1PRM failure<sup>f</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=138<br/>22%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=134<br/>39%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=139<br/>33%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="right">Without prior biologic, JAKi, or S1PRM failure</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=44<br/>30%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=45<br/>55%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">N=47<br/>69%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="4">
                                    <sup>a</sup> The placebo group consisted of subjects who were in response to 12 weeks of SKYRIZI induction and were randomized to receive placebo at the start of maintenance therapy.<br/>
                                    <sup>b</sup> SKYRIZI 180 mg at Week 12 and every 8 weeks thereafter for up to an additional 52 weeks <br/>
                                    <sup>c</sup> SKYRIZI 360 mg at Week 12 and every 8 weeks thereafter for up to an additional 52 weeks<br/>
                                    <sup>d</sup> Per mMS: SFS â¤ 1 and not greater than baseline, RBS = 0, and ES â¤ 1 without friability <br/>
                                    <sup>e</sup> Adjusted treatment difference (95% CI) based on Cochran-Mantel-Haenszel method adjusted for stratification factors <br/>
                                    <sup>f</sup> Prior failure includes inadequate response or intolerance to treatment with one or more of the following: biologic therapies, Janus Kinase inhibitors (JAKi), and/or sphingosine-1-phosphateÂ receptor modulators (S1PRM)<br/>
                                    <sup>g</sup> Clinical remission per mMS at Week 52 and corticosteroid-free for â¥90 days <br/>
                                    <sup>h</sup> ES â¤ 1 without the evidence of friability<br/>
                                    <sup>i</sup> ES â¤ 1without the evidence of friability and Geboes score â¤ 3.1 (indicating neutrophil infiltration in &lt;5% of crypts, no crypt destruction and no erosions, ulcerations or granulation tissue)<br/>
                                    <sup>j</sup> p &lt; 0.001</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">Endoscopic </content>
                           <content styleCode="italics">Assessment</content>
                           <content styleCode="italics">Â </content>
                        </paragraph>
                        <paragraph>Endoscopic remission was defined as ES of 0. In UC-2, a greater proportion of subjects treated with SKYRIZI 180 mg and SKYRIZI 360 mg compared to placebo achieved endoscopic remission at Week 52 (23% and 24% vs 15%).</paragraph>
                     </text>
                     <effectiveTime value="20250507"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="385a9fdd-c663-4a5e-864c-5047900848be"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34069-5" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">16 HOW SUPPLIED/STORAGE AND HANDLING</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">How Supplied</content>
                  </paragraph>
                  <paragraph>SKYRIZI (risankizumab-rzaa) injection is supplied in the following strengths:</paragraph>
                  <table>
                     <col width="324"/>
                     <col width="150"/>
                     <col width="150"/>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">
                              <content styleCode="bold">Strength</content>
                           </td>
                           <td styleCode="Toprule Lrule Rrule ">
                              <content styleCode="bold">Pack Size</content>
                           </td>
                           <td styleCode="Toprule Lrule Rrule ">
                              <content styleCode="bold">NDC</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">Subcutaneous Injection</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">150 mg/mL single-dose pen</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">Carton of 1</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">0074-2100-01</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">90 mg/mL single-dose prefilled syringe</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">Carton of 2</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">0074-7040-02</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule "/>
                           <td styleCode="Toprule Lrule Rrule " align="center">Carton of 4</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">0074-7042-04</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">150 mg/mL single-dose prefilled syringe</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">Carton of 1</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">0074-1050-01</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">180 mg/1.2 mL (150 mg/mL) single-dose prefilled cartridge with on-body injector</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">Kit</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">0074-1065-01</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">360 mg/2.4 mL (150 mg/mL) single-dose prefilled cartridge with on-body injector</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">Kit </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">0074-1070-01</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">Intravenous Infusion</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">600 mg/10 mL (60 mg/mL) single-dose vial</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">Carton of 1 </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">0074-5015-01</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="italics">Subcutaneous Injection</content>
                  </paragraph>
                  <paragraph>SKYRIZI 150 mg/mL prefilled syringe or prefilled pen contains a sterile, preservative-free, colorless to yellow, and clear to slightly opalescent solution. Each prefilled syringe or prefilled pen consists of a 1 mL glass syringe with a fixed 27-gauge Â½ inch needle with needle guard. </paragraph>
                  <paragraph>SKYRIZI 90 mg/mL prefilled syringe is a sterile, preservative-free, colorless to slightly yellow and clear to slightly opalescent solution. Each prefilled syringe consists of a 1 mL glass syringe with a fixed 29-gauge Â½ inch needle with needle guard.</paragraph>
                  <paragraph>SKYRIZI 180 mg/1.2 mL (150 mg/mL) cyclic olefin polymer prefilled cartridge with a septum and cap contains a sterile, preservative-free, colorless to yellow, and clear to slightly opalescent solution for use with supplied on-body injector administration device.</paragraph>
                  <paragraph>SKYRIZI 360 mg/2.4 mL (150 mg/mL) cyclic olefin polymer prefilled cartridge with a septum and cap contains a sterile, preservative-free, colorless to yellow, and clear to slightly opalescent solution for use with supplied on-body injector administration device.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Intravenous Infusion</content>
                  </paragraph>
                  <paragraph>SKYRIZIÂ 600 mg/10 mL (60 mg/mL) vial contains a sterile and preservative-free, colorless to slightly yellow, and clear to slightly opalescent solution.Â Each glass vial is closed with a stopper and blue flip cap.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Storage and Handling</content>
                  </paragraph>
                  <list>
                     <item>Store in a refrigerator at 36Â°F to 46Â° F (2Â°C to 8Â°C).<br/>
                     </item>
                     <item>Do not freeze.<br/>
                     </item>
                     <item>Do not shake.<br/>
                     </item>
                     <item>Keep in the original cartons to protect from light.<br/>
                     </item>
                     <item>Not made with natural rubber latex.</item>
                  </list>
               </text>
               <effectiveTime value="20250507"/>
            </section>
         </component>
         <component>
            <section>
               <id root="e714990b-cd06-49f2-bb3e-7421a90128bb"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>
                  <content styleCode="bold">17 PATIENT COUNSELING INFORMATION</content>
               </title>
               <text>
                  <paragraph>Advise the patient and/or caregiver to read the FDA-approved patient labeling (<linkHtml href="#MedicationGuide">Medication Guide</linkHtml> and <linkHtml href="#InstructionsforUse">Instructions for Use</linkHtml>).Â Â </paragraph>
                  <paragraph>
                     <content styleCode="underline">Hypersensitivity Reactions</content>
                  </paragraph>
                  <paragraph>Advise patients to discontinue SKYRIZI and seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_1_Hypersensitivity_Reactions">5.1</linkHtml>
                     </content>
                     <content styleCode="italics">)].</content>
                     <content styleCode="italics">Â </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Infections</content>
                  </paragraph>
                  <paragraph>Inform patients that SKYRIZI may lower the ability of their immune system to fight infections. Instruct patients of the importance of communicating any history of infections to the healthcare provider and contacting their healthcare provider if they develop any symptoms of an infection <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_2_Infections">5.2</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Hepatotoxicity in Treatment of </content>
                     <content styleCode="underline">Inflammatory Bowel Disease</content>
                  </paragraph>
                  <paragraph>Inform patients that SKYRIZI may cause liver injury, especially during the initial 12 weeks of treatment. Instruct patients to seek immediate medical attention if they experience symptoms suggestive of liver dysfunction.Â (e.g., unexplained rash, nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine)Â <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_4_Hepatotoxicity_in">5.4</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>
                     <content styleCode="italics">.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Administration of Vaccines</content>
                  </paragraph>
                  <paragraph>Advise patients that vaccination with live vaccines is not recommended during SKYRIZI treatment and immediately prior to or after SKYRIZI treatment. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines.Â Instruct patients to inform the healthcare practitioner that they are taking SKYRIZI prior to a potential vaccination <content styleCode="italics">[see Warnings and Precautions </content>
                     <content styleCode="italics">(</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_5_Administration_of">5.5</linkHtml>
                     </content>
                     <content styleCode="italics">)</content>
                     <content styleCode="italics">]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Administration Instruction</content>
                  </paragraph>
                  <paragraph>Instruct patients or caregivers to perform the first self-injected dose under the supervision and guidance of a qualified healthcare professional for training in preparation and administration of SKYRIZI, including choosing anatomical sites for administration, and proper subcutaneous injection technique <content styleCode="italics">[see </content>
                     <content styleCode="italics">
                        <linkHtml href="#InstructionsforUse">Instructions for Use</linkHtml>
                     </content>
                     <content styleCode="italics">]</content>. </paragraph>
                  <paragraph>If using SKYRIZI 90 mg/mL, instruct patients or caregivers to administerÂ two 90 mg single-dose syringes to achieve the full 180 mg maintenance dose or fourÂ 90 mg single-dose syringes to achieve the full 360 mg maintenance dose of SKYRIZIÂ for Crohnâs diseaseÂ <content styleCode="italics">[see </content>
                     <content styleCode="italics">
                        <linkHtml href="#IFU_2x90">Instructions for Use</linkHtml>
                     </content>
                     <content styleCode="italics">]</content>.Â </paragraph>
                  <paragraph>Instruct patients or caregivers in the technique of pen or syringe disposal <content styleCode="italics">[see </content>
                     <content styleCode="italics">
                        <linkHtml href="#InstructionsforUse">Instructions for Use</linkHtml>
                     </content>
                     <content styleCode="italics">]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Pregnancy</content>
                  </paragraph>
                  <paragraph>Advise patients that there is a pregnancy registry that monitors pregnancy outcomes in womenÂ exposed to SKYRIZI during pregnancyÂ <content styleCode="italics">[see </content>
                     <content styleCode="italics">Use in Specific Populations </content>
                     <content styleCode="italics">(</content>
                     <content styleCode="italics">
                        <linkHtml href="#_8_1_Pregnancy">8.1</linkHtml>
                     </content>
                     <content styleCode="italics">)</content>
                     <content styleCode="italics">]</content>.</paragraph>
                  <paragraph>Manufactured by:<br/>AbbVie Inc.<br/>North Chicago, IL 60064, USA </paragraph>
                  <paragraph>US License Number 1889<br/>SKYRIZI<sup>Â®</sup> is a registered trademark of AbbVie Biotechnology Ltd.<br/>Â© 2019-2025 AbbVie Inc.<br/>
                  </paragraph>
                  <paragraph>20092907 Â 5/2025</paragraph>
               </text>
               <effectiveTime value="20250507"/>
            </section>
         </component>
         <component>
            <section ID="MedicationGuide">
               <id root="cc03c3f4-7f4e-4d15-b2f4-4ed2865ed2aa"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="42231-1" displayName="SPL MEDGUIDE SECTION"/>
               <title/>
               <text>
                  <table>
                     <col width="160"/>
                     <col width="53"/>
                     <col width="75"/>
                     <col width="31"/>
                     <col width="10"/>
                     <col width="96"/>
                     <col width="53"/>
                     <col width="160"/>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="8" align="center">
                              <content styleCode="bold">Medication Guide</content>
                              <content styleCode="bold">
                                 <br/>SKYRIZI</content>
                              <content styleCode="bold">
                                 <sup>Â®</sup>
                              </content>
                              <content styleCode="bold"> (sky-RIZZ-ee)</content>
                              <content styleCode="bold">
                                 <br/>(risankizumab-rzaa)</content>
                              <content styleCode="bold">
                                 <br/>injection, for subcutaneous </content>
                              <content styleCode="bold">or intravenous </content>
                              <content styleCode="bold">use</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="8">
                              <content styleCode="bold">What is the most important information I should know about SKYRIZI? </content>
                              <br/>
                              <content styleCode="bold">SKYRIZI may cause serious side effects, including:</content>
                              <br/>
                              <content styleCode="bold">Serious allergic reactions.</content> Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " colspan="3">â fainting, dizziness, feeling lightheaded (low blood pressure) </td>
                           <td styleCode="Rrule " colspan="5">â chest tightness <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " colspan="3">â swelling of your face, eyelids, lips, mouth, tongue, or throat</td>
                           <td styleCode="Rrule " colspan="5">â skin rash, hives</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " colspan="3">â trouble breathing or throat tightness</td>
                           <td styleCode="Rrule " colspan="5">â itching</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule " colspan="8">
                              <content styleCode="bold">Infections.</content> SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI. Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " colspan="2">â fever, sweats, or chills</td>
                           <td colspan="4">â muscle aches</td>
                           <td styleCode="Rrule " colspan="2">â weight loss</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " colspan="2">â cough</td>
                           <td colspan="4">â warm, red, or painful skin or sores on your body different from your psoriasis</td>
                           <td styleCode="Rrule " colspan="2">â diarrhea or stomach pain</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " colspan="2">â shortness of breath</td>
                           <td colspan="4"/>
                           <td styleCode="Rrule " colspan="2">â burning when you urinate or urinating more often than normal</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " colspan="2">â blood in your mucus<br/>(phlegm)</td>
                           <td colspan="4"/>
                           <td styleCode="Rrule " colspan="2"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule " colspan="8">
                              <content styleCode="bold">See </content>
                              <content styleCode="bold">âWhat are the possible side effects of SKYRIZI?â</content>Â <content styleCode="bold">for more information about side effects.</content>Â </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="8">
                              <content styleCode="bold">What is SKYRIZI?</content>
                              <br/>SKYRIZI is a prescription medicine used to treat:<list listType="unordered" styleCode="Disc">
                                 <item>moderate to severe plaque psoriasis in adults who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).<br/>
                                 </item>
                                 <item>active psoriatic arthritis in adults.<br/>
                                 </item>
                                 <item>moderate to severe Crohnâs disease in adults.<br/>
                                 </item>
                                 <item>moderate to severe ulcerative colitis in adults.<br/>It is not known if SKYRIZI is safe and effective in children. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="8">
                              <content styleCode="bold">Who should not use SKYRIZI?</content>
                              <br/>
                              <content styleCode="bold">Do not use SKYRIZI if you are</content> allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. See the end of this Medication Guide for a complete list of ingredients in SKYRIZI.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="8">
                              <content styleCode="bold">Before using SKYRIZI, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <br/>
                              <list>
                                 <item>have any of the conditions or symptoms listed in the section <content styleCode="bold">âWhat is the most important information I should know about SKYRIZI?â</content>
                                    <br/>
                                 </item>
                                 <item>have an infection that does not go away or that keeps coming back.<br/>
                                 </item>
                                 <item>have TB or have been in close contact with someone with TB.<br/>
                                 </item>
                                 <item>have recently received or are scheduled to receive an immunization (vaccine). Medicines that interact with the immune system may increase your risk of getting an infection after receiving live vaccines.Â You should avoid receiving live vaccines right before, during, or right after treatment with SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before receiving a vaccine.<br/>
                                 </item>
                                 <item>are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm your unborn baby.<br/>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes into your breast milk.Â <br/>
                                 </item>
                                 <item>If you become pregnant while taking SKYRIZI, you are encouraged to enroll in the Pregnancy Registry. The purpose of the pregnancy registry is to collect information about the health of you and your baby. Talk to your healthcare provider or call 1-877-302-2161 to enroll in this registry.</item>
                              </list>
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements. </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="8">
                              <content styleCode="bold">How should I use SKYRIZI?</content>
                              <br/>
                              <content styleCode="bold">See the detailed âInstructions for Useâ that comes with SKYRIZI for information on how to prepare and inject a dose of SKYRIZI, and how to properly throw away (dispose of) </content>
                              <content styleCode="bold">a </content>
                              <content styleCode="bold">used SKYRIZI </content>
                              <content styleCode="bold">prefilled </content>
                              <content styleCode="bold">pen</content>
                              <content styleCode="bold">,</content>
                              <content styleCode="bold">Â </content>
                              <content styleCode="bold">prefilled syringe</content>
                              <content styleCode="bold">, or prefilled cartridge with on-body injector</content>
                              <content styleCode="bold">. </content>
                              <br/>
                              <list>
                                 <item>Use SKYRIZI exactly as your healthcare provider tells you to use it.<br/>
                                 </item>
                                 <item>Your healthcare provider will tell you how much SKYRIZI is right for you and how often you should receive it.<br/>
                                 </item>
                                 <item>Before self-injecting with SKYRIZI prefilled pen, prefilled syringe, or prefilled cartridge with on-body injector, yourÂ healthcare provider should show you how to inject SKYRIZI.<br/>
                                 </item>
                                 <item>If you miss your SKYRIZI dose, inject a dose as soon as you remember. Then, take your next dose at your regular scheduled time. Call your healthcare provider if you are not sure what to do. <br/>
                                 </item>
                                 <item>If you inject more SKYRIZI than prescribed, call your healthcare provider right away.</item>
                              </list>Adults with plaque psoriasis or psoriatic arthritisÂ will receive SKYRIZI as an injection under the skin (subcutaneous injection) using the prefilled pen or prefilled syringe.<br/>Adults with Crohnâs disease or ulcerative colitis will receive their starter doses with SKYRIZI through a vein in the arm (intravenous infusion) in a healthcare facility by a healthcare provider. After completing the starter doses, patients will receive SKYRIZI as 1 or more injections under the skin (subcutaneous injection) using the prefilled cartridge with on-body injector or prefilled syringe.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="8">
                              <content styleCode="bold">What are the possible side effects of SKYRIZI?</content>
                              <br/>
                              <content styleCode="bold">SKYRIZI may cause serious side effects</content>
                              <content styleCode="bold"> including:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">See âWhat is the most important information I should know about SKYRIZI?â</content>
                                    <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Liver problems</content>
                                    <content styleCode="bold">Â </content>
                                    <content styleCode="bold">may happen while being treated for </content>
                                    <content styleCode="bold">Crohnâs disease</content>
                                    <content styleCode="bold"> or ulcerative colitis</content>
                                    <content styleCode="bold">.</content> A person with Crohnâs disease who received SKYRIZI by intravenous infusion (through a vein in the arm)Â developed changes in liver blood tests with a rash that led to hospitalization. Your healthcare provider will do blood tests to check your liver before, during, and at least up to 12 weeks of treatment with SKYRIZI. Your healthcare provider may stop treatment with SKYRIZI if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">
                              <list listType="unordered" styleCode="Circle">
                                 <item>unexplained rash<br/>
                                 </item>
                                 <item>nausea</item>
                              </list>
                           </td>
                           <td colspan="3">
                              <list listType="unordered" styleCode="Circle">
                                 <item>vomiting<br/>
                                 </item>
                                 <item>stomach (abdominal) pain</item>
                              </list>
                           </td>
                           <td colspan="3">
                              <list listType="unordered" styleCode="Circle">
                                 <item>tiredness (fatigue)<br/>
                                 </item>
                                 <item>loss of appetite</item>
                              </list>
                           </td>
                           <td styleCode="Rrule ">
                              <list listType="unordered" styleCode="Circle">
                                 <item>yellowing of the skin and eyes (jaundice)<br/>
                                 </item>
                                 <item>dark urine</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule " colspan="8">
                              <content styleCode="bold">The most common side effect</content>
                              <content styleCode="bold">s</content>
                              <content styleCode="bold"> of S</content>
                              <content styleCode="bold">KYRIZI</content>
                              <content styleCode="bold">Â </content>
                              <content styleCode="bold">in</content>
                              <content styleCode="bold"> people</content>
                              <content styleCode="bold"> treated</content>
                              <content styleCode="bold">Â </content>
                              <content styleCode="bold">for</content>
                              <content styleCode="bold"> Crohnâs disease </content>
                              <content styleCode="bold">and ulcerative colitis</content>
                              <content styleCode="bold"> include</content>
                              <content styleCode="bold">:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " colspan="2">
                              <list listType="unordered" styleCode="Disc">
                                 <item>upper respiratory infections<br/>
                                 </item>
                                 <item>headache<br/>
                                 </item>
                                 <item>joint pain</item>
                              </list>
                           </td>
                           <td colspan="4">
                              <list listType="unordered" styleCode="Disc">
                                 <item>stomach (abdominal) pain<br/>
                                 </item>
                                 <item>injection site reactions<br/>
                                 </item>
                                 <item>low red blood cells (anemia)</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " colspan="2">
                              <list listType="unordered" styleCode="Disc">
                                 <item>fever<br/>
                                 </item>
                                 <item>back pain<br/>
                                 </item>
                                 <item>urinary tract infection<br/>
                                 </item>
                                 <item>rash</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule " colspan="8">
                              <content styleCode="bold">The most common side effects of SKYRIZI </content>
                              <content styleCode="bold">in people treated for plaque psoriasis and psoriatic arthritis </content>
                              <content styleCode="bold">include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " colspan="2">
                              <list listType="unordered" styleCode="Disc">
                                 <item>upper respiratory infections<br/>
                                 </item>
                                 <item>headache</item>
                              </list>
                           </td>
                           <td colspan="4">
                              <list listType="unordered" styleCode="Disc">
                                 <item>feeling tired<br/>
                                 </item>
                                 <item>injection site reactions</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " colspan="2">
                              <list listType="unordered" styleCode="Disc">
                                 <item>fungal skin infections</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule " colspan="8">These are not all the possible side effects of SKYRIZI.<br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="8">
                              <content styleCode="bold">How should I store SKYRIZI?</content>
                              <br/>
                              <list>
                                 <item>Store SKYRIZI in the refrigerator between 36Â°F to 46Â°F (2Â°C to 8Â°C).<br/>
                                 </item>
                                 <item>Do not freeze SKYRIZI.<br/>
                                 </item>
                                 <item>Do not shake SKYRIZI.<br/>
                                 </item>
                                 <item>Keep SKYRIZI in the original carton to protect it from light.<br/>
                                 </item>
                                 <item>SKYRIZI is not made with natural rubber latex.</item>
                              </list>
                              <content styleCode="bold">Keep SKYRIZI and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="8">
                              <content styleCode="bold">General information about the safe and effective use of SKYRIZI</content>
                              <content styleCode="bold">.</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use SKYRIZI for a condition for which it was not prescribed. Do not give SKYRIZI to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about SKYRIZI that is written for health professionals. </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="8">
                              <content styleCode="bold">What are the ingredients in SKYRIZI?</content>
                              <br/>
                              <content styleCode="bold">Active ingredient:</content> risankizumab-rzaa.<br/>
                              <content styleCode="bold">SKYRIZI </content>
                              <content styleCode="bold">90 mg/mL </content>
                              <content styleCode="bold">inactive ingredient</content>
                              <content styleCode="bold">s:</content>Â polysorbate 20, sodium succinate, sorbitol, succinic acid, and Water for Injection, USP.<br/>
                              <content styleCode="bold">SKYRIZI </content>
                              <content styleCode="bold">150 mg/mL, 180 mg/1.2 mL, 360 mg/2.4 mL, and 600 mg/</content>
                              <content styleCode="bold">Â </content>
                              <content styleCode="bold">10 </content>
                              <content styleCode="bold"> mL i</content>
                              <content styleCode="bold">nactive ingredients:</content>Â glacial acetic acid, polysorbate 20, sodium acetate, trehalose, and Water for Injection, USP. <br/>
                              <br/>
                              <br/>Manufactured by: AbbVie Inc., North Chicago, IL 60064, U.S.A.<br/>US License Number 1889<br/>SKYRIZI<sup>Â®</sup> is a registered trademark of AbbVie Biotechnology Ltd.<br/>Â© 2019-2024 AbbVie Inc.<br/>For more information, call 1-866-SKYRIZI (1-866-759-7494) or go to www.SKYRIZI.com. </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule " colspan="5">This Medication Guide has been approved by the U.S. Food and Drug Administration<br/>20086179 R2</td>
                           <td styleCode="Toprule " colspan="3" align="right">Revised: 6/2024</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250507"/>
            </section>
         </component>
         <component>
            <section>
               <id root="536818f7-7c56-4cd2-822d-6f04c474c4dd"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="59845-8" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">I</content>
                     <content styleCode="bold">NSTRUCTIONS FOR USE</content>
                     <content styleCode="bold">
                        <br/>SKYRIZI</content>
                     <content styleCode="bold">
                        <sup>Â®</sup>
                     </content> (sky-RIZZ-ee)Â Pen<br/>(risankizumab-rzaa)<br/>injection, for subcutaneous use</paragraph>
                  <paragraph>
                     <content styleCode="bold">Read Before First Use</content>
                  </paragraph>
                  <paragraph>Refer to the <content styleCode="bold">Medication Guide</content> for product information.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Read this Instructions for Use before using SKYRIZI Pen (risankizumab-rzaa) injection.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Before using SKYRIZI, you should receive training from your healthcare provider on how to inject SKYRIZI.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">SKYRIZI Single-Dose Pen</content>
                  </paragraph>
                  <paragraph>Â Â <renderMultiMedia referencedObject="MM02000002"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Important Information</content>
                  </paragraph>
                  <list>
                     <item>Store SKYRIZI in the <content styleCode="bold">refrigerator </content>at 36Â°F to 46Â°F (2Â°C to 8Â°C).<br/>
                     </item>
                     <item>Keep SKYRIZI in the original carton to protect from light until you are ready to use.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Before injecting, </content>take the SKYRIZI carton out of the refrigerator. <content styleCode="bold">Leave </content>the carton at room temperature and out of direct sunlight for <content styleCode="bold">30 to 90 minutes.</content>
                        <br/>
                     </item>
                     <item>The liquid in the inspection window should look clear to yellow and may contain tiny white or clear particles.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use SKYRIZI if the liquid is <content styleCode="bold">discolored, cloudy</content>
                        <content styleCode="bold">Â </content>or contains <content styleCode="bold">flakes </content>or <content styleCode="bold">large particles</content>.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not </content>use SKYRIZI if theÂ <content styleCode="bold">expiration date (EXP)</content> has passed.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not </content>use SKYRIZI if the liquid has been <content styleCode="bold">frozen,</content> even if it has been thawed. <br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> shake SKYRIZI.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not </content>use if the SKYRIZI Pen has been <content styleCode="bold">dropped or damaged.</content>Â <br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not </content>use SKYRIZI if carton perforations are <content styleCode="bold">broken. Return product to pharmacy.</content>
                        <br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> remove the dark gray cap until right before injection.<br/>
                     </item>
                     <item>SKYRIZI is not made with natural rubber latex.</item>
                  </list>
                  <table>
                     <col width="298"/>
                     <col width="342"/>
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold">Prepare SKYRIZI injection</content>Â <br/>
                              <renderMultiMedia referencedObject="MM02000003"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Take</content> the SKYRIZI carton out of the refrigerator. <content styleCode="bold">Leave </content>the carton at room temperature and out of direct sunlight for <content styleCode="bold">30 to 90 minutes </content>before injecting. <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Do not</content> remove the Pen from the carton while allowing SKYRIZI to reach room temperature.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not </content>warm SKYRIZI in any other way. For example, <content styleCode="bold">do not</content> warm it in a microwave or in hot water.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> use the Pen if the liquid has been frozen, even if it has been thawed.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td>Â <renderMultiMedia referencedObject="MM02000004"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Check</content> expiration date <content styleCode="bold">(EXP). Do not </content>use the Pen if expiration date has passed.<br/>
                              <content styleCode="bold">Place</content> the following on a clean, flat surface:<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>1 single-dose SKYRIZI Pen (included)<br/>
                                 </item>
                                 <item>1 alcohol swab (not included)<br/>
                                 </item>
                                 <item>1 cotton ball or gauze pad (not included)<br/>
                                 </item>
                                 <item>FDA-cleared sharps disposal container (not included). See â<content styleCode="bold">Used SKYRIZI Prefilled Pen Disposal</content>â<content styleCode="bold">Â </content>for information on how to throw away (dispose of) used Pens. </item>
                              </list>
                              <content styleCode="bold">Wash and dry</content> your hands.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Â <renderMultiMedia referencedObject="MM02000005"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Choose</content>Â an injection site:<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>on the front of your <content styleCode="bold">thighs </content>or<br/>
                                 </item>
                                 <item>yourÂ <content styleCode="bold">abdomen</content> (belly) at least 2 inches from your navelÂ (belly button)</item>
                              </list>
                              <content styleCode="bold">W</content>
                              <content styleCode="bold">ipe</content>Â the injection site in a circular motion with the alcohol swab and let it dry.<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Do not</content> touch or blow on the injection site after it is cleaned. Allow the skin to dry before injecting.Â <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject through clothes.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject into skin that is sore, bruised, red, hard, scarred, has stretch marks, or areas with psoriasis.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td>Â <renderMultiMedia referencedObject="MM02000006"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Hold</content> the Pen with the dark gray cap pointing up.<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Pull </content>the dark gray cap straight off.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Throw</content>Â the dark gray cap away.</item>
                              </list>
                              <content styleCode="bold">Check </content>the liquid through the inspection window.<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>It is normal to see 1 or more bubbles in the liquid.Â <br/>
                                 </item>
                                 <item>The liquid should look clear to yellow and may contain tiny white or clear particles.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not </content>use if the liquid is<content styleCode="bold">Â </content>
                                    <content styleCode="bold">discolored, </content>
                                    <content styleCode="bold">cloudy</content> or contains <content styleCode="bold">flakes</content> or <content styleCode="bold">large particles</content>.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td>Â <content styleCode="bold">Give SKYRIZI injection</content>
                              <br/>
                              <renderMultiMedia referencedObject="MM02000007"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Hold </content>the Pen with your fingers on the gray hand grips.<br/>
                              <content styleCode="bold">Turn</content> the Pen so that the white needle sleeve points toward the injection site and you can see the green activator button.<br/>
                              <content styleCode="bold">Pinch</content> the skin at your injection site to make a raised area and hold it firmly.<br/>
                              <content styleCode="bold">Place</content> the white needle sleeve straight (90-degree angle) against the raised injection site.</td>
                        </tr>
                        <tr>
                           <td>Â <renderMultiMedia referencedObject="MM02000008"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Hold</content> the Pen so that you can see the green activator button and inspection window. <br/>
                              <content styleCode="bold">Push and keep pressing</content> the Pen <content styleCode="bold">down </content>against the raised injection site. <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>The Pen will activate only if the white needle sleeve is pressed down against the injection site before pressing the green activator button.</item>
                              </list>
                              <content styleCode="bold">Press</content> the green activator button and hold the Pen for <content styleCode="bold">15 </content>seconds.<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>The first loud âclickâ means the <content styleCode="bold">start </content>of the injection.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td>Â <renderMultiMedia referencedObject="MM02000009"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Keep pressing</content> the Pen <content styleCode="bold">down</content> against the injection site.<br/>The injection is<content styleCode="bold"> complete</content> when: <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>the Pen has made a second âclickâÂ <content styleCode="bold">or </content>
                                    <br/>
                                 </item>
                                 <item>the yellow indicator has filled the inspection window </item>
                              </list>This takes <content styleCode="bold">up to 15 </content>seconds.</td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">After SKYRIZI injection</content>
                              <br/>
                              <renderMultiMedia referencedObject="MM0200000A"/>
                              <br/>
                           </td>
                           <td>When the injection is complete, slowly pull the Pen straight out from the skin. <br/>The white needle sleeve will cover the needle tip and make another âclick.âÂ <br/>After completing the injection, place a cotton ball or gauze pad on the skin at the injection site. <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Do not</content> rub the injection site.<br/>
                                 </item>
                                 <item>Slight bleeding at the injection site is normal.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td>Â Â <renderMultiMedia referencedObject="MM0200000B"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Throw </content>
                              <content styleCode="bold">away (dispose of)</content>Â the used Pen in a FDA-cleared <content styleCode="bold">sharps disposal container right away after use.</content>
                              <br/>
                              <content styleCode="bold">Â Â Â </content>
                              <content styleCode="bold">â </content>
                              <content styleCode="bold">Do not</content>Â dispose of used Pens in your household trash unless your community guidelines permit this.<br/>
                              <content styleCode="bold">Â Â Â </content>
                              <content styleCode="bold">â </content>
                              <content styleCode="bold">Do not </content>recycle your sharps disposal container.<br/>The dark gray cap, alcohol swab, cotton ball or gauze pad, and packaging may be placed in your household trash.<br/>
                              <content styleCode="bold">For more information, see </content>
                              <content styleCode="bold">â</content>
                              <content styleCode="bold">Used SKYRIZI Prefilled Pen Disposal</content>
                              <content styleCode="bold">â</content>
                              <content styleCode="bold">.</content>
                              <br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Important Information</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Store SKYRIZI in the <content styleCode="bold">refrigerator</content> at 36Â°F to 46Â°F (2Â°C to 8Â°C).<br/>
                     </item>
                     <item>Keep SKYRIZI in the original carton to protect from light until you are ready to use.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Before injecting</content>, take the SKYRIZI carton out of the refrigerator. <content styleCode="bold">Leave</content> the carton at room temperature and out of direct sunlight for <content styleCode="bold">30 to 90 minutes</content>.<br/>
                     </item>
                     <item>The liquid in the inspection window should look clear to yellow and may contain tiny white or clear particles.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use SKYRIZI if the liquid is <content styleCode="bold">discolored</content>, <content styleCode="bold">cloudy</content> or contains <content styleCode="bold">flakes</content> or <content styleCode="bold">large particles</content>.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use SKYRIZI if theÂ <content styleCode="bold">expiration date (EXP) </content>has passed.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use SKYRIZI if the liquid has been <content styleCode="bold">frozen</content>, even if it has been thawed. <br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> shake SKYRIZI.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use if the SKYRIZI Pen has been <content styleCode="bold">dropped or damaged</content>. <br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use SKYRIZI if carton perforations are <content styleCode="bold">broken. Return product to pharmacy</content>.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> remove the dark gray cap until right before injection.<br/>
                     </item>
                     <item>SKYRIZI is not made with natural rubber latex.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep the </content>
                     <content styleCode="bold">SKYRIZI</content>
                     <content styleCode="bold"> Pen and sharps disposal container out of the reach of children. </content>
                  </paragraph>
                  <paragraph>Call your healthcare provider or <content styleCode="bold">(866) SKYRIZI or (866) </content>
                     <content styleCode="bold">759-7494</content>Â if you need help or do not know how to proceed.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Questions About Using the SKYRIZI Pen</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Q.</content>
		Â Â Â Â Â 
	<content styleCode="bold">What if I need help on how to inject SKYRIZI? </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">A. </content>
		Â Â Â Â Â 
	Call your healthcare provider <content styleCode="bold">or (866) SKYRIZI or (866) 759-7494</content>
                     <content styleCode="bold">Â </content>if you need help.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Q.</content>
		Â Â Â Â Â 
	<content styleCode="bold">I have removed the dark gray cap and pressed the green activator button. Why isnât my injection starting?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">A.</content>
		Â Â Â Â Â 
	The green activator button will not start the injection unless the white needle sleeve is pressed firmly against the injection site.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Q.</content>
		Â Â Â Â Â 
	<content styleCode="bold">How do I know when the injection is complete?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">A.</content>
		Â Â Â Â Â 
	The injection is complete if the Pen makes a second âclickâ or the yellow indicator fills the inspection window. This takes up to <content styleCode="bold">15 </content>seconds.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Q.</content>
		Â Â Â Â Â 
	<content styleCode="bold">What should I do if there are more than a few drops of liquid on the injection site?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">A.</content>
		Â Â Â Â Â 
	Call (866) SKYRIZI or (866) 759-7494 for help.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Q.</content>
		Â Â Â Â Â 
	<content styleCode="bold">What should I do with the used Pen after my injection?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">A.</content>
		Â Â Â Â Â 
	Dispose of the used Pen in a sharps disposal container right after use. <content styleCode="bold">Do not </content>dispose of the used Pen in your household trash.</paragraph>
                  <paragraph>You can sign up to receive sharps containers for SKYRIZI Pen disposal at no additional cost by going to <content styleCode="bold">www.</content>
                     <content styleCode="bold">SKYRIZI</content>
                     <content styleCode="bold">.com </content>or calling <content styleCode="bold">(866) </content>
                     <content styleCode="bold">SKYRIZI</content>
                     <content styleCode="bold"> or (866) </content>
                     <content styleCode="bold">759-7494</content>
                     <content styleCode="bold">.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Call (866) </content>
                     <content styleCode="bold">SKYRIZI</content>
                     <content styleCode="bold"> or (866) </content>
                     <content styleCode="bold">759-7494</content>
                     <content styleCode="bold"> or go to www.</content>
                     <content styleCode="bold">SKYRIZI</content>
                     <content styleCode="bold">.com for help with your injection.</content>
                  </paragraph>
                  <table>
                     <col width="109"/>
                     <col width="528"/>
                     <tbody>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM0200000C"/>
                           </td>
                           <td>To help remember when to inject, mark your calendar with the date you give your SKYRIZI injection.</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Keep the </content>
                     <content styleCode="bold">SKYRIZI</content>
                     <content styleCode="bold"> Pen and sharps disposal container out of the reach of children. </content>
                  </paragraph>
                  <paragraph>Call your healthcare provider or (866) SKYRIZI or (866) 759-7494 if you need help or have questions about the use of SKYRIZI.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Used SKYRIZI Prefilled Pen Disposal</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>made of a heavy-duty plastic, <br/>
                     </item>
                     <item>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,<br/>
                     </item>
                     <item>upright and stable during use, <br/>
                     </item>
                     <item>leak-resistant, and<br/>
                     </item>
                     <item>properly labeled to warn of hazardous waste inside the container.</item>
                  </list>
                  <paragraph>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used Pens.</paragraph>
                  <paragraph>For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDAâs website at: www.fda.gov/safesharpsdisposal.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not</content> recycle your used sharps disposal container.</paragraph>
                  <paragraph>Manufactured by: AbbVie Inc., North Chicago, IL 60064, U.S.A. <br/>US License Number 1889<br/>SKYRIZI<sup>Â®</sup> is a registered trademark of AbbVie Biotechnology Ltd.<br/>Â© 2019-2024Â AbbVie Inc.<br/>20086179Â </paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration. </paragraph>
                  <paragraph>Revised: 6/2024</paragraph>
               </text>
               <effectiveTime value="20250507"/>
               <component>
                  <observationMedia ID="MM02000002">
                     <text>SKYRIZI Single-Dose Pen</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000003">
                     <text>Step 1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000004">
                     <text>Step 2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000005">
                     <text>Step 3</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000006">
                     <text>Step 4</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000007">
                     <text>Step 5</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000008">
                     <text>Step 6</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000009">
                     <text>Step 7</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0200000A">
                     <text>Step 8</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-0a.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0200000B">
                     <text>Step 9</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-0b.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0200000C">
                     <text>Month</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-0c.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="InstructionsforUse">
               <id root="f2236a29-363b-481b-9086-1232e039a0b8"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="59845-8" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">INSTRUCTIONS FOR USE</content>
                     <content styleCode="bold">
                        <br/>SKYRIZI</content>
                     <content styleCode="bold">
                        <sup>Â®</sup>
                     </content> (sky-RIZZ-ee)<br/>(risankizumab-rzaa)<br/>injection, for subcutaneous use <br/>150 mg/mL prefilled syringe</paragraph>
                  <paragraph>
                     <content styleCode="bold">Read Before First Use</content>
                  </paragraph>
                  <paragraph>Refer to the <content styleCode="bold">Medication Guide </content>for product information. </paragraph>
                  <paragraph>
                     <content styleCode="bold">SKYRIZI Single-Dose Prefilled Syringe</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM0300000D"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Important Information</content>
                  </paragraph>
                  <list>
                     <item>Keep SKYRIZI in the original carton to protect from light until time to use.<br/>
                     </item>
                     <item>The liquid should look clear to yellow and may contain tiny white or clear particles.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use SKYRIZI if the liquid is <content styleCode="bold">discolored, </content>
                        <content styleCode="bold">cloudy</content> or contains <content styleCode="bold">flakes</content> or <content styleCode="bold">large particles</content>. <br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use SKYRIZI if the <content styleCode="bold">expiration date (EXP:)</content> shown on the carton and prefilled syringe has passed. <br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use SKYRIZI if the liquid has been <content styleCode="bold">frozen </content>(even if thawed). <br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not </content>shake SKYRIZI. <br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use SKYRIZI if the prefilled syringe has been <content styleCode="bold">dropped or damaged</content>. <br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use SKYRIZI if carton perforations are <content styleCode="bold">broken</content>.<content styleCode="bold"> Return product to the pharmacy</content>. <br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> remove the needle cover until right before giving the injection. </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep SKYRIZI and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Please Read Complete Instructions for Use Before Using SKYRIZI </content>
                     <content styleCode="bold">Prefilled </content>
                     <content styleCode="bold">Syringe</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Before Injecting</content>
                  </paragraph>
                  <list>
                     <item>
                        <content styleCode="bold">Receive</content> training on how to inject SKYRIZI before giving injection. Call your healthcare provider or <content styleCode="bold">(866) SKYRIZI or (866) 759-7494</content> if you need help. <br/>
                     </item>
                     <item>
                        <content styleCode="bold">Mark your calendar</content> ahead of time to remember when to take SKYRIZI. <br/>
                     </item>
                     <item>
                        <content styleCode="bold">Leave</content> the carton at room temperature and out of direct sunlight for <content styleCode="bold">15 to 30 minutes</content> to warm.<list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Do not</content> remove the syringe from the carton while allowing SKYRIZI to reach room temperature.<br/>
                           </item>
                           <item>
                              <content styleCode="bold">Do not</content> warm SKYRIZI in any other way (for example, <content styleCode="bold">do not</content> warm it in a microwave or in hot water). </item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Important Information</content>
                  </paragraph>
                  <list>
                     <item>The liquid should look clear to yellow and may contain tiny white or clear particles.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use SKYRIZI if the liquid is <content styleCode="bold">discolored, </content>
                        <content styleCode="bold">cloudy</content> or contains <content styleCode="bold">flakes</content> or <content styleCode="bold">large particles</content>. <br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use SKYRIZI if the <content styleCode="bold">expiration date (EXP:)</content> shown on the carton and prefilled syringe has passed. <br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use SKYRIZI if the syringe has been <content styleCode="bold">dropped or damaged</content>. <br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use SKYRIZI if carton perforations are <content styleCode="bold">broken</content>. <content styleCode="bold">Return product to the pharmacy</content>. </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Storage Information</content>
                  </paragraph>
                  <list>
                     <item>Store SKYRIZI in the refrigerator between 36Â°F to 46Â°F (2Â°C to 8Â°C). <br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> shake SKYRIZI. <br/>
                     </item>
                     <item>Keep SKYRIZI in the original carton to protect from light until time to use.<br/>
                     </item>
                     <item>SKYRIZI is not made with natural rubber latex.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use if the liquid has been frozen (even if thawed). </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep SKYRIZI and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>Call your healthcare provider or <content styleCode="bold">(866) SKYRIZI or (866) 759-7494</content> if you need help or do not know how to proceed. </paragraph>
                  <table>
                     <col width="38"/>
                     <col width="224"/>
                     <col width="364"/>
                     <tbody>
                        <tr>
                           <td/>
                           <td>Â <renderMultiMedia referencedObject="MM0200000E"/>Â <br/>Â </td>
                           <td>
                              <content styleCode="bold">Gather </content>the supplies for the injection. <br/>
                              <list>
                                 <item>
                                    <content styleCode="bold">Do not</content> hold or pull the plunger rod when removing the prefilled syringe from the sleeve.</item>
                              </list>
                              <content styleCode="bold">Place</content> the following on a clean, flat surface: <br/>
                              <list>
                                 <item>
                                    <content styleCode="bold">1 prefilled syringe (included)</content>
                                    <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">1 alcohol swab</content>
                                    <content styleCode="bold">Â </content>(not included)Â <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">1 cotton ball</content> or gauze padÂ (not included)Â <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">FDA-cleared sharps disposal container</content>Â (not included). See â<content styleCode="bold">Used SKYRIZI Prefilled Syringe Disposal</content>â for information on how to throw away (dispose of) used prefilled syringes.</item>
                              </list>
                              <content styleCode="bold">Wash and dry</content> your hands. <br/>
                           </td>
                        </tr>
                        <tr>
                           <td/>
                           <td>
                              <renderMultiMedia referencedObject="MM0200000F"/>
                           </td>
                           <td>
                              <content styleCode="bold">Remove</content> prefilled syringe from cardboard sleeve by holding the finger grip.</td>
                        </tr>
                        <tr>
                           <td/>
                           <td>
                              <renderMultiMedia referencedObject="MM03000010"/>Â <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Pick</content> from the 3 injectable areas: <br/>
                              <list>
                                 <item>Front of <content styleCode="bold">left thigh</content> or <content styleCode="bold">right thigh</content>
                                    <br/>
                                 </item>
                                 <item>Your <content styleCode="bold">abdomen</content> (belly) at least 2 inches from your navel (belly button) </item>
                              </list>
                              <content styleCode="bold">Wipe</content> the injection site in a circular motion with the alcohol swab <content styleCode="bold">before the injection.</content>
                              <list>
                                 <item>
                                    <content styleCode="bold">Do not</content> touch or blow on the injection site after it is cleaned. Allow the skin to dry before injecting. <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject through clothes. <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject into skin that is sore, bruised, red, hard, scarred, or has stretch marks, or into areas affected by psoriasis. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td/>
                           <td>Â <renderMultiMedia referencedObject="MM03000011"/>
                              <br/>Â </td>
                           <td>
                              <content styleCode="bold">Hold</content> the prefilled syringe with covered needle facing down, as shown. <br/>
                              <content styleCode="bold">Check</content> the liquid in the prefilled syringe.<list>
                                 <item>It is normal to see 1 or more bubbles in the window.<br/>
                                 </item>
                                 <item>The liquid should look clear to yellow and may contain tiny white or clear particles.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> use the prefilled syringe if the liquid is <content styleCode="bold">discolored, </content>
                                    <content styleCode="bold">cloudy</content> or contains <content styleCode="bold">flakes</content> or <content styleCode="bold">large particles</content>. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td/>
                           <td>
                              <renderMultiMedia referencedObject="MM03000012"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Remove</content> the needle cover. <list>
                                 <item>Hold the prefilled syringe in 1 hand between the finger grip and needle cover.<br/>
                                 </item>
                                 <item>With the other hand, gently pull the needle cover straight off.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> hold or pull the plunger rod when removing the needle cover. <br/>
                                 </item>
                                 <item>You may see a drop of liquid at the end of the needle. This is normal.<br/>
                                 </item>
                                 <item>Throw away the needle cover.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> touch the needle with your fingers or let the needle touch anything. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td/>
                           <td>
                              <renderMultiMedia referencedObject="MM03000013"/>
                              <br/>Â </td>
                           <td>
                              <content styleCode="bold">Hold</content> the body of the prefilled syringe in 1 hand between the thumb and index fingers. <br/>
                              <content styleCode="bold">P</content>
                              <content styleCode="bold">inch</content> the area of cleaned skin with your other hand and hold it firmly. <br/>
                              <content styleCode="bold">Insert</content> the needle into the skin at about a <content styleCode="bold">45-degree angle</content> using a quick, short movement. Hold angle steady. </td>
                        </tr>
                        <tr>
                           <td/>
                           <td>
                              <renderMultiMedia referencedObject="MM03000014"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Slowly push</content> the plunger rod all the way in until all of the liquid is injected, and the prefilled syringe is empty. <br/>
                              <content styleCode="bold">Pull</content> the needle out of the skin while keeping the prefilled syringe at the same angle. <br/>
                              <content styleCode="bold">Release</content> the plunger rod and allow the prefilled syringe to move up until the entire needle is covered by the needle guard. <br/>
                              <content styleCode="bold">The prefilled syringe needle guard will not activate unless all the liquid has been injected</content>. <list>
                                 <item>
                                    <content styleCode="bold">Press</content> a cotton ball or gauze pad over the injection site and hold for 10 seconds. <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> rub the injection site. You may have slight bleeding. This is normal. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td/>
                           <td>
                              <renderMultiMedia referencedObject="MM03000015"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Put</content> your used prefilled syringe in a <content styleCode="bold">FDA-cleared sharps disposal container right away after use</content>. <br/>
                              <list>
                                 <item>
                                    <content styleCode="bold">Do not</content> throw away (dispose of) the used prefilled syringe in the household trash. </item>
                              </list>
                              <content styleCode="bold">For more information, see </content>
                              <content styleCode="bold">âUsed SKYRIZI Prefilled Syringe Disposalâ</content>
                              <content styleCode="bold"> section</content>. </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Questions About Using SKYRIZI</content>
                  </paragraph>
                  <table>
                     <col width="593"/>
                     <tbody>
                        <tr>
                           <td>Q.<content styleCode="bold">Â </content>
                              <content styleCode="bold">What if I need help on how to inject SKYRIZI? </content>
                           </td>
                        </tr>
                        <tr>
                           <td>A. Call your healthcare provider or <content styleCode="bold">(866) SKYRIZI or (866) 759-7494</content> if you need help. <br/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Q.Â <content styleCode="bold">What should I do with the used prefilled syringe after my injection?</content>
                           </td>
                        </tr>
                        <tr>
                           <td>A. Throw away (dispose of) the used prefilled syringe in a sharps disposal container and not your household trash. <br/>You can sign up to receive sharps containers for SKYRIZI syringe disposal at no additional cost by going to <content styleCode="bold">www.SKYRIZI</content>
                              <content styleCode="bold">.com </content>or calling <content styleCode="bold">(866) SKYRIZI or (866) 759-7494</content>. <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
		Â Â Â Â Â 
	
		Â Â Â Â Â 
	<br/>Q.<content styleCode="bold">Â </content>
                              <content styleCode="bold">How do I know when the injection is complete?</content>Â </td>
                        </tr>
                        <tr>
                           <td>A. The injection is complete when the prefilled syringe is empty, the plunger rod is pushed all the way in, and the syringe needle guard is activated. <br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Used SKYRIZI Prefilled Syringe Disposal</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">If you do not have a FDA-cleared sharps disposal container, you may use a household container that is: </content>
                  </paragraph>
                  <list>
                     <item>made of a heavy-duty plastic, <br/>
                     </item>
                     <item>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out, <br/>
                     </item>
                     <item>upright and stable during use,<br/>
                     </item>
                     <item>leak-resistant, and<br/>
                     </item>
                     <item>properly labeled to warn of hazardous waste inside the container.</item>
                  </list>
                  <paragraph>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. </paragraph>
                  <paragraph>For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDAâs website at: www.fda.gov/safesharpsdisposal. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not</content> recycle your used sharps disposal container.</paragraph>
                  <paragraph>Manufactured by: AbbVie Inc., North Chicago, IL 60064, U.S.A. <br/>US License Number 1889<br/>SKYRIZI<sup>Â®</sup> is a registered trademark of AbbVie Biotechnology Ltd.<br/>Â© 2019-2024 AbbVie Inc.<br/>20086082</paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration. </paragraph>
                  <paragraph>Revised: 6/2024Â </paragraph>
               </text>
               <effectiveTime value="20250507"/>
               <component>
                  <observationMedia ID="MM0300000D">
                     <text>SKYRIZI Single-Dose Prefilled Syringe</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-0d.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0200000E">
                     <text>Step 1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-0e.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0200000F">
                     <text>Step 2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-0f.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000010">
                     <text>Step 3</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000011">
                     <text>Step 4</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000012">
                     <text>Step 5</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000013">
                     <text>Step 6</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000014">
                     <text>Step 7</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000015">
                     <text>Step 8</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="IFU_2x90">
               <id root="7123aade-b93e-415f-9c92-02c00828cb69"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="59845-8" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Instructions for Use</content>
                     <content styleCode="bold">
                        <br/>SKYRIZI</content>
                     <content styleCode="bold">
                        <sup>Â®</sup>
                     </content> (sky-RIZZ-ee)<br/>(risankizumab-rzaa)<br/>injection, for subcutaneous use</paragraph>
                  <paragraph>2 x 90 mg/mL single-dose prefilled syringes for a total 180 mg/2 mL dose</paragraph>
                  <paragraph>
                     <content styleCode="bold">Read Before First Use</content>
                  </paragraph>
                  <paragraph>Refer to the <content styleCode="bold">Medication Guide</content> for product information.</paragraph>
                  <paragraph>
                     <content styleCode="bold">SKYRIZI Single-Dose Prefilled Syringe</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000016"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Keep SKYRIZI and all medicines out of the reach of children. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Important Information:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Keep SKYRIZI in the original carton to protect from light until time to use.<br/>
                     </item>
                     <item>The liquid should look clear to slightly yellow and may contain tiny white or clear particles.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use SKYRIZI if the liquid is <content styleCode="bold">discolored</content>, <content styleCode="bold">cloudy</content> or contains <content styleCode="bold">flakes</content> or <content styleCode="bold">large particles</content>. <content styleCode="bold">Return product</content> to pharmacy.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use SKYRIZI if the <content styleCode="bold">expiration date (EXP:)</content> shown on the carton and prefilled syringe has passed. <content styleCode="bold">Return product</content> to pharmacy.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use SKYRIZI if the liquid has been <content styleCode="bold">frozen</content> (even if thawed).<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> shake the syringe.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use SKYRIZI if the prefilled syringe has been <content styleCode="bold">dropped</content> or <content styleCode="bold">damaged</content>. <content styleCode="bold">Return product</content> to pharmacy.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use SKYRIZI if carton perforations are <content styleCode="bold">broken</content>. <content styleCode="bold">Return product to the pharmacy</content>.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> remove the needle cover until right before giving the injections.<br/>
                     </item>
                     <item>SKYRIZI is not made with natural rubber latex.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Please Read Complete Instructions for Use Before Using SKYRIZI Prefilled Syringe</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Before Injecting:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Receive</content> training on how to inject <content styleCode="bold">SKYRIZI</content> before giving injections. Call your healthcare provider or <content styleCode="bold">(866)</content>Â <content styleCode="bold">SKYRIZI</content>Â <content styleCode="bold">or (866) 759-7494</content> if you need help.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Mark your calendar </content>ahead of time to remember when to take SKYRIZI.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Leave</content> the carton at room temperature and out of direct sunlight for <content styleCode="bold">15 to 30 minutes</content> to warm.<list listType="unordered" styleCode="Circle">
                           <item>
                              <content styleCode="bold">Do not</content> remove the prefilled syringes from the carton while allowing SKYRIZI to reach room temperature.<br/>
                           </item>
                           <item>
                              <content styleCode="bold">Do not</content> warm SKYRIZI in any other way (for example, <content styleCode="bold">do not</content> warm it in a microwave or in hot water).</item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Important</content>Â <content styleCode="bold">Information</content>:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>The liquid should look clear to slightly yellow and may contain tinyÂ white or clear particles.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use SKYRIZI if the liquid is <content styleCode="bold">discolored</content>, <content styleCode="bold">cloudy</content> or contains <content styleCode="bold">flakes</content>Â or <content styleCode="bold">large</content>Â <content styleCode="bold">particles</content>. <content styleCode="bold">Return</content>Â <content styleCode="bold">product</content> to pharmacy.<br/>
                     </item>
                     <item>Do not use SKYRIZI if the <content styleCode="bold">expiration</content>Â <content styleCode="bold">date</content>Â <content styleCode="bold">(EXP:)</content> shown on the carton and prefilled syringeÂ has passed. <content styleCode="bold">Return</content>Â <content styleCode="bold">product</content> to pharmacy.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do</content>Â <content styleCode="bold">not</content> use SKYRIZI if the prefilled syringe has been <content styleCode="bold">dropped</content>Â <content styleCode="bold">or</content>Â <content styleCode="bold">damaged</content>. <content styleCode="bold">Return</content>Â <content styleCode="bold">product</content> to pharmacy.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do</content>Â <content styleCode="bold">not</content> use SKYRIZI if carton perforations are <content styleCode="bold">broken</content>. <content styleCode="bold">Return</content>Â <content styleCode="bold">product</content> to pharmacy.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Storage Information:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Store SKYRIZI in the refrigerator between <content styleCode="bold">36Â°F to 46Â°F</content> (2Â°C to 8Â°C).<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> shake SKYRIZI. <br/>
                     </item>
                     <item>Keep SKYRIZI in the original carton to protect from light until time to use.<br/>
                     </item>
                     <item>SKYRIZI is not made with natural rubber latex.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use if liquid has been frozen (even if thawed).</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep SKYRIZI and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>Call your healthcare provider or <content styleCode="bold">(866)</content>Â <content styleCode="bold">SKYRIZI</content> or <content styleCode="bold">(866) 759-7494</content> if you need help or do not know how to proceed.</paragraph>
                  <table>
                     <col width="234"/>
                     <col width="390"/>
                     <tbody>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM02000017"/>
                              <br/>
                           </td>
                           <td>
                              <renderMultiMedia referencedObject="MM03000018"/>
                              <br/>
                              <content styleCode="bold">Gather</content> the supplies for the injections and place the following on a clean, flat surface:<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">2 prefilled syringes </content>
                                    <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">2 alcohol swabs</content> and <content styleCode="bold">2 cotton balls</content> or gauze pads (not included)<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">FDA-cleared sharps disposal container</content> (not included) See â<content styleCode="bold">Used SKYRIZI Prefilled Syringe Disposal</content>â<content styleCode="bold">Â </content>for information on how to throw away (dispose of) used prefilled syringes.</item>
                              </list>
                              <content styleCode="bold">Wash and dry</content> your hands.<br/>Start with 1 prefilled syringe for first injection.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM02000019"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Pick</content> from the 3 injectable areas:<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Front of <content styleCode="bold">left thigh</content> or <content styleCode="bold">right thigh</content>
                                    <br/>
                                 </item>
                                 <item>Your <content styleCode="bold">abdomen</content> (belly) at least 2 inches from your navel (belly button)</item>
                              </list>
                              <renderMultiMedia referencedObject="MM0300001A"/>
                              <br/>
                              <content styleCode="bold">Wipe</content> the injection site in a circular motion with the alcohol swab (before <content styleCode="bold">both injections</content>)<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Do not</content> touch or blow on the injection site after it is cleaned. Allow the skin to dry before injecting.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject through clothes.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject into skin that is sore, bruised, red, hard, scarred, or has stretch marks.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM0200001B"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Hold</content> the prefilled syringe with covered needle facing down, as shown.<br/>
                              <content styleCode="bold">Check</content> the liquid in the prefilled syringe.<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>It is normal to see one or more bubbles in the window.<br/>
                                 </item>
                                 <item>The liquid should look clear to slightly yellow and may contain tiny white or clear particles.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> use the prefilled syringe if liquid is <content styleCode="bold">discolored</content>, <content styleCode="bold">cloudy</content> or contains <content styleCode="bold">flakes</content> or <content styleCode="bold">large particles</content>.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM0200001C"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Remove</content> the needle cover.<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Do not</content> hold or pull plunger rod when removing the needle cover.<br/>
                                 </item>
                                 <item>Hold the syringe in 1 hand between the finger grip and needle cover.<br/>
                                 </item>
                                 <item>With the other hand, carefully pull the needle cover straight off.<br/>
                                 </item>
                                 <item>You may see a drop of liquid at the end of the needle. This is normal.<br/>
                                 </item>
                                 <item>Throw away the needle cover.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> touch the needle with your fingers or let the needle touch anything.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM0200001D"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Hold</content> the body of the prefilled syringe in 1 hand between the thumb and index finger.<br/>
                              <content styleCode="bold">Gently pinch</content> the area of cleaned skin with your other hand and hold it firmly.<br/>
                              <content styleCode="bold">Insert</content> the needle into the skin at about a <content styleCode="bold">45-degree angle</content> using a quick, short movement. Hold angle steady.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM0200001E"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Slowly push</content> the plunger rod all the way in until all of the liquid is injected and the syringe is empty.<br/>
                              <content styleCode="bold">Pull</content> the needle out of the skin while keeping the syringe at the same angle.<br/>
                              <content styleCode="bold">Release</content> the plunger rod.<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Allow the prefilled syringe to move up until the entire needle is covered by the needle guard.</item>
                              </list>
                              <content styleCode="bold">The needle guard will not automatically activate unless all the liquid has been injected.</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Press</content> a cotton ball or gauze pad over the injection site and hold for 10 seconds.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> rub the injection site. You may have slight bleeding. This is normal.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM0200001F"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Repeat Steps 2 through 6</content> with the 2nd prefilled syringe for a full dose.<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Use the 2nd prefilled syringe right after using the 1st syringe.</item>
                              </list>
                              <renderMultiMedia referencedObject="MM0300001A"/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM02000020"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Put</content> your used prefilled syringes in an <content styleCode="bold">FDA-cleared sharps disposal container right away after use.</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Do not</content> throw away (dispose of) used prefilled syringes in the household trash.</item>
                              </list>For more information, or if you do not have an FDA-cleared sharps container see â<content styleCode="bold">Used SKYRIZI Prefilled Syringe Disposal</content>â section located on the other side of these instructions.</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Questions About Using the SKYRIZI Syringe</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Q.</content>Â <content styleCode="bold">What if I have not received in-person training from a healthcare professional?</content>
                  </paragraph>
                  <paragraph>A. Call your healthcare provider or <content styleCode="bold">(866) SKYRIZI</content> or <content styleCode="bold">(866) 759-7494</content> if you need help. <content styleCode="bold">Receive</content> training on how to inject <content styleCode="bold">SKYRIZI</content> before giving injections.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Q. What should I do with both used prefilled syringes after my injections?</content>
                  </paragraph>
                  <paragraph>A. Throw away (dispose of) both used prefilled syringes in a sharps disposal container. <content styleCode="bold">Do not</content> put in household trash. For more information, see â<content styleCode="bold">Used SKYRIZI Prefilled Syringe Disposal</content>â section.</paragraph>
                  <paragraph>You can sign up to receive sharps containers for SKYRIZI prefilled syringe disposal at no additional cost by going to <linkHtml href="http://www.SKYRIZI.com">www.SKYRIZI.com</linkHtml> or calling (866) 759-7494</paragraph>
                  <paragraph>
                     <content styleCode="bold">Q. How do I know when the injection is complete?</content>
                  </paragraph>
                  <paragraph>A. The injection is complete when the prefilled syringe is empty, the plunger rod is pushed all the way in, and the syringe needle guard is activated.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Used SKYRIZI Prefilled Syringe Disposal</content>
                  </paragraph>
                  <paragraph>Throw away (dispose of) both used prefilled syringes in a sharps disposal container. <content styleCode="bold">Do not</content> put in household trash.</paragraph>
                  <paragraph>
                     <content styleCode="bold">If you do not have an FDA-cleared sharps disposal container, you may use a household container that:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>is made of a heavy-duty plastic,<br/>
                     </item>
                     <item>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,<br/>
                     </item>
                     <item>stays upright and stable during use,<br/>
                     </item>
                     <item>is leak-resistant, and<br/>
                     </item>
                     <item>has been properly labeled to warn of hazardous waste inside the container.</item>
                  </list>
                  <paragraph>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes.</paragraph>
                  <paragraph>For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: <linkHtml href="http://www.fda.gov/safesharpsdisposal">www.fda.gov/safesharpsdisposal</linkHtml>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not</content> recycle your used sharps disposal container.</paragraph>
                  <paragraph>Manufactured by: AbbVie Inc., North Chicago, IL 60064, U.S.A.<br/>US License Number 1889<br/>SKYRIZI<sup>Â®</sup> is a trademark of AbbVie Biotechnology Ltd.<br/>Â© 2019-2024 AbbVie Inc.<br/>20078139</paragraph>
                  <paragraph>This Instructions for Use have been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>Revised: 3/2024</paragraph>
               </text>
               <effectiveTime value="20250507"/>
               <component>
                  <observationMedia ID="MM03000016">
                     <text>SKYRIZI Single-Dose Prefilled Syringe</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000017">
                     <text>A close-up of a medical equipment

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-17.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000018">
                     <text>Graphical user interface, text, application

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-18.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000019">
                     <text>A diagram of a person's body

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-19.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0300001A">
                     <text>Text

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-1a.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0200001B">
                     <text>A close-up of a syringe

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-1b.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0200001C">
                     <text>A hand holding a syringe

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-1c.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0200001D">
                     <text>A close-up of a hand holding a syringe

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-1d.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0200001E">
                     <text>A close-up of a person's hand holding a syringe

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-1e.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0200001F">
                     <text>A sign with a syringe and a needle

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-1f.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000020">
                     <text>A hand putting a syringe into a container

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-20.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="bc3e656d-6f09-456b-b9af-e34a024fd67d"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="59845-8" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Instructions for Use</content>
                     <content styleCode="bold">
                        <br/>SKYRIZI</content>
                     <content styleCode="bold">
                        <sup>Â®</sup>
                     </content> (sky-RIZZ-ee)<br/>(risankizumab-rzaa)<br/>injection, for subcutaneous use<br/>
                     <br/>4 x 90 mg/mL single-dose prefilled syringes for a total 360 mg/4 mL dose</paragraph>
                  <paragraph>
                     <content styleCode="bold">Read Before First Use</content>
                  </paragraph>
                  <paragraph>Refer to the <content styleCode="bold">Medication Guide</content> for product information.</paragraph>
                  <paragraph>
                     <content styleCode="bold">SKYRIZI Single-Dose Prefilled Syringe</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000016"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Keep SKYRIZI and all medicines out of the reach of children. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Important Information:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Keep SKYRIZI in the original carton to protect from light until time to use.<br/>
                     </item>
                     <item>The liquid should look clear to slightly yellow and may contain tiny white or clear particles.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use SKYRIZI if the liquid is <content styleCode="bold">discolored</content>, <content styleCode="bold">cloudy</content> or contains <content styleCode="bold">flakes</content> or <content styleCode="bold">large particles</content>. <content styleCode="bold">Return product</content> to pharmacy.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use SKYRIZI if the <content styleCode="bold">expiration date (EXP:)</content> shown on the carton and prefilled syringe has passed. <content styleCode="bold">Return product</content> to pharmacy.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use SKYRIZI if the liquid has been <content styleCode="bold">frozen</content> (even if thawed).<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> shake the syringe.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use SKYRIZI if the prefilled syringe has been <content styleCode="bold">dropped</content> or <content styleCode="bold">damaged</content>. <content styleCode="bold">Return product</content> to pharmacy.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use SKYRIZI if carton perforations are <content styleCode="bold">broken</content>. <content styleCode="bold">Return product to the pharmacy</content>.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> remove the needle cover until right before giving the injections.<br/>
                     </item>
                     <item>SKYRIZI is not made with natural rubber latex.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Please Read Complete Instructions for Use Before Using SKYRIZI Prefilled Syringe</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Before Injecting:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Receive</content> training on how to inject <content styleCode="bold">SKYRIZI</content> before giving injections. Call your healthcare provider or <content styleCode="bold">(866)</content>Â <content styleCode="bold">SKYRIZI</content>Â <content styleCode="bold">or (866) 759-7494</content> if you need help.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Mark your calendar </content>ahead of time to remember when to take SKYRIZI.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Leave</content> the carton at room temperature and out of direct sunlight for <content styleCode="bold">15 to 30 minutes</content> to warm.<list listType="unordered" styleCode="Circle">
                           <item>
                              <content styleCode="bold">Do not</content> remove the prefilled syringes from the carton while allowing SKYRIZI to reach room temperature.<br/>
                           </item>
                           <item>
                              <content styleCode="bold">Do not</content> warm SKYRIZI in any other way (for example, <content styleCode="bold">do not</content> warm it in a microwave or in hot water).</item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Important</content>Â <content styleCode="bold">Information</content>:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>The liquid should look clear to slightly yellow and may contain tinyÂ white or clear particles.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use SKYRIZI if the liquid is <content styleCode="bold">discolored</content>, <content styleCode="bold">cloudy</content> or contains <content styleCode="bold">flakes</content>Â or <content styleCode="bold">large</content>Â <content styleCode="bold">particles</content>. <content styleCode="bold">Return</content>Â <content styleCode="bold">product</content> to pharmacy.<br/>
                     </item>
                     <item>Do not use SKYRIZI if the <content styleCode="bold">expiration</content>Â <content styleCode="bold">date</content>Â <content styleCode="bold">(EXP:)</content> shown on the carton and prefilled syringe has passed. <content styleCode="bold">Return</content>Â <content styleCode="bold">product</content> to pharmacy.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do</content>Â <content styleCode="bold">not</content> use SKYRIZI if the prefilled syringe has been <content styleCode="bold">dropped</content>Â <content styleCode="bold">or</content>Â <content styleCode="bold">damaged</content>. <content styleCode="bold">Return</content>Â <content styleCode="bold">product</content> to pharmacy.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do</content>Â <content styleCode="bold">not</content> use SKYRIZI if carton perforations are <content styleCode="bold">broken</content>. <content styleCode="bold">Return</content>Â <content styleCode="bold">product</content> to pharmacy.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Storage Information:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Store SKYRIZI in the refrigerator between <content styleCode="bold">36Â°F to 46Â°F</content> (2Â°C to 8Â°C).<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> shake SKYRIZI. <br/>
                     </item>
                     <item>Keep SKYRIZI in the original carton to protect from light until time to use.<br/>
                     </item>
                     <item>SKYRIZI is not made with natural rubber latex.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use if liquid has been frozen (even if thawed).</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep SKYRIZI and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>Call your healthcare provider or <content styleCode="bold">(866)</content>Â <content styleCode="bold">SKYRIZI</content> or <content styleCode="bold">(866) 759-7494</content> if you need help or do not know how to proceed.</paragraph>
                  <table>
                     <col width="234"/>
                     <col width="390"/>
                     <tbody>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM02000021"/>
                              <br/>
                           </td>
                           <td>
                              <renderMultiMedia referencedObject="MM03000022"/>
                              <br/>
                              <content styleCode="bold">Gather</content> the supplies for the injections and place the following on a clean, flat surface:<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">4 prefilled syringes </content>
                                    <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">4 alcohol swabs</content> and <content styleCode="bold">4 cotton balls</content> or gauze pads (not included)<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">FDA-cleared sharps disposal container</content> (not included) See â<content styleCode="bold">Used SKYRIZI Prefilled Syringe Disposal</content>â<content styleCode="bold">Â </content>for information on how to throw away (dispose of) used prefilled syringes.</item>
                              </list>
                              <content styleCode="bold">Wash and dry</content> your hands.<br/>Start with 1 prefilled syringe for first injection.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM02000023"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Pick</content> from the 3 injectable areas:<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Front of <content styleCode="bold">left thigh</content> or <content styleCode="bold">right thigh</content>
                                    <br/>
                                 </item>
                                 <item>Your <content styleCode="bold">abdomen</content> (belly) at least 2 inches from your navel (belly button)</item>
                              </list>
                              <renderMultiMedia referencedObject="MM03000024"/>
                              <br/>
                              <content styleCode="bold">Wipe</content> the injection site in a circular motion with the alcohol swab (before <content styleCode="bold">all four injections</content>)<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Do not</content> touch or blow on the injection site after it is cleaned. Allow the skin to dry before injecting.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject through clothes.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject into skin that is sore, bruised, red, hard, scarred, or has stretch marks.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM02000025"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Hold</content> the prefilled syringe with covered needle facing down, as shown.<br/>
                              <content styleCode="bold">Check</content> the liquid in the prefilled syringe.<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>It is normal to see one or more bubbles in the window.<br/>
                                 </item>
                                 <item>The liquid should look clear to slightly yellow and may contain tiny white or clear particles.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> use the prefilled syringe if liquid is <content styleCode="bold">discolored</content>, <content styleCode="bold">cloudy</content> or contains <content styleCode="bold">flakes</content> or <content styleCode="bold">large</content>Â <content styleCode="bold">particles</content>.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM02000026"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Remove</content> the needle cover.<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Do not</content> hold or pull plunger rod when removing the needle cover.<br/>
                                 </item>
                                 <item>Hold the syringe in 1 hand between the finger grip and needle cover.<br/>
                                 </item>
                                 <item>With the other hand, carefully pull the needle cover straight off.<br/>
                                 </item>
                                 <item>You may see a drop of liquid at the end of the needle. This is normal.<br/>
                                 </item>
                                 <item>Throw away the needle cover.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> touch the needle with your fingers or let the needle touch anything.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM02000027"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Hold</content> the body of the prefilled syringe in 1 hand between the thumb and index finger.<br/>
                              <content styleCode="bold">Gently pinch</content> the area of cleaned skin with your other hand and hold it firmly.<br/>
                              <content styleCode="bold">Insert</content> the needle into the skin at about a <content styleCode="bold">45-degree angle</content> using a quick, short movement. Hold angle steady.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM02000028"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Slowly push</content> the plunger rod all the way in until all of the liquid is injected and the syringe is empty.<br/>
                              <content styleCode="bold">Pull</content> the needle out of the skin while keeping the syringe at the same angle.<br/>
                              <content styleCode="bold">Release</content> the plunger rod.<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Allow the prefilled syringe to move up until the entire needle is covered by the needle guard.</item>
                              </list>
                              <content styleCode="bold">The needle guard will not automatically activate unless all the liquid has been injected.</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Press</content> a cotton ball or gauze pad over the injection site and hold for 10 seconds.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> rub the injection site. You may have slight bleeding. This is normal.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM02000029"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Repeat Steps 2 through 6</content> with the 2nd, 3rd, and 4th prefilled syringe for a <content styleCode="bold">full dose</content>.<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Use the 2nd, 3rd, and 4th prefilled syringe right after using the 1st syringe.</item>
                              </list>
                              <renderMultiMedia referencedObject="MM0300002A"/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM0200002B"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Put</content> your used prefilled syringes in an <content styleCode="bold">FDA-cleared sharps disposal container right away after use</content>.<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Do not throw away (dispose of) used prefilled syringes in the household trash.</item>
                              </list>For more information, or if you do not have an FDA-cleared sharps container see â<content styleCode="bold">Used SKYRIZI Prefilled Syringe Disposal</content>â section located on the other side of these instructions.</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Questions About Using the SKYRIZI Syringe</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Q.</content>Â <content styleCode="bold">What if I have not received in-person training from a healthcare professional?</content>
                  </paragraph>
                  <paragraph>A. Call your healthcare provider or <content styleCode="bold">(866) SKYRIZI</content> or <content styleCode="bold">(866) 759-7494</content> if you need help. <content styleCode="bold">Receive</content> training on how to inject <content styleCode="bold">SKYRIZI</content> before giving injections.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Q. What should I do with all four used prefilled syringes after my injections?</content>
                  </paragraph>
                  <paragraph>A. Throw away (dispose of) all 4 used prefilled syringes in a sharps disposal container. <content styleCode="bold">Do not</content> put in household trash. For more information, see <content styleCode="bold">âUsed SKYRIZI Prefilled Syringe Disposalâ</content> section.</paragraph>
                  <paragraph>You can sign up to receive sharps containers for SKYRIZI prefilled syringe disposal at no additional cost by going to <linkHtml href="http://www.SKYRIZI.com">www.SKYRIZI.com</linkHtml> or calling (866) 759-7494</paragraph>
                  <paragraph>
                     <content styleCode="bold">Q. How do I know when the injection is complete?</content>
                  </paragraph>
                  <paragraph>A. The injection is complete when the prefilled syringe is empty, the plunger rod is pushed all the way in, and the syringe needle guard is activated.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Used SKYRIZI Prefilled Syringe Disposal</content>
                  </paragraph>
                  <paragraph>Throw away (dispose of) all four used prefilled syringes in a sharps disposal container. <content styleCode="bold">Do not</content> put in household trash.</paragraph>
                  <paragraph>
                     <content styleCode="bold">If you do not have an FDA-cleared sharps disposal container, you may use a household container that:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>is made of a heavy-duty plastic,<br/>
                     </item>
                     <item>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,<br/>
                     </item>
                     <item>stays upright and stable during use,<br/>
                     </item>
                     <item>is leak-resistant, and<br/>
                     </item>
                     <item>has been properly labeled to warn of hazardous waste inside the container.</item>
                  </list>
                  <paragraph>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes.</paragraph>
                  <paragraph>For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: <linkHtml href="http://www.fda.gov/safesharpsdisposal">www.fda.gov/safesharpsdisposal</linkHtml>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not</content> recycle your used sharps disposal container.</paragraph>
                  <paragraph>Manufactured by: AbbVie Inc., North Chicago, IL 60064, U.S.A.<br/>US License Number 1889<br/>SKYRIZI<sup>Â®</sup> is a trademark of AbbVie Biotechnology Ltd.<br/>Â© 2019-2024 AbbVie Inc.<br/>
                  </paragraph>
                  <paragraph>This Instructions for Use have been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>Revised: 3/2024</paragraph>
               </text>
               <effectiveTime value="20250507"/>
               <component>
                  <observationMedia ID="MM02000021">
                     <text>A close-up of a medical equipment

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-21.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000022">
                     <text>Graphical user interface, application

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-22.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000023">
                     <text>A diagram of a person's body

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-23.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000024">
                     <text>Text

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-24.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000025">
                     <text>A hand holding a syringe

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-25.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000026">
                     <text>A hand holding a syringe

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-26.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000027">
                     <text>A close-up of a hand holding a syringe

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-27.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000028">
                     <text>A close-up of a person holding a syringe

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-28.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000029">
                     <text>A blue and red sign with red text

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-29.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0300002A">
                     <text>Text

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-2a.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0200002B">
                     <text>A syringe in a container

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-2b.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="c7f78cc1-13e6-4441-bf5d-657a2b015f61"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="59845-8" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Instructions for Use</content>
                     <br/>
                     <content styleCode="bold">SKYRIZI</content>
                     <content styleCode="bold">
                        <sup>Â®</sup>
                     </content>
                     <content styleCode="bold"> (sky-RIZZ-ee)</content>Â <content styleCode="bold">On-Body Injector</content>
                     <br/>
                     <content styleCode="bold">risankizumab-rzaa</content>
                  </paragraph>
                  <paragraph>injection, for subcutaneous use only</paragraph>
                  <paragraph>On-Body Injector and 180 mg/1.2 mL Prefilled Cartridge,<br/> On-Body Injector and 360 mg/2.4 mL Prefilled Cartridge</paragraph>
                  <paragraph>Read this Instructions for Use before you start using SKYRIZI and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.</paragraph>
                  <paragraph>Refer to the Medication Guide for SKYRIZI product information. Call your healthcare provider, call (866) SKYRIZI or (866) 759-7494 or go to SKYRIZI.com<content styleCode="bold">Â </content>if you need help.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Important information you need to know before injecting SKYRIZI</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Receive training on how to inject SKYRIZI before giving an injection. <br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not </content>shake the SKYRIZI carton, On-Body Injector or prefilled cartridge. <br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not </content>remove the On-Body Injector or prefilled cartridge from the carton until you are ready to inject.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> wait more than 5 minutes to start the injection after loading the cleaned prefilled cartridge into the On-Body Injector. Waiting will dry out the medicine and the On-Body Injector will not work afterwards. <br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not </content>touch the start button until you place the On-Body Injector loaded with the prefilled cartridge onto your skin and are ready to inject. <br/>â¦ You can only press the start button 1-time.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not </content>use On-Body Injector or prefilled cartridge if either has been dropped or damaged.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not </content>reuse On-Body Injector or prefilled cartridge. The On-Body Injector and prefilled cartridge are for 1-time (single-dose) use only.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not </content>let the On-Body Injector get wet with water or any other liquids. <br/>
                     </item>
                     <item>This single-dose On-Body Injector is designed for use with SKYRIZI prefilled cartridge only. <br/>
                     </item>
                     <item>Physical activity should be limited during the injection process. Moderate physical activities can be done, such as walking, reaching and bending. <br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not </content>use SKYRIZI if the expiration date (EXP:) has passed. <br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use the prefilled cartridge if the liquid isÂ <content styleCode="bold">discolored,</content>
                        <content styleCode="bold"> cloudy</content> or contains <content styleCode="bold">flakes</content> or <content styleCode="bold">large</content>Â <content styleCode="bold">particles</content>. The liquid should look clear to yellow and may contain tiny white or clear particles.Â <br/>
                     </item>
                     <item>The On-Body Injector and the prefilled cartridge are not made with natural rubber latex.<br/>
                     </item>
                     <item>Keep SKYRIZI and all medicines out of the reach of children. </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Storage and preparation for use</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Keep SKYRIZI in the original carton to protect from light and physical damage until time to use.<br/>
                     </item>
                     <item>Store SKYRIZI in your refrigerator between 36Â°F to 46Â°F (2Â°C to 8Â°C). <br/>
                     </item>
                     <item>When ready to use, take the carton out of the refrigerator and leave it at room temperature for at least 45 minutes up to 90 minutes<content styleCode="bold">Â </content>to allow SKYRIZI to warm.<list listType="unordered" styleCode="Circle">
                           <item>The On-Body Injector will not work if left at <content styleCode="bold">room temperature </content>for less than <content styleCode="bold">45 minutes.</content>
                           </item>
                        </list>
                        <br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> leave out in direct sunlight.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> remove the On-body Injector or prefilled cartridge from the carton while allowing SKYRIZI to reach room temperature.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> warm SKYRIZI in any other way. For example, <content styleCode="bold">do not</content> warm it in a microwave or in hot water. <br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not </content>use if liquid has been frozen (even if thawed).<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not </content>use SKYRIZI if carton perforations are broken. Return product to the pharmacy.<content styleCode="bold">Â </content>
                        <br/>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use the On-Body Injector and prefilled cartridge if the white paper tray seal is missing or damaged and return the carton to the pharmacy.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Get to know your SKYRIZI On-Body Injector and prefilled cartridge</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM0200002C"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM0200002D"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM0200002E"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM0200002F"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Please read complete Instructions for Use before using SKYRIZI. Call your healthcare provider or (866) SKYRIZI or (866) 759-7494 or go to www.SKYRIZI.com if you need help or if you do not know how to proceed.</content>
                  </paragraph>
                  <table>
                     <col width="61"/>
                     <col width="251"/>
                     <col width="312"/>
                     <tbody>
                        <tr>
                           <td colspan="3">
                              <content styleCode="bold">Step 1 Get ready</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3">
                              <content styleCode="bold">Before using SKYRIZI, you should receive training on how to inject SKYRIZI.</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM02000030"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold"> Check expiration date</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Remove the carton<content styleCode="bold">Â </content>from the refrigerator. <br/>
                                 </item>
                                 <item>Check expiration date (EXP:) on the carton. <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not </content>use SKYRIZI if the expiration date (EXP:)<content styleCode="bold">Â </content>has passed.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM02000031"/>
                           </td>
                           <td>
                              <content styleCode="bold">Wait at least 45 minutes</content>Â <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Leave unopened carton at room temperature to warm.<br/>
                                 </item>
                                 <item>Keep out of direct sunlight. <br/>
                                 </item>
                                 <item>Wait at least 45 minutes up to a maximum of 90 minutes<content styleCode="bold">Â </content>to allow SKYRIZI to warm. <list listType="unordered" styleCode="Circle">
                                       <item>The On-Body Injector will not work if left at <content styleCode="bold">room temperature </content>for less than<content styleCode="bold"> 45 minutes.</content>
                                       </item>
                                    </list>
                                    <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not </content>warm SKYRIZI in any other way (for example, <content styleCode="bold">do not </content>warm it in a microwave or in hot water). </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM02000032"/>
                           </td>
                           <td>
                              <content styleCode="bold">Open the carton and remove the plastic tray</content>Â <list listType="unordered" styleCode="Disc">
                                 <item>Lift up<content styleCode="bold">Â </content>the flap on the side of the carton. <br/>
                                 </item>
                                 <item>Take out<content styleCode="bold">Â </content>the plastic tray. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM02000033"/>
                           </td>
                           <td>
                              <content styleCode="bold">Gather all supplies and wash hands</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Place the following on a clean surface: <br/>â¦ plastic tray containing the On-Body Injector and prefilled cartridge (included)<br/>â¦ 2 alcohol wipes (not included)<br/>â¦ cotton ball or gauze pad (not included)<br/>â¦ sharps disposal container (not included) (see âDisposing of SKYRIZIâ)<br/>
                                 </item>
                                 <item>Wash and dry your hands.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM02000034"/>
                              <br/>
                           </td>
                           <td>Â <br/>
                              <content styleCode="bold">Remove the white paper tray seal</content>Â <list listType="unordered" styleCode="Disc">
                                 <item>Locate<content styleCode="bold">Â </content>the black arrow. <br/>
                                 </item>
                                 <item>Peel away<content styleCode="bold">Â </content>the white paper tray seal from the plastic tray. <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not </content>use the On-Body Injector and prefilled cartridge if the white paper tray seal is missing or damaged and return the carton to the pharmacy.<content styleCode="bold">Â </content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM02000035"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Lift the plastic cover</content>Â <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Locate<content styleCode="bold">Â </content>the<content styleCode="bold">Â </content>rounded opening on the top cover. <br/>
                                 </item>
                                 <item>Insert your pointer finger in the opening and place your thumb on the opposite side. <br/>
                                 </item>
                                 <item>Lift the cover<content styleCode="bold">Â </content>to remove and set aside. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM02000036"/>
                           </td>
                           <td>
                              <content styleCode="bold">Inspect the On-Body Injector</content>
                              <content styleCode="bold">Â </content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Check<content styleCode="bold">Â </content>that the On-Body Injector is intact and undamaged. <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> close the gray door before the prefilled cartridge is loaded.<br/>
                                 </item>
                                 <item>The gray door should be slightly open. <br/>
                                 </item>
                                 <item>If the gray door does not open, press in firmly<content styleCode="bold">Â </content>on the gray door ridges (left side of door) and swing open the door. <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not </content>use On-Body Injector if you drop it, discover missing pieces, or it is damaged.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> let the On-Body Injector get wet with water or any other liquids.</item>
                              </list>
                              <renderMultiMedia referencedObject="MM03000037"/>
                              <content styleCode="bold">Â </content>
                              <content styleCode="bold">Do not</content> touch the gray start button<content styleCode="bold">Â </content>until it is time to inject. It can be pressed 1-time<content styleCode="bold">Â </content>only.  <br/>If the gray start button is pressed before placing it on your body, the On-Body Injector can no longer be used. Call (866) SKYRIZI or (866) 759-7494.<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Do not</content> touch the needle cover or the needle.<br/>
                                 </item>
                                 <item>Proceed to Set up On-Body Injector. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3">
                              <content styleCode="bold">Step 2 Set up On-Body Injector</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM02000038"/>Â Â </td>
                           <td>
                              <content styleCode="bold">Fully open the gray door</content>
                              <br/>
                              <renderMultiMedia referencedObject="MM03000037"/>
                              <content styleCode="bold">Â </content>Avoid touching the needle cover or the needle<content styleCode="bold">Â </content>on the back of the On-Body Injector. The needle is behind the needle cover. <list listType="unordered" styleCode="Disc">
                                 <item>Swing the gray door<content styleCode="bold">Â </content>all the way to the right to open it. <br/>
                                 </item>
                                 <item>If the gray door does not open, press in firmly<content styleCode="bold">Â </content>on the gray door ridges (left side of door) and swing open the door. <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not </content>close the gray door before the prefilled cartridge is loaded.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> touch the needle cover or needle. <br/>
                                 </item>
                                 <item>Put the On-Body Injector aside.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM02000039"/>
                           </td>
                           <td>
                              <content styleCode="bold">Inspect the prefilled cartridge</content>Â <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Carefully remove the prefilled cartridge from the plastic tray. <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not </content>twist or remove cartridge top. <br/>
                                 </item>
                                 <item>Check the prefilled cartridge to make sure: <br/>â¦ The expiration date<content styleCode="bold">Â </content>(EXP:)<content styleCode="bold">Â </content>has not passed.<br/>â¦ The liquid should look clear to yellow and may contain tiny white or clear particles. It is normal to see one or more bubbles. <br/>â¦ The prefilled cartridge parts appear intact, and the clear plastic is not cracked or broken. <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not </content>use if the expiration date<content styleCode="bold">Â </content>(EXP:)<content styleCode="bold">Â </content>has passed. <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not </content>use if the liquid is cloudy, discolored, or contains flakes or large particles. <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not </content>use if the liquid has been frozen<content styleCode="bold">Â </content>(even if thawed). <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not </content>use the prefilled cartridge if you drop it, discover missing pieces, or it is damaged. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM0200003A"/>
                           </td>
                           <td>
                              <content styleCode="bold">Clean the smaller bottom tip of the prefilled cartridge</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Locate<content styleCode="bold">Â </content>the smaller bottom tip of the prefilled cartridge.<br/>
                                 </item>
                                 <item>Clean the smaller bottom tip of the prefilled cartridge with an alcohol wipe. Make sure to use the alcohol wipe to clean the center of the smaller bottom tip<content styleCode="bold">Â </content>of the prefilled cartridge. <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not </content>touch the smaller bottom tip of the prefilled cartridge after cleaning. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM0200003B"/>Â <br/>
                           </td>
                           <td>
                              <br/>
                              <content styleCode="bold">Load the cleaned prefilled cartridge into the On-Body Injector</content>Â <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Do not </content>twist or remove the prefilled cartridge top. <br/>
                                 </item>
                                 <item>Insert the<content styleCode="bold">Â </content>smaller bottom tip of the prefilled cartridge into the On-Body Injector first. <br/>
                                 </item>
                                 <item>Firmly push down on the prefilled cartridge top until you hear a âclickâ.Â <br/>
                                 </item>
                                 <item>After loading the prefilled cartridge, you may see a few drops of medicine on the back of the On-Body Injector. This is normal.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM0300003C"/>
                           </td>
                           <td colspan="2">
                              <content styleCode="bold">Make sure that you start the injection within 5 minutes after inserting the prefilled cartridge into the On-Body Injector. Waiting will dry out the medicine and the On-Body Injector will not work afterwards.</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM0200003D"/>Â </td>
                           <td>
                              <br/>
                              <content styleCode="bold">Close the gray door</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Swing the gray door to the left, then squeeze firmly<content styleCode="bold">Â </content>and listen for the gray door to "snap" shut. <br/>
                                 </item>
                                 <item>The gray door should stay locked after loading the prefilled cartridge.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not </content>close the gray door if the prefilled cartridge is not fully inserted or is missing. <br/>
                                 </item>
                                 <item>Proceed without delay to Prepare to inject</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3">
                              <content styleCode="bold">Step 3 Prepare to inject</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3">
                              <content styleCode="bold">Keep electronic devices including cell phones at least 12 inches (30 cm) from On-Body Injector until injection is complete</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM0200003E"/>
                           </td>
                           <td>
                              <content styleCode="bold">Pick your injection area</content>Â <br/>Locate a firm and flat area<content styleCode="bold">Â </content>on your bare skin. Make sure the area is clear of clothing: <list listType="unordered" styleCode="Disc">
                                 <item>Your abdomen<content styleCode="bold">Â </content>(belly) at least 2 inches from your navel (belly button). <br/>
                                 </item>
                                 <item>The front of your left thigh or your right thigh. <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not </content>inject into areas of the skin<content styleCode="bold">Â </content>that naturally fold or bulge<content styleCode="bold">Â </content>because the On-Body Injector could fall off during wear. <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not </content>inject into skin that is sore, bruised, red, hard, scarred, or has stretch marks, moles or excessive hair. You can trim the excessive hair from the injection area. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM0200003F"/>
                           </td>
                           <td>
                              <content styleCode="bold">Clean the injection area</content>Â <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Clean<content styleCode="bold">Â </content>injection area with an alcohol wipe. <br/>
                                 </item>
                                 <item>Allow the injection area to completely dry. <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not </content>touch cleaned injection area before placing the On-Body Injector on the skin. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM02000040"/>Â Â </td>
                           <td>
                              <content styleCode="bold">Peel both tabs to expose adhesive</content>Â <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Turn the On-Body Injector over<content styleCode="bold">Â </content>to find both green pull tabs. </item>
                              </list>
                              <renderMultiMedia referencedObject="MM03000037"/>
                              <content styleCode="bold">Â </content>Avoid touching the needle cover (needle inside). <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Peel<content styleCode="bold">Â </content>away the large section<content styleCode="bold">Â </content>using the green pull tab to expose the adhesive. <br/>
                                 </item>
                                 <item>Peel<content styleCode="bold">Â </content>away the small section<content styleCode="bold">Â </content>using the green pull tab to expose the adhesive. This will remove the clear plastic strip, activating the On-Body Injector. <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not </content>pull the adhesive material off the On-Body Injector or allow the sticky side to fold and stick to itself. <br/>
                                 </item>
                                 <item>Check the status light<content styleCode="bold">Â </content>when the On-Body Injector beeps. <br/>
                                 </item>
                                 <item>The status light will flash blue<content styleCode="bold">Â </content>when the On-Body Injector is activated. <br/>
                                 </item>
                                 <item>If the status light does not flash blue, call (866) SKYRIZI or (866) 759-7494.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not </content>press the gray start button yet. <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not </content>touch the needle cover or the needle. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="center">Â Â <br/>
                              <renderMultiMedia referencedObject="MM02000041"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM02000042"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Prepare the On-Body Injector for placement</content>Â <list listType="unordered" styleCode="Disc">
                                 <item>For the abdomen<content styleCode="bold">Â </content>(belly), move and hold the skin to create a firm, flat surface for injection at least 2 inches from your navel<content styleCode="bold">Â </content>(belly button). Make sure to adjust your posture (sit up straight) to avoid skin folds and bulges.<br/>
                                 </item>
                                 <item>You do not need to pull the skin flat for the front of left thigh or right thigh. <br/>
                                 </item>
                                 <item>Make sure to position the On-Body Injector so that you can see the blue status light. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM02000043"/>
                           </td>
                           <td>
                              <content styleCode="bold">Place the On-Body Injector on your skin</content>Â <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>When the blue light flashes, the On-Body Injector is ready. Place<content styleCode="bold">Â </content>the On-Body Injector onto the cleaned skin with the status light visible. <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not </content>place the On-Body Injector on clothes. Only place on bare skin. <br/>
                                 </item>
                                 <item>Run your finger around the adhesive material to secure it. Make sure all of the adhesive is attached to your skin.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not </content>move or adjust the On-Body Injector after it has been placed on your skin. <br/>
                                 </item>
                                 <item>When the On-Body Injector is on your skin, proceed to Inject medicine</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3">
                              <content styleCode="bold">Step 4 Inject medicine</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM02000044"/>Â </td>
                           <td>
                              <content styleCode="bold">Start injection</content>Â <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Firmly press<content styleCode="bold">Â </content>the gray start button until you hear a click. Then release the gray start button. <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> touch the gray start button until you place the On-Body Injector loaded with the prefilled cartridge onto your skin and are ready to inject. You can only press the start button 1 time.<br/>
                                 </item>
                                 <item>You may feel a needle pinch. <br/>
                                 </item>
                                 <item>Check the status light<content styleCode="bold">Â </content>when the On-Body Injector beeps. <br/>
                                 </item>
                                 <item>After starting the injection, the status light will continuously flash green. <br/>
                                 </item>
                                 <item>You will hear pumping<content styleCode="bold">Â </content>sounds as the On-Body Injector delivers the medicine. <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not </content>continue to use the On-Body Injector if status light flashes red and beeps. Carefully remove from skin if the status light flashes red. Call (866) SKYRIZI or (866) 759-7494. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2">
                              <renderMultiMedia referencedObject="MM02000045"/>
                           </td>
                           <td>
                              <br/>Â <content styleCode="bold">Wait for the injection to finish </content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>It may take up to 5 minutes<content styleCode="bold">Â </content>to complete full dose of medicine. The On-Body Injector will automatically stop when the injection is finished. </item>
                              </list>During the injection:<br/>â¦ the status light will continue to flash green.<br/>â¦ you will hear pumping<content styleCode="bold">Â </content>sounds as the On-Body Injector continues delivering the medicine.<br/>â¦ moderate physical activities can be done, such as walking, reaching and bending. <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Do not </content>continue to use the On-Body Injector if the status light flashes red and beeps. Carefully remove it from the skin if the status light flashes red and beeps. Call (866) SKYRIZI or (866) 759-7494. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM02000046"/>
                           </td>
                           <td>
                              <content styleCode="bold">Injection is finished</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>The On-Body Injector will stop on its own.<br/>
                                 </item>
                                 <item>After the injection is finished, you will hear beeps and the status light will change to solid green. Check the status light. If it has changed to solid green, this means that the injection is finished.<br/>
                                 </item>
                                 <item>When the injection is finished, proceed to next step.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2">
                              <renderMultiMedia referencedObject="MM02000047"/>
                           </td>
                           <td>
                              <br/>
                              <br/>
                              <br/>
                              <br/>
                              <br/>
                              <br/>
                              <br/>
                              <br/>
                              <br/>
                              <br/>
                              <br/>
                              <br/>
                              <br/>
                              <br/>
                              <br/>
                              <content styleCode="bold">Remove the On-Body Injector</content>Â <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Do not</content>
                                    <content styleCode="bold">Â </content>put your fingers on the back side of the On-Body Injector when removing it from your skin. <br/>
                                 </item>
                                 <item>When the injection is done, grab the corner of the adhesive to carefully peel the On-Body Injector from the skin. </item>
                              </list>
                              <renderMultiMedia referencedObject="MM03000037"/> Avoid touching the needle cover<content styleCode="bold">Â </content>or needle<content styleCode="bold">Â </content>on the back of the On-Body Injector. <list listType="unordered" styleCode="Disc">
                                 <item>After removing the On-Body Injector, you will hear several beeps<content styleCode="bold">Â </content>and the status light will turn off. <br/>
                                 </item>
                                 <item>The needle cover will cover the needle when the On-Body Injector is removed from the skin.<br/>
                                 </item>
                                 <item>It is normal to see a few small drops of liquid on your skin after removing the On-Body Injector. If you see more than a few small drops of liquid left on your skin, call (866) SKYRIZI or (866) 759-7494.<br/>
                                 </item>
                                 <item>Press a cotton ball or gauze pad over the injection site on your skin and hold for 10 seconds. <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> rub the injection site. <br/>
                                 </item>
                                 <item>Slight bleeding at the injection site is normal.<br/>
                                 </item>
                                 <item>Proceed to Confirm and dispose</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3"/>
                        </tr>
                        <tr>
                           <td colspan="2" align="center">
                              <content styleCode="bold">Step 5 Confirm and dispose</content>
                           </td>
                           <td/>
                        </tr>
                        <tr>
                           <td colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM02000048"/>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Check the On-Body Injector </content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Inspect the medicine window and status light. <br/>
                                 </item>
                                 <item>Check to see that the used white plunger fills the medicine window and the solid green light turns off, letting you know that all the medicine has been injected. </item>
                              </list>
                              <renderMultiMedia referencedObject="MM03000037"/> If the used white plunger does not fill the window, call (866) SKYRIZI or (866) 759-7494<content styleCode="bold">.</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM02000049"/>Â <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Put the used On-Body Injector in an FDA-cleared sharps disposal container right away after use</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Leave the prefilled cartridge in the On-Body Injector. <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not </content>throw away (dispose of) the used On-Body Injector in your household trash. <br/>
                                 </item>
                                 <item>For more information, see â<content styleCode="bold">Disposing of SKYRIZIâ</content> section.</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM0200004A"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Please read complete Instructions for Use before using SKYRIZI. Call your healthcare provider or (866) SKYRIZI or (866) 759-7494 or go to www.SKYRIZI.com if you need help or if you do not know how to proceed.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Commonly asked questions</content>Â </paragraph>
                  <paragraph>
                     <content styleCode="bold">Q. </content>
                     <content styleCode="bold">Â </content>
                     <content styleCode="bold">What if I cannot open the On-Body Injector door to insert the prefilled cartridge? </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">A.</content>Â Â To open the On-Body Injector door, press in firmly on the left side of the door to release the door latch. If you are still unable to open the door, call (866) SKYRIZI or (866) 759-7494.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Q. </content>
                     <content styleCode="bold">Â </content>
                     <content styleCode="bold">What if I push the </content>
                     <content styleCode="bold">gray </content>
                     <content styleCode="bold">start button before I place the On-Body Injector on my skin? </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">A.  </content>The gray start button may be pressed just 1 time only. If the gray start button is pressed before placing it on your body, it can no longer be used. Call (866) SKYRIZI or (866) 759-7494. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Q. </content>
                     <content styleCode="bold"> What if the On-Body Injector does not beep and the blue status light does not flash when I remove the green pull tabs? </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">A.</content> Peeling off small green pull tab will remove the clear plastic strip, activating the On-Body Injector. If all of the adhesive paper has been removed and the On-Body Injector still does not turn on, call (866) SKYRIZI or (866) 759-7494. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Q.  </content>
                     <content styleCode="bold">What if I push the start button as instructed after placing the On-Body Injector on the skin and the light remains blue? </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">A.</content>Â Â Firmly press the gray start button again. If the status light remains blue or flashes red, remove the On-Body Injector by carefully peeling it away from your skin. Do not re-apply the On-Body Injector. Call (866) SKYRIZI or (866) 759-7494. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Q.</content>
                     <content styleCode="bold">Â </content>
                     <content styleCode="bold">Â </content>
                     <content styleCode="bold">What if the status light flashes red and beeps while wearing the On-Body Injector? </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">A.</content>Â Â If the status light continuously flashes red and beeps, do not use the On-Body Injector. If it is attached to your body, carefully remove it. Call (866) SKYRIZI or (866) 759-7494. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Q.</content>
                     <content styleCode="bold">Â </content>
                     <content styleCode="bold">Â </content>
                     <content styleCode="bold">What should I do if the On-Body Injector comes off my body during the injection? </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">A.</content>Â Â The loaded On-Body Injector can no longer be used. Do not re-apply it to your body. Call (866) SKYRIZI or (866) 759-7494. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Q.</content>
                     <content styleCode="bold">Â </content>
                     <content styleCode="bold">Â </content>
                     <content styleCode="bold">How do I know when the injection is complete? </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">A.</content>Â Â The injection is complete when the On-Body Injector beeps, the white plunger has completely filled the medicine window, and the status light turns from flashing green to solid green. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Q.</content>
                     <content styleCode="bold">Â Â </content>
                     <content styleCode="bold">What should I do if there are more than a few drops of liquid on the injection area? </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">A.</content>Â Â Call (866) SKYRIZI or (866) 759-7494<content styleCode="bold">Â </content>for help. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Q.  </content>
                     <content styleCode="bold">What should I do with the used On-Body Injector after my injection? </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">A.</content>Â Â Throw away (dispose of) used On-Body Injector in a FDA-clearedÂ sharps disposal container and not your household trash. You can receive a sharps container for SKYRIZI disposal at no additional cost by going to www.SKYRIZI.com or by calling (866) SKYRIZI or (866) 759-7494. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Q.</content>
                     <content styleCode="bold">Â </content>
                     <content styleCode="bold">Â </content>
                     <content styleCode="bold">What if I have not received in-person training from a healthcare professional? </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">A.</content>Â Â Call your healthcare provider or (866) SKYRIZI or (866) 759-7494 if you need help.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Receive </content>training on how to inject<content styleCode="bold"> SKYRIZI </content>before giving injections.</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM02000041"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Disposing of SKYRIZI </content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Put SKYRIZI in an FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) SKYRIZI in your household trash. <br/>
                     </item>
                     <item>If you do not have an FDA-cleared sharps disposal container, you may use a household container that is: <br/>â¦ made of a heavy-duty plastic,<br/>â¦ can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out, <br/>â¦ upright and stable during use, <br/>â¦ leak-resistant, and <br/>â¦ properly labeled to warn of hazardous waste inside the container. </item>
                  </list>
                  <paragraph>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. </paragraph>
                  <paragraph>For more information about safe sharps disposal in the state that you live in, go to the FDAâs website at: www.fda.gov/safesharpsdisposal.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not</content> recycle your used sharps disposal container. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Additional information</content>
                  </paragraph>
                  <paragraph>â Type BF applied part.</paragraph>
                  <paragraph>â <renderMultiMedia referencedObject="MM0300004B"/> On-Body Injector sterilized using ethylene oxide.</paragraph>
                  <paragraph>â Altitude range is -1,312 feet to 10,499 feet (-400 meters to 3,200 meters).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Electromagnetic Compatibility (EMC) of the On-Body Injector</content>
                  </paragraph>
                  <paragraph>The On-Body Injector is intended for home use or use in a professional healthcare environment and complies with ISO 11608-1:2014 and IEC 60601-1-2:2014. </paragraph>
                  <paragraph>Care should be taken to use the On-Body Injector within the following specific limits and environments to avoid adversely impacting the performance (missed or incomplete SKYRIZI dose).</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Keep electronic devices including cell phones at least 12 inches (30 cm) from the On-Body Injector until injection is complete. The potential impact of electronic interference is unknown when the On-Body Injector is operated within 12 inches (30 cm).<br/>
                     </item>
                     <item>Do not expose the On-Body Injector to Magnetic Resonance (MR) Environment (e.g., MRI).<br/>
                     </item>
                     <item>If it is used adjacent to other electrical equipment, observe the On-Body Injector and other equipment to ensure it is operating normally.</item>
                  </list>
                  <paragraph>Emissions</paragraph>
                  <table>
                     <col width="301"/>
                     <col width="337"/>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">Emissions test name</td>
                           <td styleCode="Toprule Lrule Rrule ">Test levels</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">Radiated Radio frequency electromagnetic fields</td>
                           <td styleCode="Toprule Lrule Rrule ">Per CISPR 11, class B</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Electromagnetic Immunity</paragraph>
                  <table>
                     <col width="302"/>
                     <col width="336"/>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">Test Name </td>
                           <td styleCode="Toprule Lrule Rrule ">Test Levels</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">Electrostatic discharge (ESD)</td>
                           <td styleCode="Toprule Lrule Rrule ">Â± 8 kV contact<br/>Â± 2 kV, Â± 4 kV, Â± 8 kV, Â± 15 kV air</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">Radio frequency electromagnetic field</td>
                           <td styleCode="Toprule Lrule Rrule ">10 V/m <br/>80 MHz â 2.7 GHz </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">Power frequency 50 Hz magnetic field </td>
                           <td styleCode="Toprule Lrule Rrule ">30 A/m<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>The enclosure port immunity to RF wireless communications equipment complies with IEC 60601-1-2:2014.Â </paragraph>
                  <paragraph>Â Â </paragraph>
                  <paragraph>
                     <content styleCode="bold">Glossary of symbols </content>
                  </paragraph>
                  <table>
                     <col width="114"/>
                     <col width="443"/>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">
                              <content styleCode="bold">Symbol</content>
                           </td>
                           <td styleCode="Toprule Lrule Rrule ">
                              <content styleCode="bold">Description of Symbol</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">
                              <renderMultiMedia referencedObject="MM0300004C"/>
                           </td>
                           <td styleCode="Toprule Lrule Rrule ">Keep dry</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">
                              <renderMultiMedia referencedObject="MM0300004D"/>
                           </td>
                           <td styleCode="Toprule Lrule Rrule ">Sterilized using ethylene oxide</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">
                              <renderMultiMedia referencedObject="MM0300004E"/>
                           </td>
                           <td styleCode="Toprule Lrule Rrule ">Do not re-use</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">
                              <renderMultiMedia referencedObject="MM0300004F"/>
                           </td>
                           <td styleCode="Toprule Lrule Rrule ">Do not use if package is damaged and consult instructions for use</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">
                              <renderMultiMedia referencedObject="MM03000050"/>
                           </td>
                           <td styleCode="Toprule Lrule Rrule ">Date of manufacture</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">
                              <renderMultiMedia referencedObject="MM03000051"/>
                           </td>
                           <td styleCode="Toprule Lrule Rrule ">Batch code</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">
                              <renderMultiMedia referencedObject="MM03000052"/>
                           </td>
                           <td styleCode="Toprule Lrule Rrule ">Catalogue number</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">
                              <renderMultiMedia referencedObject="MM03000053"/>
                           </td>
                           <td styleCode="Toprule Lrule Rrule ">Serial number</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">
                              <renderMultiMedia referencedObject="MM03000054"/>
                           </td>
                           <td styleCode="Toprule Lrule Rrule ">Refer to instruction manual / booklet</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">
                              <renderMultiMedia referencedObject="MM03000055"/>
                           </td>
                           <td styleCode="Toprule Lrule Rrule ">Type BF Applied Part </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">
                              <renderMultiMedia referencedObject="MM03000056"/>
                           </td>
                           <td styleCode="Toprule Lrule Rrule ">MR Unsafe</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Manufactured by: <br/>AbbVie Inc., North Chicago, IL 60064, U.S.A. <br/>US License Number 1889<br/>SKYRIZIÂ® is a registered trademark of AbbVie Biotechnology Ltd.<br/>Â©2024 AbbVie Inc. <br/>This Instructions for Use has been approved by the U.S. Food and Drug Administration. </paragraph>
                  <paragraph>Revised: 6/2024</paragraph>
                  <paragraph>20086115</paragraph>
               </text>
               <effectiveTime value="20250507"/>
               <component>
                  <observationMedia ID="MM0200002C">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-2c.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0200002D">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-2d.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0200002E">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-2e.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0200002F">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-2f.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000030">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-30.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000031">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-31.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000032">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-32.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000033">
                     <text>Text, whiteboard

Description automatically generated with medium confidence</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-33.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000034">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-34.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000035">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-35.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000036">
                     <text>Graphical user interface

Description automatically generated with medium confidence</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-36.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000037">
                     <text>Avoid</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-37.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000038">
                     <text>A picture containing diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-38.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000039">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-39.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0200003A">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-3a.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0200003B">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-3b.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0300003C">
                     <text>Caution Symbol </text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-3c.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0200003D">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-3d.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0200003E">
                     <text>A picture containing text, vector graphics

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-3e.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0200003F">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-3f.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000040">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-40.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000041">
                     <text>Graphical user interface, text, application

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-41.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000042">
                     <text>A picture containing application

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-42.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000043">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-43.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000044">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-44.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000045">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-45.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000046">
                     <text>A close-up of a cell phone

Description automatically generated with medium confidence</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-46.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000047">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-47.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000048">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-48.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000049">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-49.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0200004A">
                     <text>Graphical user interface

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-4a.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0300004B">
                     <text>Sterilized</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-4b.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0300004C">
                     <text>A picture containing text, ax, tool, chest of drawers

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-4c.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0300004D">
                     <text>Sterile</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-4d.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0300004E">
                     <text>Icon

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-4e.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0300004F">
                     <text>Icon

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-4f.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000050">
                     <text>Date-of-manufacture</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-50.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000051">
                     <text>A picture containing text, clipart

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-51.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000052">
                     <text>Icon

Description automatically generated with medium confidence</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-52.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000053">
                     <text>Text

Description automatically generated with medium confidence</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-53.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000054">
                     <text>Icon

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-54.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000055">
                     <text>Icon

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-55.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000056">
                     <text>Icon

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-56.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="16343622-b591-4bfc-89ff-e9e2d1b3253a"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>NDC 0074-2100-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">One 1 mL Single-Dose Prefilled Pen</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Skyriz</content>
                     <content styleCode="bold">i</content>
                     <content styleCode="bold">
                        <sup>Â®</sup>
                     </content>
                     <content styleCode="bold">Â </content>PEN<content styleCode="bold"> 150 mg/mL</content>
                  </paragraph>
                  <paragraph>risankizumab-rzaa Injection </paragraph>
                  <paragraph>FOR SUBCUTANEOUS USE ONLY</paragraph>
                  <paragraph>Return to pharmacy if carton perforations are broken.</paragraph>
                  <paragraph>
                     <content styleCode="bold">ATTENTION PHARMACIST:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Each patient is required to receive </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">the enclosed Medication Guide.</content>
                  </paragraph>
                  <paragraph>This entire carton is dispensed as a unit.</paragraph>
                  <paragraph>AREA FOR PHARMACY LABEL</paragraph>
                  <paragraph>www.SKYRIZI.com</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">abbvie</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000057"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250507"/>
               <component>
                  <observationMedia ID="MM03000057">
                     <text>NDC 0074-2100-01
One 1 mL Single-Dose Prefilled Pen
SkyriziÂ® PEN 150 mg/mL
risankizumab-rzaa Injection 
FOR SUBCUTANEOUS USE ONLY
Return to pharmacy if carton perforations are broken.
ATTENTION PHARMACIST:
Each patient is required to receive 
the enclosed Medication Guide.
This entire carton is dispensed as a unit.
www.SKYRIZI.com
Rx only
abbvie

</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-57.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="9030c688-b811-4031-a9a4-d74edbc4b2f1"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>NDC 0074-1050-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">One 1 mL Single-Dose Prefilled Syringe</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Skyriz</content>
                     <content styleCode="bold">i</content>
                     <content styleCode="bold">
                        <sup>Â®</sup>
                     </content>
                     <content styleCode="bold"> 150 mg/mL</content>
                  </paragraph>
                  <paragraph>risankizumab-rzaa </paragraph>
                  <paragraph>injection </paragraph>
                  <paragraph>FOR SUBCUTANEOUS USE ONLY</paragraph>
                  <paragraph>Return to pharmacy if carton perforations are broken.</paragraph>
                  <paragraph>This entire carton is dispensed as a unit.</paragraph>
                  <paragraph>AREA FOR PHARMACY LABEL</paragraph>
                  <paragraph>www.SKYRIZI.com</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">A</content>
                     <content styleCode="bold">bbvie</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM02000058"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250507"/>
               <component>
                  <observationMedia ID="MM02000058">
                     <text>NDC 0074-1050-01
One 1 mL Single-Dose Prefilled Syringe
SkyriziÂ® 150 mg/mL
risankizumab-rzaa 
injection 
FOR SUBCUTANEOUS USE ONLY
Return to pharmacy if carton perforations are broken.
This entire carton is dispensed as a unit.
AREA FOR PHARMACY LABEL
www.SKYRIZI.com
Rx only
Abbvie
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-58.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="78e5c083-f86c-4216-bdc4-8f944f5cfda5"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>NDC 0074-1070-01Â </paragraph>
                  <paragraph>
                     <content styleCode="bold">1</content>
                     <content styleCode="bold"> x </content>
                     <content styleCode="bold">2.4</content>
                     <content styleCode="bold"> mL </content>
                     <content styleCode="bold">P</content>
                     <content styleCode="bold">refilled </content>
                     <content styleCode="bold">Cartridge</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1 On-Body Injector</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Skyriz</content>
                     <content styleCode="bold">i</content>
                     <content styleCode="bold">
                        <sup>Â®</sup>
                     </content>
                  </paragraph>
                  <paragraph>risankizumab-rzaa Injection </paragraph>
                  <paragraph>
                     <content styleCode="bold">3</content>
                     <content styleCode="bold">60</content>
                     <content styleCode="bold"> mg/</content>
                     <content styleCode="bold">2.4</content>
                     <content styleCode="bold"> mL</content>
                  </paragraph>
                  <paragraph>(150 mg/mL)</paragraph>
                  <paragraph>FOR SUBCUTANEOUS USE ONLY </paragraph>
                  <paragraph>Single-Dose</paragraph>
                  <paragraph>
                     <content styleCode="bold">SKYRIZI.com</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">abbvie</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM02000059"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250507"/>
               <component>
                  <observationMedia ID="MM02000059">
                     <text>NDC 0074-1070-01 
1 x 2.4 mL Prefilled Cartridge
1 On-Body Injector
SkyriziÂ®
risankizumab-rzaa Injection 
360 mg/2.4 mL
(150 mg/mL)
FOR SUBCUTANEOUS USE ONLY 
Single-Dose
SKYRIZI.com
Rx only
abbvie
 
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-59.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="5d687636-b604-4651-bff7-e5d350f65202"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>NDC 0074-5015-01Â </paragraph>
                  <paragraph>
                     <content styleCode="bold">Skyriz</content>
                     <content styleCode="bold">i</content>
                     <content styleCode="bold">
                        <sup>Â®</sup>
                     </content>
                  </paragraph>
                  <paragraph>risankizumab-rzaa Injection </paragraph>
                  <paragraph>
                     <content styleCode="bold">600</content>
                     <content styleCode="bold"> mg/</content>
                     <content styleCode="bold">10</content>
                     <content styleCode="bold"> mL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(60 mg/mL)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR INTR</content>
                     <content styleCode="bold">A</content>
                     <content styleCode="bold">VENOUS USE ONLY </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Must be diluted prior to use</content>
                  </paragraph>
                  <paragraph>One 10 mL Single-Dose Vial-</paragraph>
                  <paragraph>Discard Unused Portion</paragraph>
                  <paragraph>ATTENTION: Dispense the enclosed Medication Guide to each patient.</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>abbvie</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM0200005A"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250507"/>
               <component>
                  <observationMedia ID="MM0200005A">
                     <text>NDC 0074-5015-01 
SkyriziÂ®
risankizumab-rzaa Injection 
600 mg/10 mL
(60 mg/mL)
FOR INTRAVENOUS USE ONLY 
Must be diluted prior to use
One 10 mL Single-Dose Vial-
Discard Unused Portion
ATTENTION: Dispense the enclosed Medication Guide to each patient.
Rx only
abbvie
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-5a.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="444410c6-9e15-44be-811e-4ab424924987"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>NDC 0074-1069-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">Skyrizi</content>
                     <content styleCode="bold">
                        <sup>Â®</sup>
                     </content>
                  </paragraph>
                  <paragraph>risankizumab-rzaa</paragraph>
                  <paragraph>Injection</paragraph>
                  <paragraph>
                     <content styleCode="bold">360 mg/2.4 mL</content>
                  </paragraph>
                  <paragraph>(150 mg/mL)</paragraph>
                  <paragraph>FOR SUBCUTANEOUS USE ONLY</paragraph>
                  <paragraph>Single-Dose</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM0300005B"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250507"/>
               <component>
                  <observationMedia ID="MM0300005B">
                     <text>NDC 0074-1069-01
SkyriziÂ®
risankizumab-rzaa
Injection
360 mg/2.4 mL
(150 mg/mL)
FOR SUBCUTANEOUS USE ONLY
Single-Dose
Rx Only
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-5b.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="92ae2e2a-f43c-477d-acba-33912c903563"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>NDC 0074-1069-02</paragraph>
                  <paragraph>NOT FOR SALE</paragraph>
                  <paragraph>
                     <content styleCode="bold">Skyrizi</content>
                     <content styleCode="bold">
                        <sup>Â®</sup>
                     </content>
                  </paragraph>
                  <paragraph>risankizumab-rzaa</paragraph>
                  <paragraph>Injection</paragraph>
                  <paragraph>
                     <content styleCode="bold">360 mg/2.4 mL</content>
                  </paragraph>
                  <paragraph>(150 mg/mL)</paragraph>
                  <paragraph>FOR SUBCUTANEOUS USE ONLY</paragraph>
                  <paragraph>Single-Dose</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM0300005C"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250507"/>
               <component>
                  <observationMedia ID="MM0300005C">
                     <text>NDC 0074-1069-02
NOT FOR SALE
SkyriziÂ®
risankizumab-rzaa
Injection
360 mg/2.4 mL
(150 mg/mL)
FOR SUBCUTANEOUS USE ONLY
Single-Dose
Rx Only
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-5c.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="71ea81aa-4828-4c84-ba07-3acae7664f34"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>NDC 0074-1065-01 </paragraph>
                  <paragraph>
                     <content styleCode="bold">1 x 1.2 mL Prefilled Cartridge</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1 On-Body Injector</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Skyrizi</content>
                     <content styleCode="bold">
                        <sup>Â®</sup>
                     </content>
                  </paragraph>
                  <paragraph>risankizumab-rzaa Injection </paragraph>
                  <paragraph>
                     <content styleCode="bold">180 mg/1.2 mL</content>
                  </paragraph>
                  <paragraph>(150 mg/mL)</paragraph>
                  <paragraph>FOR SUBCUTANEOUS USE ONLY </paragraph>
                  <paragraph>Single-Dose</paragraph>
                  <paragraph>
                     <content styleCode="bold">SKYRIZI.com</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">abbvie</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM0200005D"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250507"/>
               <component>
                  <observationMedia ID="MM0200005D">
                     <text>NDC 0074-1065-01 
1 x 1.2 mL Prefilled Cartridge
1 On-Body Injector
SkyriziÂ®
risankizumab-rzaa Injection 
180 mg/1.2 mL
(150 mg/mL)
FOR SUBCUTANEOUS USE ONLY 
Single-Dose
SKYRIZI.com
Rx only
abbvie
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-5d.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="cf694957-5dd9-4cb6-9f8f-79d8ac9d7932"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>NDC 0074-1066-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">Skyrizi</content>
                     <content styleCode="bold">
                        <sup>Â®</sup>
                     </content>
                  </paragraph>
                  <paragraph>risankizumab-rzaa</paragraph>
                  <paragraph>Injection</paragraph>
                  <paragraph>
                     <content styleCode="bold">180 mg/1.2 mL</content>
                  </paragraph>
                  <paragraph>(150 mg/mL)</paragraph>
                  <paragraph>FOR SUBCUTANEOUS USE ONLY</paragraph>
                  <paragraph>Single-Dose</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM0300005E"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250507"/>
               <component>
                  <observationMedia ID="MM0300005E">
                     <text>NDC 0074-1066-01
SkyriziÂ®
risankizumab-rzaa
Injection
180 mg/1.2 mL
(150 mg/mL)
FOR SUBCUTANEOUS USE ONLY
Single-Dose
Rx Only
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-5e.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="070143aa-e07d-431e-82f4-3d0218ec4b4b"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>NDC 0074-1066-02</paragraph>
                  <paragraph>NOT FOR SALE</paragraph>
                  <paragraph>
                     <content styleCode="bold">Skyrizi</content>
                     <content styleCode="bold">
                        <sup>Â®</sup>
                     </content>
                  </paragraph>
                  <paragraph>risankizumab-rzaa</paragraph>
                  <paragraph>Injection</paragraph>
                  <paragraph>
                     <content styleCode="bold">180 mg/1.2 mL</content>
                  </paragraph>
                  <paragraph>(150 mg/mL)</paragraph>
                  <paragraph>FOR SUBCUTANEOUS USE ONLY</paragraph>
                  <paragraph>Single-Dose</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM0300005F"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250507"/>
               <component>
                  <observationMedia ID="MM0300005F">
                     <text>NDC 0074-1066-02
NOT FOR SALE
SkyriziÂ®
risankizumab-rzaa
Injection
180 mg/1.2 mL
(150 mg/mL)
FOR SUBCUTANEOUS USE ONLY
Single-Dose
Rx Only
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-5f.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="b970192f-d5b4-424a-85bc-715a9c1675d2"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>NDC 0074-7034-02</paragraph>
                  <paragraph>
                     <content styleCode="bold">2 x 1 mL Prefilled Syringes</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Skyriz</content>
                     <content styleCode="bold">i</content>
                     <content styleCode="bold">
                        <sup>Â®</sup>
                     </content>
                  </paragraph>
                  <paragraph>risankizumab-rzaa Injection </paragraph>
                  <paragraph>
                     <content styleCode="bold">90 mg/mL per syringe</content>
                  </paragraph>
                  <paragraph>2 x 90 mg/mL. Single-Dose Prefilled</paragraph>
                  <paragraph>Syringes for a total 180 mg/2 mL dose</paragraph>
                  <paragraph>FOR SUBCUTANEOUS USE ONLY</paragraph>
                  <paragraph>FOR HEALTHCARE PROVIDER ADMINISTRATION ONLY</paragraph>
                  <paragraph>www. SKYRIZI.com</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">abbvie</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000060"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250507"/>
               <component>
                  <observationMedia ID="MM03000060">
                     <text>NDC 0074-7034-02
2 x 1 mL Prefilled Syringes
SkyriziÂ®
risankizumab-rzaa Injection 
90 mg/mL per syringe
2 x 90 mg/mL. Single-Dose Prefilled
Syringes for a total 180 mg/2 mL dose
FOR SUBCUTANEOUS USE ONLY
FOR HEALTHCARE PROVIDER ADMINISTRATION ONLY
www. SKYRIZI.com
Rx Only
abbvie

</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-60.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="84843a22-aaf4-4ba0-af19-2209075440d6"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>NDC 0074-7032-90</paragraph>
                  <paragraph>
                     <content styleCode="bold">One 1 mL Single-Dose Prefilled Syringe</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Skyriz</content>
                     <content styleCode="bold">i</content>
                     <content styleCode="bold">
                        <sup>Â®</sup>
                     </content>
                  </paragraph>
                  <paragraph>risankizumab-rzaa Injection </paragraph>
                  <paragraph>
                     <content styleCode="bold">90 mg/mL</content>
                  </paragraph>
                  <paragraph>FOR SUBCUTANEOUS USE ONLY</paragraph>
                  <paragraph>FOR HEALTHCARE PROVIDER ADMINISTRATION ONLY</paragraph>
                  <paragraph>www. SKYRIZI.com</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">abbvie</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000061"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250507"/>
               <component>
                  <observationMedia ID="MM03000061">
                     <text>NDC 0074-7032-90
One 1 mL Single-Dose Prefilled Syringe
SkyriziÂ®
risankizumab-rzaa Injection 
90 mg/mL
FOR SUBCUTANEOUS USE ONLY
FOR HEALTHCARE PROVIDER ADMINISTRATION ONLY
www. SKYRIZI.com
Rx Only
abbvie

</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-61.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="d8323167-151b-414d-a2e4-2878e729c099"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>NDC 0074-7036-04</paragraph>
                  <paragraph>
                     <content styleCode="bold">4 x 1 mL Prefilled Syringes</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Skyriz</content>
                     <content styleCode="bold">i</content>
                     <content styleCode="bold">
                        <sup>Â®</sup>
                     </content>
                  </paragraph>
                  <paragraph>risankizumab-rzaa Injection </paragraph>
                  <paragraph>
                     <content styleCode="bold">90 mg/mL per syringe</content>
                  </paragraph>
                  <paragraph>4 x 90 mg/mL Single-Dose Prefilled</paragraph>
                  <paragraph>Syringes for a total 360 mg/4 mL dose</paragraph>
                  <paragraph>FOR SUBCUTANEOUS USE ONLY</paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR HEALTHCARE PROVIDER ADMINISTRATION ONLY</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">ATTENTION PHARMACIST:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Each patient is required to receive the enclosed Medication Guide. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">The entire carton is to be dispensed as a unit. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Return to Pharmacy if carton seal is broken or missing. </content>
                  </paragraph>
                  <paragraph>www. SKYRIZI.com</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">A</content>
                     <content styleCode="bold">bbvie</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM02000062"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250507"/>
               <component>
                  <observationMedia ID="MM02000062">
                     <text>NDC 0074-7036-04
4 x 1 mL Prefilled Syringes
SkyriziÂ®
risankizumab-rzaa Injection 
90 mg/mL per syringe
4 x 90 mg/mL Single-Dose Prefilled
Syringes for a total 360 mg/4 mL dose
FOR SUBCUTANEOUS USE ONLY
FOR HEALTHCARE PROVIDER ADMINISTRATION ONLY
ATTENTION PHARMACIST:
Each patient is required to receive the enclosed Medication Guide. 
The entire carton is to be dispensed as a unit. 
Return to Pharmacy if carton seal is broken or missing. 
www. SKYRIZI.com
Rx Only
Abbvie
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-62.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="6928bd47-d94e-4451-a699-5560acce5a26"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>NDC 0074-7032-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">Skyrizi</content>
                     <sup>Â®</sup>
                     <sup>Â </sup>
                     <content styleCode="bold">90 mg/mL</content>
                  </paragraph>
                  <paragraph>risankizumab-rzaa</paragraph>
                  <paragraph>Injection</paragraph>
                  <paragraph>For Subcutaneous Use Only</paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR HEALTHCARE PROVIDER ADMINISTRATION ONLY</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR A 350 MG DOES,</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOUR 90 MG SYRINGES ARE REQUIRED,</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">INJECT ALL 4 SYRINGES FOR A FULL DOSE</content>
                  </paragraph>
                  <paragraph>www.SKYRIZI.com</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>abbvie</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM02000063"/>
                  </paragraph>
                  <paragraph>NDC 0074-7040-02</paragraph>
                  <paragraph>
                     <content styleCode="bold">2 x 90 mg/mL Single Dose Prefilled Syringes</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Skyriz</content>
                     <content styleCode="bold">i</content>
                     <content styleCode="bold">
                        <sup>Â®</sup>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">90 mg/mL per syringe</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">2 x 90 mg/mL Single-Dose Prefilled</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Syringes for a total 180 mg/2 mL dose</content>
                  </paragraph>
                  <paragraph>risankizumab-rzaa </paragraph>
                  <paragraph>Injection </paragraph>
                  <paragraph>FOR SUBCUTANEOUS USE ONLY</paragraph>
                  <paragraph>
                     <content styleCode="bold">Return to pharmacy if carton perforations are broken.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">ATTENTION PHARMACIST:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Each patient is required to receive </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">the enclosed Medication Guide.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">This entire carton is dispensed as a unit.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR A 180 MG DOSE,</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">TWO 90 MG SYRINGES ARE REQUIRED.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">INJECT 2 SYRINGES FOR A FULL DOSE.</content>
                  </paragraph>
                  <paragraph>www.SKYRIZI.com</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">abbvie</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000064"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250507"/>
               <component>
                  <observationMedia ID="MM02000063">
                     <text>NDC 0074-7032-01
SkyriziÂ® 90 mg/mL
risankizumab-rzaa
Injection
For Subcutaneous Use Only
FOR HEALTHCARE PROVIDER ADMINISTRATION ONLY

FOR A 350 MG DOES,
FOUR 90 MG SYRINGES ARE REQUIRED,
INJECT ALL 4 SYRINGES FOR A FULL DOSE
www.SKYRIZI.com
Rx Only
abbvie
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-63.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000064">
                     <text>NDC 0074-7040-02
2 x 90 mg/mL Single Dose Prefilled Syringes
SkyriziÂ®
90 mg/mL per syringe
2 x 90 mg/mL Single-Dose Prefilled
Syringes for a total 180 mg/2 mL dose
risankizumab-rzaa 
Injection 
FOR SUBCUTANEOUS USE ONLY
Return to pharmacy if carton perforations are broken.
ATTENTION PHARMACIST:
Each patient is required to receive 
the enclosed Medication Guide.
This entire carton is dispensed as a unit.
FOR A 180 MG DOSE,
TWO 90 MG SYRINGES ARE REQUIRED.
INJECT 2 SYRINGES FOR A FULL DOSE.
www.SKYRIZI.com
Rx only
abbvie
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="skyrizi-64.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>